Evicenter
MarkdownMedical informationP&T meetings
Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Last updated
221 sources

Section 3 of 6

Product information and disease description

443 evidence topics · 157 sources

Product description

Phase of product development

Regulatory status: Approved; NDA submitted September 2025 and approved September 2026
Development history: discovery at Pfizer and transfer to Cerevel Therapeutics
FDA expedited program designations

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Dosage forms and strengths
Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
  • Price basis: AbbVie wholesale acquisition cost (WAC) price list effective 9 November 2026, $4,900.00 per 30-count bottle of the 5 mg, 10 mg, or 15 mg tablet and $4,900.00 per titration pack carton of 100 tablets; the price is the same at every strength.
  • Dosing basis: a 40-day titration from 0.25 mg to 3 mg once daily, supplied by one titration pack, then a maintenance dosage of 5 mg once daily from day 41, which may be increased in 5 mg increments to a maximum of 15 mg once daily; each maintenance dose is one tablet, so a 30-count bottle is a 30-day supply.
  • Base case: maintenance at 5 mg, 10 mg, or 15 mg once daily, $4,900 per 30-day supply ÷ 30 days = $163.33 per day × 365 days = $59,617 per year; ÷ 12 = $4,968 per month. First year including titration: $4,900 for the 40-day titration pack + $163.33 × 325 days ($53,083) = $57,983 per year; ÷ 12 = $4,832 per month. Later years: $59,617 per year.
  • Range: $8,517 to $178,850 per year ($710 to $14,904 per month). Maintenance dose taken every 7 days with a strong CYP3A inhibitor: $4,900 per 210 days = $23.33 per day × 365 = $8,517 per year ($710 per month); every 3 days with a moderate CYP3A inhibitor: $4,900 per 90 days × 365 = $19,872 per year ($1,656 per month). Maintenance dose taken twice daily with a moderate CYP3A inducer: $4,900 per 15 days × 365 = $119,233 per year ($9,936 per month); three times daily, up to the 45 mg daily maximum: $4,900 per 10 days × 365 = $178,850 per year ($14,904 per month). A patient already on a moderate CYP3A inducer titrates twice daily with two titration packs ($9,800 for 40 days).
  • Rationale for the range: flat pricing across strengths makes the cost independent of the 5 mg, 10 mg, or 15 mg maintenance dose; the label's CYP3A dosage modifications change the number of tablets used (strong inhibitor every 7 days, moderate inhibitor every 3 days, moderate inducer twice daily from day 8 of concomitant use and up to three times daily); the label reports no clinically significant pharmacokinetic differences with severe renal impairment not requiring dialysis or with mild or moderate hepatic impairment, so these add no variation; the titration pack lowers first-year cost because its 100 tablets cover 40 days at the price of a 30-day bottle.
  • Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
Reported list price of tavapadon attributed to a William Blair analyst and to ICER public meeting slides, September and October 2026
DrugQuoted estimateQuoted annual cost used in model
Tavapadon“Reported WAC”“$58,800”
Branded and generic Parkinson's disease comparators: United States National Average Drug Acquisition Cost, week of 23 September 2026
Product and strengthQuoted record descriptionQuoted acquisition cost per unitQuoted pricing unit
Opicapone 50 mg capsule“ONGENTYS 50 MG CAPSULE”“24.76028”“EA”
Safinamide 100 mg tablet“XADAGO 100 MG TABLET”“36.32581”“EA”
Carbidopa-levodopa extended-release 36.25 mg-145 mg capsule“RYTARY ER 36.25 MG-145 MG CAP”“3.97630”“EA”
Pramipexole 1 mg tablet (generic)“PRAMIPEXOLE 1 MG TABLET”“0.06192”“EA”
Ropinirole 3 mg tablet (generic)“ROPINIROLE HCL 3 MG TABLET”“0.07680”“EA”
Carbidopa-levodopa 25-100 mg tablet (generic)“CARBIDOPA-LEVODOPA 25-100 TAB”“0.07589”“EA”
Rotigotine, monoamine oxidase B inhibitor, catechol-O-methyltransferase inhibitor, and amantadine comparators: United States National Average Drug Acquisition Cost, week of 23 September 2026
Product and strengthQuoted record descriptionQuoted acquisition cost per unitQuoted pricing unit
Rotigotine 2 mg/24 hours transdermal patch (Neupro)“NEUPRO 2 MG”/ “24 HR PATCH”“28.26022”“EA”
Rasagiline 1 mg tablet (generic)“RASAGILINE MESYLATE 1 MG TAB”“0.92551”“EA”
Selegiline 5 mg capsule (generic)“SELEGILINE HCL 5 MG CAPSULE”“0.75631”“EA”
Entacapone 200 mg tablet (generic)“ENTACAPONE 200 MG TABLET”“0.32457”“EA”
Carbidopa-levodopa-entacapone 25-100-200 mg tablet (generic)“CARBIDOPA-LEVODOPA-ENTACAPONE 25-100-200 MG TAB”“0.69542”“EA”
Amantadine 100 mg capsule (generic)“AMANTADINE 100 MG CAPSULE”“0.14251”“EA”
Gocovri and Nourianz: wholesale acquisition cost filings with the California Department of Health Care Access and Information
Product and packageQuoted manufacturerQuoted drug product descriptionQuoted WAC effective dateQuoted WAC increase amount (USD)Quoted WAC after increase (USD)
Gocovri (amantadine extended-release) 137 mg, 60 capsules“Adamas Pharmaceuticals, Inc.”“Gocovri Oral Capsule Extended Release 24 Hour 137 MG Package Size 60 Package Quantity 1”“01/01/2023”“149.67”“3142.96”
Nourianz (istradefylline) 20 mg, 90 tablets“Kyowa Kirin, Inc.”“Nourianz Oral Tablet 20 MG, 90 Each, Bottle”“01/05/2024”“270.39”“5678.15”
Nourianz (istradefylline) 40 mg, 90 tablets“Kyowa Kirin, Inc.”“Nourianz Oral Tablet 40 MG, 90 Each, Bottle”“01/05/2024”“270.39”“5678.15”
Branded Parkinson's disease adjunctive therapies: Medicare Part D spending, 2024
Brand (generic)Quoted total spending, 2024 (USD)Quoted beneficiaries, 2024Quoted average spending per dosage unit, 2024 (USD)Quoted average spending per beneficiary, 2024 (USD)
Ongentys (opicapone)“15354274.26”“3276”“21.749437532”“4686.8969048”
Xadago (safinamide)“7677985.91”“759”“37.323213575”“10115.923465”
Nourianz (istradefylline)“50721486.03”“3610”“62.728700759”“14050.273139”
Neupro (rotigotine)“90068151.36”“14920”“27.60090549”“6036.7393673”
Gocovri (amantadine extended-release)“99842781.69”“4906”“55.422069989”“20351.15811”
Inbrija (inhaled levodopa)“27688440.22”“2431”“20.495381225”“11389.732711”
Rytary (carbidopa-levodopa extended-release)“271784313.29”“34890”“4.2578095671”“7789.7481596”
Monoamine oxidase B inhibitors, catechol-O-methyltransferase inhibitors, and amantadine products: Medicare Part D beneficiaries, claims, and spending per dosage unit, 2024
Brand name in the record (generic)Quoted beneficiaries, 2024Quoted claims, 2024Quoted average spending per dosage unit, 2024 (USD)
Rasagiline Mesylate (rasagiline, generic)“31737”“146909”“3.2972061315”
Selegiline HCl (selegiline, generic)“11299”“50495”“0.9994398084”
Xadago (safinamide)“759”“4385”“37.323213575”
Entacapone (entacapone, generic)“26289”“128596”“0.9670266984”
Carbidopa-Levodopa-Entacapone (carbidopa, levodopa, and entacapone, generic)“9136”“50738”“1.3434262576”
Ongentys (opicapone)“3276”“16686”“21.749437532”
Amantadine (amantadine, generic)“104318”“526882”“0.5229425868”
Gocovri (amantadine extended-release)“4906”“30705”“55.422069989”
American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Adverse reactions in at least 3% of participants and at least 2% more than placebo, Studies 1 and 2 (without concomitant levodopa)
Adverse reactionJuvmo (N=505), %Placebo (N=328), %
Nausea“27”“2”
Headache (multiple related terms)“17”“5”
Dizziness“14”“4”
Fatigue (includes asthenia)“10”“3”
Dysgeusia“8”“0”
Vomiting“7”“<1”
Dry mouth“5”“<1”
Anxiety“5”“2”
Hypotension“4”“1”
Dyspepsia“4”“1”
Abnormal dreams“4”“<1”
Orthostatic hypotension“4”“<1”
Hallucination (multiple related terms)“3”“0”
Gastroesophageal reflux disease“3”“<1”
Constipation“3”“1”
Adverse reactions in at least 3% of participants and at least 2% more than placebo, Study 3 (with concomitant levodopa)
Adverse reactionJuvmo (N=251), %Placebo (N=254), %
Nausea“14”“4”
Dyskinesia“10”“2”
Dizziness“8”“3”
Headache (multiple related terms)“7”“3”
Hallucination (multiple related terms)“7”“1”
Orthostatic hypotension“6”“1”
Hypotension“4”“<1”
Abdominal pain“3”“<1”
Asthenia“3”“0”
Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on tavapadon
Effects of tavapadon on other drugs
Dosing and administration
Dosage
Titration schedule
Treatment daysQuoted dosage
Days 1 to 4“0.25 mg once daily”
Days 5 to 8“0.5 mg once daily”
Days 9 to 12“0.75 mg once daily”
Days 13 to 16“1 mg once daily”
Days 17 to 20“1.5 mg once daily”
Days 21 to 24“2.25 mg once daily”
Days 25 to 40“3 mg once daily”
Maintenance, day 41 and thereafter“5 mg once daily”
Maximum dosage“15 mg once daily”
Dosage modification when initiating a CYP3A inhibitor during maintenance
Current maintenance dosageStrong CYP3A inhibitorModerate CYP3A inhibitor
5 mg once daily“5 mg every 7 days”“5 mg every 3 days”
10 mg once daily“10 mg every 7 days”“10 mg every 3 days”
15 mg once daily“15 mg every 7 days”“15 mg every 3 days”
Dosage for patients already on long-term moderate CYP3A inducers
Treatment daysQuoted dosage
Days 1 to 4“0.25 mg twice daily”
Days 5 to 8“0.5 mg twice daily”
Days 9 to 12“0.75 mg twice daily”
Days 13 to 16“1 mg twice daily”
Days 17 to 20“1.5 mg twice daily”
Days 21 to 24“2.25 mg twice daily”
Days 25 to 40“3 mg twice daily”
Maintenance, day 41 and thereafter“5 mg twice daily”
Maximum dosage“45 mg daily”
Administration
Access and distribution
Package configurations and National Drug Codes
Co-prescribed/Concomitant therapies
Effect of tavapadon on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Cardiovascular effects of tavapadon and other oral or transdermal dopamine agonists
Receptor selectivity and adverse effects of tavapadon compared with D2 agonists in a commentary

“Among the currently marketed antiparkinsonian medications, L-DOPA (decarboxylated into dopamine) and apomorphine (a mixed D1/D2 agonist) are the only drugs that stimulate both receptor subtypes simultaneously. Conversely, all other antiparkinsonian dopamine agonists (eg, pramipexole, ropinirole, rotigotine, and others) are D2-selective, and no selective D1 agonists are available, highlighting a gap in our understanding of dopaminergic mechanisms and possibly in management of patients with Parkinson’s disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The proportion of nausea and orthostatic hypotension in TEMPO-2 does not suggest a better profile on these peripheral side-effects than D2 agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The same applies to dyskinesia. Its incidence was low in TEMPO-2, comparable to D2 agonist trials, as expected in a short-term trial in levodopa-naive patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“On the other hand, somnolence was not a concern in TEMPO-2, as changes in Epworth Sleep Scale scores did not differ between groups, whereas sleepiness induced by D2 agonists is easily detected in small and short trials, even at low doses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Place of product in therapy

Disease description

Definition and etiology
Parkinsonism as the core clinical feature

“Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Parkinsonism is defined as bradykinesia, in combination with either rest tremor, rigidity, or both. These features must be clearly demonstrable and not attributable to confounding factors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Bradykinesia is defined as slowness of movement AND decrement in amplitude or speed (or progressive hesitations/halts) as movements are continued.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Although bradykinesia also occurs in voice, face, and axial/gait domains, limb bradykinesia must be documented to establish a diagnosis of PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Rest tremor refers to a 4- to 6-Hz tremor in the fully resting limb, which is suppressed during movement initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Although postural instability is a feature of parkinsonism, it is not part of the MDS-PD criteria for parkinsonism caused by PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This is reflected in a new diagnostic classification, prodromal PD, which is considered to be a true stage of PD (ie, prodromal PD is PD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Epidemiology
Incidence of Parkinson's disease
Prevalence of Parkinson's disease
Natural history, survival, and mortality
Prodromal phase before motor diagnosis

“Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“we proposed that early PD should be divided into three stages: preclinical PD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“(neurodegenerative processes have commenced, but there are no evident symptoms or signs); prodromal PD (symptoms and signs are present, but are yet insufficient to define disease); and clinical PD (i.e., diagnosis of PD based on presence of classical motor signs).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The speed of progression from prodromal to full clinical stages varies among patients and cannot be reliably predicted on the individual level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Polysomnogram-proven RBD: Prospective studies show that more than 75% will develop disease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Some studies in cohorts (e.g., RBD cohorts) have clearly documented prodromal durations of >20 years in duration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Based upon an overall assessment of the literature, we posited an average prodromal period of 10 years, but this was extremely subjective; the true value may differ considerably.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Mortality relative to people without Parkinson's disease

“Eighty-eight studies were included in the review with variable study methods and quality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Almost all studies reported increased mortality in PD (vs. controls), with mortality ratios ranging from 0.9 to 3.8, with major between-study heterogeneity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Inception cohorts were more consistent with a pooled mortality ratio of approximately 1.5.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The overall mortality ratio in the inception cohorts (9 studies; 1,801 patients; median follow-up duration, 9 years) was 1.52 (95% CI, 1.25-1.78), but heterogeneity was high” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Most of the heterogeneity was because of a single study (Hoehn, 1967)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“and when this study was removed, the overall mortality ratio was 1.41 (95% CI, 1.28-1.55) with low heterogeneity” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The non-inception cohorts (33 studies; 27,480 patients; median follow-up duration, 7 years) had mortality ratios ranging from 0.90 to 3.79, with major heterogeneity” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A funnel plot (Supplemental Data Figure 1) did not show any evidence of publication bias or other small-study effect (Egger’s test, P = 0.87).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Univariable metaregression of sex on these data showed no significant differences between males and females (P = 0.17).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Most mortality ratios lay between 1.2 and 2.4, but, because of the major heterogeneity in the included studies, calculation of an overall measure was inappropriate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Forty-five studies (27,458 patients) reported survival proportion at specific times” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The regression coefficient was –0.045 (95% CI, –0.056-0.033).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“On average, PD survival reduced by approximately 5% every year of follow-up, although there was significant heterogeneity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Eighteen studies reported median survival, 5 inception and 13 non-inception cohorts (Supplemental Data Table 6), which ranged from 6 to 22 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Meta-analysis of 10 studies (1,306 patients) reporting the mean disease duration at death (Fig. 4) showed major heterogeneity” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In post-mortem studies, mean duration until death ranged from 6.9 to 14.3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Increasing age and presence of dementia were most commonly associated with increased mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Treatment also may alter prognosis over time, but we did not find any robust evidence that L-dopa has reduced mortality, and we are not aware of data to suggest that any other treatments alter survival.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Only 5 studies met all 4 quality criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Most of the studies in this review were from Europe or North America, so generalizability to other geographical areas may be limited.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Mortality and causes of death over 15 and 20 years in a levodopa-era incident cohort

“The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Eighty-two deaths were observed but only 44 were expected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The excess of observed deaths was 86% (SMR, 1.86; 95% confidence interval [CI], 1.48–2.31; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean age of death was 75.5 years (SD = 8.1): 74.8 years (SD=7.9) for men and 76.4 (SD = 8.3) for women.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, the median time from onset of disease to death was 12.2 years (95% CI, 10.3–14.0 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For men, the median survival was 11.9 years (95% CI, 9.7–14.0 years), and for women 12.9 years (95% CI, 9.6–16.1 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The difference in survival between men and women and the difference between randomization groups was not statistically significant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients randomly assigned to L-dopa survived for a median of 13.1 years (95% CI, 10.5–15.6 years), whereas patients randomly assigned to bromocriptine survived for a median of 11.6 years (95% CI, 8.7–14.4 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Variables that were statistically significant univariately to predict death by 15 years were older age at onset (P < 0.001), Hoehn and Yahr Stage 3 at baseline (P < 0.003), rapid prestudy disease progression rate (P < 0.005), imbalance at baseline (P < 0.03), dementia at baseline (P < 0.05), increased tremor score at baseline (P < 0.02), dementia noted within 15 years (P < 0.001), and imbalance developing within the 15 years (P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In multivariate analysis, the variables were the older the age of onset and the higher the risk of mortality (P < 0.001), increasing by approximately 15% per year of age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Imbalance noted within 15 years increased the risk of death almost threefold (P < 0.03).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“pneumonia being the most common cause (22 of 82, 27%) with a SMR >10.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Parkinson’s disease was considered to have contributed to the deaths of 43 patients (52%) because of pneumonia, inanition, pulmonary embolism, suicide, and patients who were Stage 5 who had cardiovascular or cerebrovascular events but who were considered unsuitable for rehabilitation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Significantly lower than expected death rates were observed from carcinoma (12 vs. 24.2 expected; SMR, 0.50; 95% CI, 0.26–0.87).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Deaths due to cardiovascular disease (15 vs. 13.5 expected) were not significantly increased.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In this study, the SMR is 1.58 at 10 years and 1.86 at 15 years” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“After 20 years follow-up of newly diagnosed patients with Parkinson’s disease (PD), 100 of 136 (74%) have died.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mortality rate fell in the first 3 years of treatment, then rose compared to the general population, the standardized mortality ratio from 15 to 20 years reaching 3.1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In the first 3 years, five died compared with an expected 9.2 deaths (SMR = 0.5, 95% CI 0.2–1.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Between 3 and 20 years, 95 died compared with an expected 38.7 deaths (SMR = 2.5, 95% CI = 2.0–3.0).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The SMR was similar for the periods 3 to 5, 5 to 10, 10 to 15, and 15 to 20 years (chi-square test statistic for between period differences = 2.6 for 3 degrees of freedom, P = 0.5) but showed a trend to increase with duration of disease compared to the age matched Australian population after falling in the early years of treatment: SMR = 0.5 at 0 to 3 years, 1.8 at 3 to 5 years, 2.3 at 5 to 10 years, 2.7 at 10 to 15 years and 3.1 at 15 to 20 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean age at death was 76 years (SD = 7.5), 75 years for men and 78 years for women after a mean of 121 and 132 months from entry to the study, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The median time from historical onset of disease to death was 12.4 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Pneumonia was the most common cause of death, 26 of 103 (25%), generally occurring in Hoehn and Yahr stage 5.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“PD was considered to have been a significant contributor to the death of 55 of 103 (54%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Once dementia was diagnosed (excluding those diagnosed at baseline), the median survival was 54 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Although dementia was predictive of death (P = 0.001) univariately, it is so strongly associated with increasing age as to render it insignificant when age is corrected for multivariately.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Trends in Parkinson's disease mortality in the United States, 1999 to 2019

“Analyses focused on the data from 479,059 deaths due to PD from 1999 to 2019.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The age-adjusted mortality from PD increased from 5.4 (95% confidence interval [CI] 5.3–5.5) per 100,000 population in 1999 to 8.8 (95% CI, 8.7–8.9) per 100,000 population in 2019, with an average annual percent change of 2.4%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Age-adjusted PD mortality rates were twice as high in men as in women and were greater in White individuals than those from other racial/ethnic groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Between 1999 and 2019, the number of deaths from PD in the US population was more than doubled, from 14,593 to 35,311” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The state-level estimates of the increases ranged from 3.1 to 8.4 per 100,000 in 1999 to 4.6 to 11.7 per 100,000 in 2019” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Death resulting from PD was ascertained by its designation as the underlying cause of death in death certificates with codes G20 to G21 of the ICD-10, which was implemented in 1999.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Thus, in our study, only PD as the underlying cause of death was counted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

GroupDeaths, 1999Death rate per 100,000 (95% CI), 1999Deaths, 2019Death rate per 100,000 (95% CI), 2019Average annual percent change (95% CI), 1999 to 2019
All ages, crude rate“14,593”View highlighted excerpt for this quote“5.2 (5.1–5.3)”View highlighted excerpt for this quote“35,311”View highlighted excerpt for this quote“10.8 (10.6–10.9)”View highlighted excerpt for this quote“3.6 (3.0–4.2)”View highlighted excerpt for this quote
All ages, age-adjusted rateNot applicable“5.4 (5.3–5.5)”View highlighted excerpt for this quoteNot applicable“8.8 (8.7–8.9)”View highlighted excerpt for this quote“2.4 (1.8–3.0)”View highlighted excerpt for this quote
Aged 64 years or younger, crude rate“295”View highlighted excerpt for this quote“0.1 (0.1–0.1)”View highlighted excerpt for this quote“876”View highlighted excerpt for this quote“0.3 (0.3–0.3)”View highlighted excerpt for this quote“5.0 (3.4–6.6)”View highlighted excerpt for this quote
Aged 65 to 74 years, crude rate“2,020”View highlighted excerpt for this quote“11.0 (10.5–11.4)”View highlighted excerpt for this quote“5,276”View highlighted excerpt for this quote“16.8 (16.3–17.2)”View highlighted excerpt for this quote“1.9 (1.4–2.5)”View highlighted excerpt for this quote
Aged 75 to 84 years, crude rate“7,110”View highlighted excerpt for this quote“58.2 (56.8–59.5)”View highlighted excerpt for this quote“14,902”View highlighted excerpt for this quote“93.3 (91.8–94.8)”View highlighted excerpt for this quote“2.2 (1.8–2.5)”View highlighted excerpt for this quote
Aged 85 years or older, crude rate“5,168”View highlighted excerpt for this quote“124.4 (121.0–127.8)”View highlighted excerpt for this quote“14,257”View highlighted excerpt for this quote“215.9 (212.3–219.4)”View highlighted excerpt for this quote“2.7 (2.0–3.5)”View highlighted excerpt for this quote
Men, age-adjusted rate“8,262”View highlighted excerpt for this quote“8.4 (8.2–8.6)”View highlighted excerpt for this quote“21,592”View highlighted excerpt for this quote“13.1 (13.0–13.3)”View highlighted excerpt for this quote“2.2 (1.7–2.7)”View highlighted excerpt for this quote
Women, age-adjusted rate“6,331”View highlighted excerpt for this quote“3.7 (3.6–3.8)”View highlighted excerpt for this quote“13,719”View highlighted excerpt for this quote“5.8 (5.7–5.9)”View highlighted excerpt for this quote“2.1 (1.7–2.5)”View highlighted excerpt for this quote
Hispanic, age-adjusted rate“389”View highlighted excerpt for this quote“3.5 (3.2–3.9)”View highlighted excerpt for this quote“2,126”View highlighted excerpt for this quote“6.5 (6.2–6.8)”View highlighted excerpt for this quote“3.0 (2.7–3.3)”View highlighted excerpt for this quote
Non-Hispanic White, age-adjusted rate“13,475”View highlighted excerpt for this quote“5.8 (5.7–5.9)”View highlighted excerpt for this quote“30,307”View highlighted excerpt for this quote“9.7 (9.6–9.8)”View highlighted excerpt for this quote“2.5 (1.9–3.1)”View highlighted excerpt for this quote
Non-Hispanic Black, age-adjusted rate“502”View highlighted excerpt for this quote“2.4 (2.2–2.6)”View highlighted excerpt for this quote“1,655”View highlighted excerpt for this quote“4.7 (4.5–5.0)”View highlighted excerpt for this quote“3.5 (2.7–4.3)”View highlighted excerpt for this quote
Non-Hispanic, other, age-adjusted rate“200”View highlighted excerpt for this quote“3.4 (2.9–3.8)”View highlighted excerpt for this quote“1,182”View highlighted excerpt for this quote“5.6 (5.3–6.0)”View highlighted excerpt for this quote“2.5 (1.7–3.4)”View highlighted excerpt for this quote
Large central metropolitan, age-adjusted rate“3,894”View highlighted excerpt for this quote“5.1 (5.0–5.3)”View highlighted excerpt for this quote“8,907”View highlighted excerpt for this quote“8.2 (8.1–8.4)”View highlighted excerpt for this quote“2.4 (1.7–3.1)”View highlighted excerpt for this quote
Large fringe metropolitan, age-adjusted rate“3,400”View highlighted excerpt for this quote“5.7 (5.5–5.9)”View highlighted excerpt for this quote“9,008”View highlighted excerpt for this quote“9.2 (9.0–9.4)”View highlighted excerpt for this quote“2.4 (1.7–3.2)”View highlighted excerpt for this quote
Medium metropolitan, age-adjusted rate“3,136”View highlighted excerpt for this quote“5.6 (5.4–5.8)”View highlighted excerpt for this quote“7,768”View highlighted excerpt for this quote“9.0 (8.8–9.2)”View highlighted excerpt for this quote“2.4 (1.5–3.2)”View highlighted excerpt for this quote
Small metropolitan, age-adjusted rate“1,592”View highlighted excerpt for this quote“6.0 (5.7–6.2)”View highlighted excerpt for this quote“3,707”View highlighted excerpt for this quote“9.3 (9.0–9.6)”View highlighted excerpt for this quote“2.3 (2.0–2.7)”View highlighted excerpt for this quote
Micropolitan, age-adjusted rate“1,510”View highlighted excerpt for this quote“5.3 (5.0–5.5)”View highlighted excerpt for this quote“3,464”View highlighted excerpt for this quote“9.1 (8.8–9.5)”View highlighted excerpt for this quote“2.5 (2.1–2.9)”View highlighted excerpt for this quote
Noncore, age-adjusted rate“1,061”View highlighted excerpt for this quote“4.4 (4.2–4.7)”View highlighted excerpt for this quote“2,457”View highlighted excerpt for this quote“8.3 (8.0–8.7)”View highlighted excerpt for this quote“2.9 (2.4–3.4)”View highlighted excerpt for this quote
Pathophysiology
Striatal direct and indirect pathways and D1 and D2 dopamine receptors

“Dopamine has opponent affects on the function of these pathways due to the segregation of the D1- and D2-dopamine receptors in the spiny projection neurons giving rise to the direct and indirect pathways.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The direct pathway originates from Drd1a-expressing SPNs that project to the GPi and SNr output nuclei.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The indirect pathway originates from Drd2-expressing SPNs that project only to the external segment of the globus pallidus (GPe), which together with the subthalamic nucleus (STN) contain transynaptic circuits connecting to the basal output nuclei.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Taken together these findings led to the proposal that in Parkinson’s disease the loss of striatal dopamine produces decreased activity in the direct striatonigral pathway and increased activity in the indirect pathway through the multisynaptic pathway through the GPe and STN to SNr.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Imbalance in activity between these pathways, with activity in the indirect pathway predominating over the disinhibition of direct pathway activity required for the generation of movements was proposed to produce bradykinetic symptoms of Parkinson’s disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Diagnosis
Movement Disorder Society clinical diagnostic criteria

“The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Clinically Established PD: Maximizing specificity, the category is anchored with the goal that the large majority (ie, at least 90%) will have PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Clinically Probable PD: Balancing sensitivity and specificity, the category is anchored with the goal that at least 80% of patients diagnosed as probable PD truly have PD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Diagnosis of clinically established PD requires: 1. Absence of absolute exclusion criteria 2. At least two supportive criteria 3. No red flags” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Diagnosis of clinically probable PD can be made in: 1. Absence of absolute exclusion criteria 2. Presence of red flags counterbalanced by supportive criteria, ie, if one red flag is present there must also be at least one supportive criterion; if two red flags, at least two supportive criteria are needed. If there are more than two red flags, clinically probable PD cannot be diagnosed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“As outlined in our introductory manuscript, the MDS-PD criteria do not consider dementia as an exclusion criterion for PD, regardless of when it occurs in relation to parkinsonism onset.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Full diagnostic certainty is impossible during life; between 75% and 95% of patients diagnosed with PD by experts have their diagnosis confirmed on autopsy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Supportive criteria in the Movement Disorder Society clinical diagnostic criteria

“Clear and dramatic beneficial response to dopaminergic therapy. To meet this criterion, during initial treatment, patients should have returned to normal or near-normal level of function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Presence of levodopa-induced dyskinesia” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Rest tremor of a limb, documented on clinical examination (in the past, or on current examination)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Positive results from at least one ancillary diagnostic test having a specificity greater than 80% for differential diagnosis of PD from other parkinsonian conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Such a marker must have been assessed as 80% or more specific in the differential diagnosis of parkinsonism (compared with gold-standard clinical or clinicopathologic diagnosis) in most studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Olfactory loss (in the anosmic or clearly hyposmic range, adjusted for age and sex)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Metaiodobenzylguanidine scintigraphy clearly documenting cardiac sympathetic denervation” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Note that although dopaminergic neuroimaging can help distinguish parkinsonism (ie, degeneration of the nigrostriatal system) from PD-mimics without parkinsonism (eg, essential tremor), it does not qualify as a criterion for the differentiation of PD from other parkinsonian conditions like atypical parkinsonian syndromes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Absolute exclusion criteria in the Movement Disorder Society clinical diagnostic criteria

“A benchmark for an absolute exclusion was occurrence in less than 3% of true PD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The presence of any of these features rules out PD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Unequivocal cerebellar abnormalities on examination, such as cerebellar gait, limb ataxia, or cerebellar oculomotor abnormalities (eg, sustained gaze-evoked nystagmus, macro square wave jerks, hypermetric saccades)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Downward vertical supranuclear gaze palsy, or selective slowing of downward vertical saccades” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive aphasia, defined according to consensus criteria” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“within the first 5 y of disease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Other forms of dementia are not an exclusion criterion for PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Parkinsonian features restricted to the lower limbs for more than 3 y” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and time-course consistent with drug-induced parkinsonism” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Absence of observable response to high-dose levodopa despite at least moderate severity of disease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Unequivocal cortical sensory loss (ie, graphesthesia, stereognosis with intact primary sensory modalities), clear limb ideomotor apraxia, or progressive aphasia” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Normal functional neuroimaging of the presynaptic dopaminergic system” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Documentation of an alternative condition known to produce parkinsonism and plausibly connected to the patient’s symptoms, or the expert evaluating physician, based on the full diagnostic assessment, believes that an alternative syndrome is more likely than PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Red flags in the Movement Disorder Society clinical diagnostic criteria

“Red flags rule out probable PD diagnosis only when they cannot be counterbalanced by supportive criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Rapid progression of gait impairment requiring regular use of wheelchair within 5 y of onset” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A complete absence of progression of motor symptoms or signs over 5 or more years unless stability is related to treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Early bulbar dysfunction, defined as one of severe dysphonia, dysarthria (speech unintelligible most of the time), or severe dysphagia (requiring soft food, NG tube, or gastrostomy feeding) within the first 5 y of disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Inspiratory respiratory dysfunction defined as either diurnal or nocturnal inspiratory stridor or frequent inspiratory sighs” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Severe autonomic failure in the first 5 y of disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“orthostatic decrease of blood pressure within 3 min of standing by at least 30 mm Hg systolic or 15 mm Hg diastolic, in the absence of dehydration, medication, or other diseases that could plausibly explain autonomic dysfunction” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Severe urinary incontinence or urinary retention in the first 5 y of disease (excluding longstanding low-volume stress incontinence in women), which is not simply functional incontinence (ie, inability to get to the bathroom in a reasonable time).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Recurrent (>1/y) falls because of impaired balance within 3 y of onset.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The presence of disproportionate anterocollis (dystonic in nature) or contractures of hand or feet within the first 10 y.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Absence of any of the common nonmotor features of disease despite 5 y disease duration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Otherwise unexplained pyramidal tract signs, defined as pyramidal weakness or clear pathologic hyperreflexia (excluding mild reflex asymmetry in the more affected limb, and isolated extensor plantar response).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Bilateral symmetric parkinsonism throughout the disease course. The patient or caregiver reports bilateral symptom onset with no side predominance, and no side predominance is observed on objective examination.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Validation of the criteria against expert clinical diagnosis

“From 8 centers, we recruited 626 parkinsonism patients (434 PD, 192 non-PD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of 434 patients diagnosed with PD, 94.5% met the International Parkinson and Movement Disorder Society criteria for probable PD (5.5% false-negative rate). Of 192 non-PD patients, 88.5% were identified as non-PD by the criteria (11.5% false-positive rate). The overall accuracy for probable PD was 92.6%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In comparison, United Kingdom Brain Bank criteria had lower sensitivity (89.2%, P = 0.008), specificity (79.2%, P = 0.018), and overall accuracy (86.4%, P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In the non-PD group, the commonest conditions were multiple system atrophy (38%), progressive supranuclear palsy (33%), and corticobasal syndrome (10%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, 59.3% of PD patients met MDS criteria for clinically established PD. Only 1.6% of non-PD patients met clinically established criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Moreover, if optimal specificity is desired, the clinically established criteria had very high specificity (98.4%) with a reasonable sensitivity of 59%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Validation of the criteria: frequency of individual criteria items
Criterion itemPD (n = 434), %Non-PD parkinsonism (n = 192), %
Supportive criterion: excellent levodopa response“73.4 (n = 364)”View highlighted excerpt for this quote“19.9 (n = 151)”View highlighted excerpt for this quote
Supportive criterion: dyskinesia“34.0 (n = 382)”View highlighted excerpt for this quote“7.0 (n = 157)”View highlighted excerpt for this quote
Supportive criterion: asymmetric rest tremor“56.5”View highlighted excerpt for this quote“13.6”View highlighted excerpt for this quote
Supportive criterion: positive ancillary test“67.6”View highlighted excerpt for this quote“38.3”View highlighted excerpt for this quote
Supportive criterion: abnormal olfaction“67.4”View highlighted excerpt for this quote“36.6”View highlighted excerpt for this quote
Any absolute exclusion“3.2”View highlighted excerpt for this quote“64.1”View highlighted excerpt for this quote
Absolute exclusion: cerebellar abnormalities“0.2”View highlighted excerpt for this quote“14.2”View highlighted excerpt for this quote
Absolute exclusion: vertical supranuclear gaze palsy“1.2”View highlighted excerpt for this quote“29.2”View highlighted excerpt for this quote
Absolute exclusion: frontotemporal dementia“0.2”View highlighted excerpt for this quote“1.1”View highlighted excerpt for this quote
Absolute exclusion: leg-only parkinsonism“0.5”View highlighted excerpt for this quote“2.6”View highlighted excerpt for this quote
Absolute exclusion: dopamine blocker or depleter“0.5”View highlighted excerpt for this quote“4.2”View highlighted excerpt for this quote
Absolute exclusion: absent levodopa response“1.3 (n = 393)”View highlighted excerpt for this quote“33.8 (n = 157)”View highlighted excerpt for this quote
Absolute exclusion: cortical sensory loss“0”View highlighted excerpt for this quote“13.1”View highlighted excerpt for this quote
Absolute exclusion: normal dopamine imaging“0 (n = 42)”View highlighted excerpt for this quote“13.0 (n = 23)”View highlighted excerpt for this quote
Any red flag“19.1”View highlighted excerpt for this quote“84.4”View highlighted excerpt for this quote
Red flag 1: rapid progression of gait impairment“1.4”View highlighted excerpt for this quote“22.7”View highlighted excerpt for this quote
Red flag 2: absence of progression over 5 years“1.2”View highlighted excerpt for this quote“0.6”View highlighted excerpt for this quote
Red flag 3: severe bulbar dysfunction within 5 years“0”View highlighted excerpt for this quote“18.0”View highlighted excerpt for this quote
Red flag 4: inspiratory stridor“0.2”View highlighted excerpt for this quote“9.0”View highlighted excerpt for this quote
Red flag 5: severe autonomic failure within 5 years“9.7”View highlighted excerpt for this quote“40.1”View highlighted excerpt for this quote
Red flag 6: recurrent falls within 3 years“3.7”View highlighted excerpt for this quote“51.3”View highlighted excerpt for this quote
Red flag 7: anterocollis or contractures“2.6”View highlighted excerpt for this quote“10.2”View highlighted excerpt for this quote
Red flag 8: absent nonmotor features after 5 years“1.6”View highlighted excerpt for this quote“1.6”View highlighted excerpt for this quote
Red flag 9: pyramidal tract signs“1.8”View highlighted excerpt for this quote“25.8”View highlighted excerpt for this quote
Red flag 10: bilateral symmetric parkinsonism“1.9”View highlighted excerpt for this quote“25.1”View highlighted excerpt for this quote
Research criteria for prodromal Parkinson's disease
Likelihood ratios of risk and prodromal markers: 2015 research criteria
Marker typeMarkerPositive likelihood ratioNegative likelihood ratio
Risk markerMale sex“1.2 (male)”View highlighted excerpt for this quote“0.8 (female)”View highlighted excerpt for this quote
Risk markerRegular pesticide exposure“1.5”View highlighted excerpt for this quoteNot applicable
Risk markerOccupational solvent exposure“1.5”View highlighted excerpt for this quoteNot applicable
Risk markerNonuse of caffeine“1.35”View highlighted excerpt for this quote“0.88”View highlighted excerpt for this quote
Risk markerCurrent smokerNot applicable“0.45”View highlighted excerpt for this quote
Risk markerNever smoker“1.25”View highlighted excerpt for this quoteNot applicable
Risk markerFormer smokerNot applicable“0.8”View highlighted excerpt for this quote
Risk markerSibling with PD onset before age 50 years“7.5”View highlighted excerpt for this quoteNot applicable
Risk markerAny other first-degree relative with PD“2.5”View highlighted excerpt for this quoteNot applicable
Risk markerKnown gene mutation“see Supporting Table II”View highlighted excerpt for this quoteNot applicable
Risk markerSubstantia nigra hyperechogenicity“4.7”View highlighted excerpt for this quote“0.45”View highlighted excerpt for this quote
Prodromal markerPolysomnography-proven RBD“130”View highlighted excerpt for this quote“0.62”View highlighted excerpt for this quote
Prodromal markerPositive RBD screening questionnaire with more than 80% specificity“2.3”View highlighted excerpt for this quote“0.76”View highlighted excerpt for this quote
Prodromal markerDopaminergic PET or SPECT clearly abnormal“40”View highlighted excerpt for this quote“0.65”View highlighted excerpt for this quote
Prodromal markerPossible subthreshold parkinsonism (UPDRS above 3, excluding action tremor)“10”View highlighted excerpt for this quote“0.70”View highlighted excerpt for this quote
Prodromal markerAbnormal quantitative motor testing“3.5”View highlighted excerpt for this quote“0.60”View highlighted excerpt for this quote
Prodromal markerOlfactory loss“4.0”View highlighted excerpt for this quote“0.43”View highlighted excerpt for this quote
Prodromal markerConstipation“2.2”View highlighted excerpt for this quote“0.80”View highlighted excerpt for this quote
Prodromal markerExcessive daytime somnolence“2.2”View highlighted excerpt for this quote“0.88”View highlighted excerpt for this quote
Prodromal markerSymptomatic hypotension“2.1”View highlighted excerpt for this quote“0.87”View highlighted excerpt for this quote
Prodromal markerSevere erectile dysfunction“2.0”View highlighted excerpt for this quote“0.90”View highlighted excerpt for this quote
Prodromal markerUrinary dysfunction“1.9”View highlighted excerpt for this quote“0.90”View highlighted excerpt for this quote
Prodromal markerDepression with or without anxiety“1.8”View highlighted excerpt for this quote“0.85”View highlighted excerpt for this quote
Likelihood ratios of risk and prodromal markers: 2019 update

“Markers not included previously entered the revised criteria if evidence from 2 prospective studies was now available. The median positive likelihood ratio (LR+) and median negative likelihood ratio (LR−) of all available evidence of a respective marker was used as the revised predictive value.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Abnormal dopaminergic PET/SPECT scan (43.3, previously 40.0) and olfactory loss (6.4, previous 4.0) have substantial increases in LR+ relative to their previous value, as new evidence is considered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Modest increases in LR+ are observed for possible RBD (questionnaire-based; LR+ = 2.8, previous = 2.3), constipation (2.5, previous = 2.2), excessive daytime somnolence (2.7, previous = 2.2), symptomatic hypotension (3.2, previous = 2.1), and erectile dysfunction (3.4, previous = 2.0).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For risk markers of male sex, regular pesticide and occupational solvent exposure, and nonuse of caffeine, no new prospective evidence has, to our knowledge, been published that would have changed their LRs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Neurogenic OH is LR+ = 18.5, LR− = 0.88; symptomatic OH is LR+ = 3.2, LR− = 0.80.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For instance, the cumulative PD risk of a GBA mutation carrier is ~18% at 65 years of age but only 2% in the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Using these risk values as estimates of sensitivity and specificity of the marker, the LR+ can be calculated (LR+ = 9).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“When a sibling or parent of an individual has been diagnosed with PD, an OR of 2–3.5 is estimated” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Marker typeMarkerPositive likelihood ratioNegative likelihood ratio
Risk markerMale sex“1.2 (male)”View highlighted excerpt for this quote“0.8 (female)”View highlighted excerpt for this quote
Risk markerRegular pesticide exposure“1.5”View highlighted excerpt for this quoteNot applicable
Risk markerOccupational solvent exposure“1.5”View highlighted excerpt for this quoteNot applicable
Risk markerNonuse of caffeine“1.35”View highlighted excerpt for this quote“0.88”View highlighted excerpt for this quote
Risk markerCurrent smokerNot applicable“0.51”View highlighted excerpt for this quote
Risk markerNever smoker“1.2”View highlighted excerpt for this quoteNot applicable
Risk markerFormer smokerNot applicable“0.91”View highlighted excerpt for this quote
Risk markerFirst-degree relative with PD“2.5”View highlighted excerpt for this quoteNot applicable
Risk markerKnown gene mutation with intermediate-strength penetrance“LR+ dependent on age-related penetrance, see Table 2”View highlighted excerpt for this quoteNot applicable
Risk markerPolygenic risk score“1.57 (highest quartile of PRS scores)”View highlighted excerpt for this quote“0.45 (lowest quartile)”View highlighted excerpt for this quote
Risk markerSubstantia nigra hyperechogenicity“3.4”View highlighted excerpt for this quote“0.38”View highlighted excerpt for this quote
Risk markerDiabetes mellitus (type II)“1.5”View highlighted excerpt for this quote“0.97”View highlighted excerpt for this quote
Risk markerPhysical inactivity“1.3”View highlighted excerpt for this quote“0.91”View highlighted excerpt for this quote
Risk markerLow plasma urate levels“1.8 (in men)”View highlighted excerpt for this quote“0.88 (in men)”View highlighted excerpt for this quote
Prodromal markerPolysomnography-proven RBD“130”View highlighted excerpt for this quote“0.65”View highlighted excerpt for this quote
Prodromal markerPossible RBD (questionnaire)“2.8”View highlighted excerpt for this quote“0.89”View highlighted excerpt for this quote
Prodromal markerDopaminergic PET or SPECT clearly abnormal“43.3”View highlighted excerpt for this quote“0.66”View highlighted excerpt for this quote
Prodromal markerSubthreshold parkinsonism“9.6”View highlighted excerpt for this quote“0.55”View highlighted excerpt for this quote
Prodromal markerAbnormal quantitative motor testing“3.5”View highlighted excerpt for this quote“0.60”View highlighted excerpt for this quote
Prodromal markerOlfactory loss“6.4”View highlighted excerpt for this quote“0.40”View highlighted excerpt for this quote
Prodromal markerConstipation“2.5”View highlighted excerpt for this quote“0.82”View highlighted excerpt for this quote
Prodromal markerExcessive daytime somnolence“2.7”View highlighted excerpt for this quote“0.86”View highlighted excerpt for this quote
Prodromal markerNeurogenic orthostatic hypotension“18.5”View highlighted excerpt for this quote“0.88”View highlighted excerpt for this quote
Prodromal markerSymptomatic orthostatic hypotension“3.2”View highlighted excerpt for this quote“0.80”View highlighted excerpt for this quote
Prodromal markerErectile dysfunction“3.4 (in men)”View highlighted excerpt for this quote“0.87 (in men)”View highlighted excerpt for this quote
Prodromal markerUrinary dysfunction“2.0”View highlighted excerpt for this quote“0.90”View highlighted excerpt for this quote
Prodromal markerDepression with or without anxiety“1.6”View highlighted excerpt for this quote“0.88”View highlighted excerpt for this quote
Prodromal markerGlobal cognitive deficit“1.8”View highlighted excerpt for this quote“0.88”View highlighted excerpt for this quote
Likelihood ratios of intermediate-strength genetic variants by age: 2019 update
Age group, yearsPD risk, noncarriersPD risk, GBA mutation carriersGBA positive likelihood ratioPD risk, LRRK2 mutation carriersLRRK2 positive likelihood ratio
50 to 54“0.4%”View highlighted excerpt for this quote“8%”View highlighted excerpt for this quote“20.0”View highlighted excerpt for this quote“~1%”View highlighted excerpt for this quote“2.5”View highlighted excerpt for this quote
55 to 59“0.75%”View highlighted excerpt for this quote“11%”View highlighted excerpt for this quote“14.7”View highlighted excerpt for this quote“3%”View highlighted excerpt for this quote“4.0”View highlighted excerpt for this quote
60 to 64“1.25%”View highlighted excerpt for this quote“14%”View highlighted excerpt for this quote“11.2”View highlighted excerpt for this quote“7%”View highlighted excerpt for this quote“5.6”View highlighted excerpt for this quote
65 to 69“2.0%”View highlighted excerpt for this quote“18%”View highlighted excerpt for this quote“9.0”View highlighted excerpt for this quote“15%”View highlighted excerpt for this quote“7.5”View highlighted excerpt for this quote
70 to 74“2.5%”View highlighted excerpt for this quote“21%”View highlighted excerpt for this quote“8.4”View highlighted excerpt for this quote“29%”View highlighted excerpt for this quote“11.6”View highlighted excerpt for this quote
75 to 79“3.5%”View highlighted excerpt for this quote“25%”View highlighted excerpt for this quote“7.1”View highlighted excerpt for this quote“32%”View highlighted excerpt for this quote“9.1”View highlighted excerpt for this quote
80 and over“4%”View highlighted excerpt for this quote“30%”View highlighted excerpt for this quote“7.5”View highlighted excerpt for this quote“42%”View highlighted excerpt for this quote“10.5”View highlighted excerpt for this quote
Limitations of the prodromal research criteria
Biological research frameworks: neuronal alpha-synuclein disease integrated staging system

“Neuronal α-synuclein disease is defined by the presence of pathological n-αsyn species detected in vivo (S; the first biological anchor) regardless of the presence of any specific clinical syndrome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Neuronal α-synuclein disease is defined by the presence of n-αsyn (S) and stage-dependent evidence of dopaminergic neuronal dysfunction (D).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Stages 0–1 occur without signs or symptoms and are defined by the presence of pathogenic variants in the SNCA gene (stage 0), S alone (stage 1A), or S and D (stage 1B). The presence of clinical manifestations marks the transition to stage 2 and beyond. Stage 2 is characterised by subtle signs or symptoms but without functional impairment. Stages 2B–6 require both S and D and stage-specific increases in functional impairment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, at present, only a CSF α-synuclein seed amplification assay has undergone robust validation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This assay is positive in more than 95% of autopsy-confirmed cases of Parkinson’s disease or dementia with Lewy bodies” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A quantitative dopamine transporter SPECT biomarker, the specific binding ratio in the lowest putamen adjusted for age and sex, is used to categorise individuals with dopamine transporter deficit (D+) or without dopamine transporter deficit (D–).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We have conceptualised functional impairment qualitatively as progressing along the continuum of slight, mild, moderate, and severe, and provide categorical descriptors of this progression (table 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Although operational definitions of anchors for functional impairment for stages 3–6 are beyond the scope of this Position Paper, they are crucial for future versions of the NSD-ISS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, MDS-UPDRS has limited sensitivity to detect changes in function in early disease stages and new scales and approaches need to be developed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among individuals with clinically diagnosed sporadic Parkinson’s disease and with evidence of dopaminergic dysfunction, about 7% do not have n-αsyn, relevant genetic variants, or alternative known biology” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Presently, the NSD-ISS is intended for research use only; its application in the clinical setting is premature and inappropriate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Biological research frameworks: SynNeurGe classification

“Our classification acknowledges the complexity and heterogeneity of the disease by use of a three-component system (SynNeurGe): presence or absence of pathological α-synuclein (S) in tissues or CSF; evidence of underlying neurodegeneration (N) defined by neuroimaging procedures; and documentation of pathogenic gene variants (G) that cause or strongly predispose to Parkinson’s disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“α-synuclein positivity, detected by use of these assays, has been found in multiple biological samples, with the highest sensitivities in skin and CSF (0·92 [95% CI 0·87–0·95] and 0·90 [0·86–0·93], respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The data suggest that only skin biopsies, with specific methods (appendix pp 6–8), provide adequate diagnostic sensitivity and specificity to distinguish between patients with Parkinson’s disease, people with rapid eye movement (REM)-sleep behaviour disorder as a presumed early clinical manifestation of Parkinson’s disease, and healthy controls to be considered useful for a biological classification.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In our proposed criteria, evidence of any of the findings listed in table 2 is sufficient to define neurodegeneration in biologically suspected Parkinson’s disease (appendix pp 23–34).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, available methods have inadequate specificity to differentiate between people with Parkinson’s disease and those with other neurodegenerative forms of parkinsonism, and they focus on a limited number of neuroanatomical systems, chiefly the nigrostriatal dopaminergic projection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Reduced striatal uptake (typically asymmetric and with a caudal to rostral pattern) can be detected by use of molecular imaging markers for the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), or aromatic amino acid decarboxylase (F-dopa).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Reduced tracer uptake on metaiodobenzylguanidine SPECT provides sufficient evidence of peripheral cardiac sympathetic denervation to define the presence of neurodegeneration in people with Parkinson’s disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The first category includes the most likley fully penetrant variants: SNCA triplications, SNCA missense variants, and biallelic PRKN, PINK1, and PARK7 missense, nonsense, small indels, and copy number variants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The second category includes the genetic variants that confer a strong predisposition to Parkinson’s disease but with incomplete penetrance, such as SNCA duplications and variants in LRRK2, VPS35, and CHCHD2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The third category includes the genetic variants that result in intermediate and lower predispositions, including pathogenic GBA1 variants” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Biallelic variants in PRKN predispose to a Parkinson’s type synucleinopathy in approximately 20% of cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“No regulatory agencies, such as the US Food and Drug Administration, have formally approved the methods for defining the presence of pathological α-synuclein that we have endorsed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We emphasise the initial application of these criteria exclusively for research.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Clinical presentation - signs and symptoms
Motor symptoms: clinical subtypes and rate of progression

“Individuals with a diffuse malignant subtype (9%-16% of individuals with Parkinson disease) have prominent early motor and nonmotor symptoms, poor response to medication, and faster disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Individuals with mild motor-predominant Parkinson disease (49%-53% of individuals with Parkinson disease) have mild symptoms, a good response to dopaminergic medications (eg, carbidopa-levodopa, dopamine agonists), and slower disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“When individuals are categorized this way, the mild motor-predominant form is the most common (49%-53%), followed by the intermediate form (35%-39%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In a clinical-pathologic assessment of the 3 proposed subtypes, the diffuse malignant group had a mean (SD) time from diagnosis to first milestone (regular falls, wheelchair dependence, dementia, or residential/nursing home placement) of 3.5 (3.2) years, compared with 8.2 (5.3) years for the intermediate form and 14.3 (5.7) years for the mild motor-predominant form.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Mean (SD) survival after diagnosis was 8.1 (5.4) years for the diffuse malignant group, 13.2 (6.7) years for the intermediate subtype, and 20.2 (7.8) years for the mild motor-predominant form.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Motor symptoms: postural instability and freezing of gait
Freezing of gait: motor fluctuations and levodopa dose as risk factors

“Thus, 232 patients whose PD diagnosis remained unchanged were eligible for this long-term study of FOG in PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Mean (SD) age at motor onset was 64.9 (9.9) years and mean age at baseline was 73.5 (8.4) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The majority of patients (75%) had mild to moderate disease (HY stage ≤3) at study entry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We found that higher doses of levodopa, but not dopamine agonists, at baseline were a significant predictor of new-onset FOG during follow-up in a dose-dependent fashion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For a 100 mg increase in levodopa dose at baseline, the risk of incident FOG during the 12-year study period increased with 30%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We found that non-freezers who presented with motor fluctuations at study entry were at more than 3-fold increased risk to develop incident FOG during the 12-year follow-up period as compared with patients without motor fluctuations at baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This finding also implies that motor fluctuations not only co-exist but may precede the onset of FOG in PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In contrast, dyskinesias at baseline were associated with a statistically non-significant but still more than 60% reduced risk of incident FOG during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Finally, FOG was assessed by history using a single item derived from the UPDRS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Baseline variable (participants without freezing of gait at baseline)Odds ratio for incident freezing of gait (95% CI)p-value
Age at onset, per 10 years increase“1.33 (0.89–2.00)”View highlighted excerpt for this quote“0.161”View highlighted excerpt for this quote
Disease duration, per 10 years increase“1.07 (0.41–2.78)”View highlighted excerpt for this quote“0.888”View highlighted excerpt for this quote
Female sex“0.95 (0.52–1.74)”View highlighted excerpt for this quote“0.872”View highlighted excerpt for this quote
UPDRS motor score, per 10 points increase“1.32 (0.94–1.86)”View highlighted excerpt for this quote“0.115”View highlighted excerpt for this quote
Psychosis“5.97 (0.71–49.93)”View highlighted excerpt for this quote“0.099”View highlighted excerpt for this quote
MMSE, per 5 points increase“1.13 (0.80–1.61)”View highlighted excerpt for this quote“0.486”View highlighted excerpt for this quote
Levodopa dose (levodopa-equivalent), per 100 mg increase“1.30 (1.07–1.58)”View highlighted excerpt for this quote“0.009”View highlighted excerpt for this quote
Dopamine agonist dose (levodopa-equivalent), per 100 mg increase“1.13 (0.76–1.68)”View highlighted excerpt for this quote“0.558”View highlighted excerpt for this quote
Dyskinesias“0.39 (0.15–1.05)”View highlighted excerpt for this quote“0.062”View highlighted excerpt for this quote
Motor fluctuations“3.45 (1.08–11.02)”View highlighted excerpt for this quote“0.036”View highlighted excerpt for this quote
Follow-up time, per year increase“1.11 (1.02–1.22)”View highlighted excerpt for this quote“0.023”View highlighted excerpt for this quote
Freezing of gait: clinical features associated with freezing of gait during 12 years of follow-up
Variable at each visit (all participants)Odds ratio for freezing of gait (95% CI)p-value
Age at onset, per 10 years increase“1.32 (1.00–1.75)”View highlighted excerpt for this quote“0.052”View highlighted excerpt for this quote
Disease duration, per 10 years increase“1.38 (0.88–2.18)”View highlighted excerpt for this quote“0.158”View highlighted excerpt for this quote
Female sex“0.74 (0.49–1.13)”View highlighted excerpt for this quote“0.166”View highlighted excerpt for this quote
UPDRS motor score, per 10 points increase“1.46 (1.25–1.71)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Psychosis“1.85 (1.12–3.05)”View highlighted excerpt for this quote“0.016”View highlighted excerpt for this quote
MMSE, per 5 points increase“0.94 (0.78–1.13)”View highlighted excerpt for this quote“0.521”View highlighted excerpt for this quote
Levodopa dose (levodopa-equivalent), per 100 mg increase“1.12 (1.03–1.21)”View highlighted excerpt for this quote“0.006”View highlighted excerpt for this quote
Dopamine agonist dose (levodopa-equivalent), per 100 mg increase“1.16 (0.87–1.55)”View highlighted excerpt for this quote“0.303”View highlighted excerpt for this quote
Dyskinesias“1.88 (1.14–3.09)”View highlighted excerpt for this quote“0.013”View highlighted excerpt for this quote
Motor fluctuations“1.68 (1.05–2.68)”View highlighted excerpt for this quote“0.030”View highlighted excerpt for this quote
Motor fluctuations: cumulative incidence in a population-based incident cohort
Motor complications: point prevalence and cumulative incidence by year of follow-up in drug-naive participants
Measure1 year2 years3 years4 years5 years
Any motor complications: point prevalence, %“10.9”View highlighted excerpt for this quote“13.6”View highlighted excerpt for this quote“22.8”View highlighted excerpt for this quote“23.2”View highlighted excerpt for this quote“38.0”View highlighted excerpt for this quote
Any motor complications: cumulative incidence, %“14.3”View highlighted excerpt for this quote“24.3”View highlighted excerpt for this quote“32.8”View highlighted excerpt for this quote“40.7”View highlighted excerpt for this quote“52.4”View highlighted excerpt for this quote
Motor fluctuations: point prevalence, %“7.7”View highlighted excerpt for this quote“10.2”View highlighted excerpt for this quote“18.1”View highlighted excerpt for this quote“17.1”View highlighted excerpt for this quote“31.0”View highlighted excerpt for this quote
Motor fluctuations: cumulative incidence, %“10.6”View highlighted excerpt for this quote“19.0”View highlighted excerpt for this quote“26.5”View highlighted excerpt for this quote“33.9”View highlighted excerpt for this quote“42.9”View highlighted excerpt for this quote
Dyskinesias: point prevalence, %“3.8”View highlighted excerpt for this quote“4.5”View highlighted excerpt for this quote“5.2”View highlighted excerpt for this quote“9.8”View highlighted excerpt for this quote“12.7”View highlighted excerpt for this quote
Dyskinesias: cumulative incidence, %“6.3”View highlighted excerpt for this quote“9.5”View highlighted excerpt for this quote“12.7”View highlighted excerpt for this quote“18.0”View highlighted excerpt for this quote“24.3”View highlighted excerpt for this quote
Concomitant dyskinesias and motor fluctuations: point prevalence, %“0.5”View highlighted excerpt for this quote“1.1”View highlighted excerpt for this quote“0.5”View highlighted excerpt for this quote“3.7”View highlighted excerpt for this quote“5.7”View highlighted excerpt for this quote
Concomitant dyskinesias and motor fluctuations: cumulative incidence, %“2.6”View highlighted excerpt for this quote“4.2”View highlighted excerpt for this quote“6.3”View highlighted excerpt for this quote“11.1”View highlighted excerpt for this quote“14.8”View highlighted excerpt for this quote
Levodopa use, %“41.5”View highlighted excerpt for this quote“56.8”View highlighted excerpt for this quote“67.1”View highlighted excerpt for this quote“78.7”View highlighted excerpt for this quote“84.2”View highlighted excerpt for this quote
Dopamine agonist use, %“44.8”View highlighted excerpt for this quote“47.7”View highlighted excerpt for this quote“48.6”View highlighted excerpt for this quote“53.7”View highlighted excerpt for this quote“53.8”View highlighted excerpt for this quote
Other dopaminergic medications, %“23.5”View highlighted excerpt for this quote“30.7”View highlighted excerpt for this quote“33.5”View highlighted excerpt for this quote“29.9”View highlighted excerpt for this quote“32.9”View highlighted excerpt for this quote
Total levodopa equivalent dose (SD)“252 (169)”View highlighted excerpt for this quote“333 (161)”View highlighted excerpt for this quote“424 (224)”View highlighted excerpt for this quote“514 (250)”View highlighted excerpt for this quote“587 (334)”View highlighted excerpt for this quote
Motor complications: baseline risk factors and levodopa dose in drug-naive participants

“We found that lower age but not gender was a strong and independent predictor of motor fluctuations, with a nearly 6-fold increased risk in patients younger than 60 years compared to those aged 80 or older.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For example, the cumulative 5-year incidence of motor fluctuations in patients aged >80 was 11% while it was 41% for patients aged 60–79 and 64% for patients below 60 years at baseline (Fig. 2a).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In contrast, gender was the most important independent predictor of dyskinesias, with an almost 3-fold increased risk in females.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We found that more severe parkinsonism at diagnosis (in the drug-naïve state) independently predicted early development of motor fluctuations and dyskinesias, suggesting that dopamine depletion is a principal underlying cause of both of these motor complications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A subgroup of patients (36/189) never used levodopa.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among these, only 5 (13.9%) experienced motor fluctuations, and 4 (11.1%) had dyskinesias.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The corresponding rates in levodopa-treated patients were 49.7% and 27.5%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This implies that actual levodopa dose rather than initial treatment with levodopa is crucial for the development of motor complications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, these data indicate that levodopa treatment in low doses should not be withheld in patients with early PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Outcome and factor (Cox regression)Hazard ratio95% CIp-value
Any motor complications: age at diagnosis, per year“0.97”View highlighted excerpt for this quote“0.95–0.99”View highlighted excerpt for this quote“p = 0.013”View highlighted excerpt for this quote
Any motor complications: female gender“1.84”View highlighted excerpt for this quote“1.23–2.77”View highlighted excerpt for this quote“p = 0.003”View highlighted excerpt for this quote
Any motor complications: baseline UPDRS motor score, per unit“1.04”View highlighted excerpt for this quote“1.01–1.06”View highlighted excerpt for this quote“p = 0.001”View highlighted excerpt for this quote
Any motor complications: time since motor onset, per year“0.97”View highlighted excerpt for this quote“0.86–1.09”View highlighted excerpt for this quote“p = 0.593”View highlighted excerpt for this quote
Motor fluctuations: age, per year“0.96”View highlighted excerpt for this quote“0.94–0.98”View highlighted excerpt for this quote“p = 0.001”View highlighted excerpt for this quote
Motor fluctuations: baseline UPDRS motor score, per unit“1.03”View highlighted excerpt for this quote“1.01–1.05”View highlighted excerpt for this quote“p = 0.016”View highlighted excerpt for this quote
Motor fluctuations: female vs. male gender“1.48”View highlighted excerpt for this quote“0.94–2.33”View highlighted excerpt for this quote“p = 0.087”View highlighted excerpt for this quote
Motor fluctuations: time since motor onset, per year“1.03”View highlighted excerpt for this quote“0.91–1.16”View highlighted excerpt for this quote“p = 0.675”View highlighted excerpt for this quote
Dyskinesias: female gender“2.73”View highlighted excerpt for this quote“1.49–4.98”View highlighted excerpt for this quote“p = 0.001”View highlighted excerpt for this quote
Dyskinesias: baseline UPDRS motor score, per unit“1.05”View highlighted excerpt for this quote“1.02–1.08”View highlighted excerpt for this quote“p = 0.001”View highlighted excerpt for this quote
Dyskinesias: age, per year“0.98”View highlighted excerpt for this quote“0.95–1.02”View highlighted excerpt for this quote“p = 0.262”View highlighted excerpt for this quote
Dyskinesias: time since motor onset, per year“0.91”View highlighted excerpt for this quote“0.75–1.10”View highlighted excerpt for this quote“p = 0.332”View highlighted excerpt for this quote
Dyskinesias, model adding body weight: female gender“2.34”View highlighted excerpt for this quote“1.21–4.53”View highlighted excerpt for this quote“p = 0.011”View highlighted excerpt for this quote
Dyskinesias, model adding body weight: body weight, per kg“0.99”View highlighted excerpt for this quote“0.96–1.01”View highlighted excerpt for this quote“p = 0.239”View highlighted excerpt for this quote
Motor fluctuations: initial levodopa vs. initial dopamine agonist“1.84”View highlighted excerpt for this quote“1.09–3.10”View highlighted excerpt for this quote“p = 0.023”View highlighted excerpt for this quote
Dyskinesias: initial levodopa vs. initial dopamine agonist“0.88”View highlighted excerpt for this quote“0.42–1.85”View highlighted excerpt for this quote“p = 0.744”View highlighted excerpt for this quote
Motor fluctuations, model adding levodopa dose at onset: initial levodopa vs. initial dopamine agonist“1.37”View highlighted excerpt for this quote“0.87–2.87”View highlighted excerpt for this quote“p = 0.137”View highlighted excerpt for this quote
Motor fluctuations, model adding levodopa dose at onset: levodopa dose, per 100 mg“1.13”View highlighted excerpt for this quote“1.01–1.26”View highlighted excerpt for this quote“p = 0.037”View highlighted excerpt for this quote
Dyskinesias, model adding levodopa dose at onset: levodopa dose, per 100 mg“1.28”View highlighted excerpt for this quote“1.16–1.42”View highlighted excerpt for this quote“p < 0.001”View highlighted excerpt for this quote
Motor complications: severity and reversal on oral therapy within 5 years of diagnosis

“Motor fluctuations were predictable in the majority of patients, with no more than 5.1% experiencing unpredictable or sudden off periods, respectively, during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Few patients (≤5.1%) spent larger proportions (>25%) of their day in off.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Similarly, few patients (≤3.8%) experienced dyskinesias larger proportions of their day and very few rated their dyskinesias as severe (≤0.6%) or painful (≤1.8%) within the first 5 years of diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of 78 patients who had experienced motor fluctuations during follow-up, 29 did not so at study end, indicating reversal in 37%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with persistent motor fluctuations were younger than those in whom motor fluctuations reversed on oral treatment (62.3 (SD 9.1) vs. 68.8 (SD 6.9) years, p = 0.001), but did not differ in gender, baseline motor severity, or LED at final visit (all p > 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nineteen of the 39 had no dyskinesias at final visit, indicating reversal in 49%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients whose dyskinesias reversed did not differ from those with persistent dyskinesias in terms of age, gender, baseline motor severity or LED at final visit (all p > 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“No patients were considered in need of advanced, device-aided therapies by their study neurologists during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A further caveat of our observation of substantial reversal is that follow-up was limited to the first 5 years of the disease, which may be regarded a relative limitation of our study given the slowly progressive nature of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Motor complications: onset of OFF periods and frequency and severity of dyskinesia
Motor fluctuations: early-morning OFF periods and associated non-motor symptoms

“We report data from a consecutive series of 320 patients with a mean age of 70.0 years (range: 42–90 years) and a mean disease duration of 7.0 years (range: 0–24 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The results demonstrate that EMO periods are common and occur in 59.7% of subjects across all disease stages in line with other reports.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, importantly, in 88.0% of those, EMOs were found to be associated with NMS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“with a mean disease duration of 8.0 years (range: 0–24) and a median H&Y stage of 3.0 (range: 1.0–5.0)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“129 patients (40.3%), mean age 70.7 years (range: 42–90), mean disease duration of 5.5 years (range: 0–20) and a median H&Y stage of 2.5 (range: 1.0–5.0) reported no EMO.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The predominant NMS associated with EMO were urinary urgency, anxiety, dribbling of saliva, pain, low mood, limb paresthesia and dizziness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The most common NMS during EMO included urinary urgency (61.3% of all EMO positive cases), anxiety (49.7%), dribbling of saliva (46.6%), pain (46.6%), low mood (45.5%) or paresthesia (42.6%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In some patients these NMS were exclusive to the morning and did not reoccur throughout the day (pain in 23.4%, urgency in 23.3%, anxiety in 20.6%, dribbling of saliva in 18.6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We found that the clinical characteristics of the EMO positive and the EMO negative group match quite closely in terms of age, but differ slightly in H&Y and noticeably in duration of disease, both being higher in the EMO positive group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This suggests that EMO is more likely to occur with advanced motor disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“An important issue was that prior to this study these NMS were never discussed by patients with any healthcare professionals although they were intrusive and have an adverse effect on QoL” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The definition of EMO and NMS were arbitrary and NMS were recorded in a retrospective fashion based on the recollection of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Non-motor symptoms: overall prevalence and most frequent symptoms

“We found that 98.6% of patients with PD reported the presence of NMSs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The most common were as follows: fatigue (58%), anxiety (56%), leg pain (38%), insomnia (37%), urgency and nocturia (35%), drooling of saliva and difficulties in maintaining concentration (31%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Mean (SD) number of NMS per patient was 7.8 (4.9), ranging from 0 to 32.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Frequency of NMS increased along with the disease duration and severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We performed a multicenter survey using a semistructured interview in 1,072 consecutive patients with Parkinson’s disease (PD) enrolled during 12 months in 55 Italian centers to assess the prevalence of nonmotor symptoms (NMSs), their association with cognitive impairment, and the impact on patients’ quality of life (QoL).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“There were 647 (60.4%) males with a mean age of 66.8 (SD, 9.6) years, and 425 (39.6%) females with a mean age of 68.2 (SD, 9.1) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Dopaminergic treatment was as follows: levodopa (N = 189 patients, 17.6%), dopamine agonists (N = 199 patients, 18.6%), or both (N = 577 patients, 53.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“NMS in the psychiatric domain were the most frequent (67%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Pain, fatigue, and psychiatric NMSd were significantly more prevalent in women, namely 67.5, 65.9, and 73.9%, respectively, versus 56.6, 53.0, and 62.1% in men (Chi-square test, P < 0.0042, with Bonferroni’s correction).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Eleven percent (N = 119) of patients with PD had MMSE score lower than 23.8.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Cognitive impairment (MMSE ≤ 23.8) was associated with greater frequency of apathy, attention/memory, fatigue, psychiatric, and respiratory features (Fisher exact Test; P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“When patients were asked about NMS at PD onset, joint/muscular pain (298; 27.8%), anxiety (272; 25.4%), fatigue (252; 23.5%), and depression (240; 22.4%) were the most frequently recalled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In particular, psychiatric NMS, mainly anxiety and depression, were reported by 61.1% of patients at HY stage 1, representing the most common NMS in early disease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We acknowledge that our study has two major limitations: (1) lack of normal controls to assess differences with PD, (2) recruitment of patients mainly in early stages of disease, as revealed by the low mean score of the UPDRS-part III scale (mean = 24.2), the low median stage of the Hoehn and Yahr scale (2), and the relative short mean disease duration (5.1 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Non-motor symptoms: prevalence by domain and Hoehn and Yahr stage
Non-motor symptom domainAll stages (N = 1,072), n (%)Hoehn and Yahr 1 (N = 167), n (%)Hoehn and Yahr 1.5 to 2 (N = 515), n (%)Hoehn and Yahr 2.5 to 3 (N = 325), n (%)Hoehn and Yahr 4 to 5 (N = 49), n (%)
Gastrointestinal“654 (61.0)”View highlighted excerpt for this quote“76 (45.5)”View highlighted excerpt for this quote“280 (54.4)”View highlighted excerpt for this quote“250 (76.9)”View highlighted excerpt for this quote“36 (73.5)”View highlighted excerpt for this quote
Pain“653 (60.9)”View highlighted excerpt for this quote“85 (50.9)”View highlighted excerpt for this quote“302 (58.6)”View highlighted excerpt for this quote“218 (67.1)”View highlighted excerpt for this quote“39 (79.6)”View highlighted excerpt for this quote
Urinary“614 (57.3)”View highlighted excerpt for this quote“72 (43.1)”View highlighted excerpt for this quote“266 (51.7)”View highlighted excerpt for this quote“222 (68.3)”View highlighted excerpt for this quote“44 (89.8)”View highlighted excerpt for this quote
Cardiovascular“158 (14.7)”View highlighted excerpt for this quote“22 (13.2)”View highlighted excerpt for this quote“70 (13.6)”View highlighted excerpt for this quote“53 (16.3)”View highlighted excerpt for this quote“11 (22.5)”View highlighted excerpt for this quote
Sleep“687 (64.1)”View highlighted excerpt for this quote“80 (47.9)”View highlighted excerpt for this quote“312 (60.6)”View highlighted excerpt for this quote“245 (75.4)”View highlighted excerpt for this quote“40 (81.6)”View highlighted excerpt for this quote
Fatigue“623 (58.1)”View highlighted excerpt for this quote“63 (37.7)”View highlighted excerpt for this quote“291 (56.5)”View highlighted excerpt for this quote“224 (68.9)”View highlighted excerpt for this quote“40 (81.6)”View highlighted excerpt for this quote
Apathy“328 (30.6)”View highlighted excerpt for this quote“41 (24.6)”View highlighted excerpt for this quote“138 (26.8)”View highlighted excerpt for this quote“119 (36.6)”View highlighted excerpt for this quote“24 (49.0)”View highlighted excerpt for this quote
Attention/memory“479 (44.7)”View highlighted excerpt for this quote“63 (37.7)”View highlighted excerpt for this quote“208 (40.4)”View highlighted excerpt for this quote“168 (51.7)”View highlighted excerpt for this quote“32 (65.3)”View highlighted excerpt for this quote
Skin“260 (24.3)”View highlighted excerpt for this quote“24 (14.4)”View highlighted excerpt for this quote“102 (19.8)”View highlighted excerpt for this quote“112 (34.5)”View highlighted excerpt for this quote“16 (32.7)”View highlighted excerpt for this quote
Psychiatric“716 (66.8)”View highlighted excerpt for this quote“102 (61.1)”View highlighted excerpt for this quote“326 (63.3)”View highlighted excerpt for this quote“238 (73.2)”View highlighted excerpt for this quote“41 (83.7)”View highlighted excerpt for this quote
Respiratory“191 (17.8)”View highlighted excerpt for this quote“16 (9.6)”View highlighted excerpt for this quote“80 (15.5)”View highlighted excerpt for this quote“74 (22.8)”View highlighted excerpt for this quote“15 (30.6)”View highlighted excerpt for this quote
Miscellaneous“515 (48.0)”View highlighted excerpt for this quote“62 (37.1)”View highlighted excerpt for this quote“247 (48.0)”View highlighted excerpt for this quote“168 (51.7)”View highlighted excerpt for this quote“29 (59.2)”View highlighted excerpt for this quote
Non-motor symptoms: frequency by domain and change with disease progression

“Select nonmotor symptoms (hyposmia, rapid eye movement sleep behavior disorder, depression, constipation) start in prodromal Parkinson disease, but the nonmotor symptom burden increases as Parkinson disease progresses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Sensory symptoms include hyposmia (occurring in >90% of individuals with Parkinson disease), visual disturbances (22%-78%), and somatosensory dysfunction and pain (30%-85%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Autonomic symptoms include constipation, orthostatic hypotension, and urinary dysfunction (eg, nocturia, urgency, frequency), all increasing in frequency with disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Neuropsychiatric symptoms include anxiety (60%), apathy (60%), and depression (35%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Psychosis occurs in approximately 40% of individuals with Parkinson disease, usually in later stages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“An estimated 30% to 50% of individuals with Parkinson disease have rapid eye movement sleep behavior disorder.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Psychiatric symptoms: depression prevalence by study setting and diagnostic method

“For major depressive disorder, population studies report significantly lower prevalences than studies in outpatient samples” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Studies in hospital inpatient settings report significantly higher prevalences than studies in the population, general practices, outpatient settings, and nursing homes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The reported prevalence of major depressive disorder in studies using a (semi) structured interview to establish DSM criteria ranges from 2.3% to 55.6% with a weighted mean of 19%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In studies using DSM criteria without a structured interview the prevalence rates of major depressive disorder ranges from 2.9% to 7.7% with a weighted mean of 7%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Clinically significant depressive symptoms were present in 2.7% to 57.8% with a weighted mean of 33% in studies using a (semi) structured interview, 7.3% to 47% with a weighted mean of 27% in studies using DSM criteria, and in 13% to 89% with a weighted mean of 42% in studies using a cut-off on a depression rating scale.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Especially the fact that PD patients may be effectively treated with an antidepressant for their depressive disorder, and hence not be recognized as having suffered from depression, may lead to under-reporting in this review.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Psychiatric symptoms: anxiety

“The average point prevalence of anxiety disorders in PD was 31%, with nonepisodic anxiety being more prevalent than episodic anxiety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Based on anxiety rating scale cutoff scores, clinically significant anxiety symptoms were present in a weighted average of 25.7%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 39 studies were in outpatient settings, often in movement disorder clinics, and 5 were population based.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 49 studies included in the qualitative synthesis, 45 met the cut-off score of 14 points on the QUADAS tool (92%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This is a substantial percentage that exceeds the average point prevalence of depressive disorders in PD (17%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A large community survey from the World Health Organization found a 12-month prevalence of 8.3% of any anxiety disorder.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, an extensive review of epidemiological surveys on anxiety disorders in the general population found a 12-month prevalence of panic disorder, with a range of 0.7% to 3.1%, GAD 0.2% to 4.3%, and social phobia 0.6% to 7.9%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Most of the studies were conducted at specialized movement disorder clinics where they may encounter more complex patients with a higher prevalence of anxiety disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, studies have indicated that still more than half of clinically significant anxiety cases are not recognized by clinicians, and therefore anxiety is undertreated both in PD and in the general elderly population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Psychiatric symptoms: anxiety disorder prevalence by DSM subtype
Anxiety disorderNumber of studiesTotal participants with Parkinson's diseaseRange, %Weighted prevalence, %
Any anxiety disorder“13”View highlighted excerpt for this quote“2399”View highlighted excerpt for this quote“24.5–46.7”View highlighted excerpt for this quote“31.0”View highlighted excerpt for this quote
Generalized anxiety disorder“14”View highlighted excerpt for this quote“2080”View highlighted excerpt for this quote“2.6–52.5”View highlighted excerpt for this quote“14.1”View highlighted excerpt for this quote
Panic disorder“13”View highlighted excerpt for this quote“2040”View highlighted excerpt for this quote“2.3–30.0”View highlighted excerpt for this quote“6.8”View highlighted excerpt for this quote
Agoraphobia“7”View highlighted excerpt for this quote“1684”View highlighted excerpt for this quote“1.6–15.5”View highlighted excerpt for this quote“8.6”View highlighted excerpt for this quote
Social phobia“11”View highlighted excerpt for this quote“1823”View highlighted excerpt for this quote“6.8–50.0”View highlighted excerpt for this quote“13.8”View highlighted excerpt for this quote
Other phobia“4”View highlighted excerpt for this quote“705”View highlighted excerpt for this quote“2.4–16.7”View highlighted excerpt for this quote“13.0”View highlighted excerpt for this quote
Obsessive-compulsive disorder“9”View highlighted excerpt for this quote“1270”View highlighted excerpt for this quote“0.3–13.3”View highlighted excerpt for this quote“2.6”View highlighted excerpt for this quote
Anxiety not otherwise specified“4”View highlighted excerpt for this quote“766”View highlighted excerpt for this quote“2.4–22.0”View highlighted excerpt for this quote“13.3”View highlighted excerpt for this quote
Two or more comorbid anxiety disorders, among participants diagnosed with anxiety“4”View highlighted excerpt for this quote“1337”View highlighted excerpt for this quote“23.7–37.0”View highlighted excerpt for this quote“31.1”View highlighted excerpt for this quote
Clinically relevant anxiety symptoms by rating scale cutoff“27”View highlighted excerpt for this quote“7212”View highlighted excerpt for this quote“6.9–55.0”View highlighted excerpt for this quote“25.7”View highlighted excerpt for this quote
Autonomic symptoms: constipation and Parkinson's disease risk by study subgroup
SubgroupNumber of studiesPooled estimate (95% CI)I2 (%)
Study design: case-control“11”View highlighted excerpt for this quote“2.21 [1.72–2.83]”View highlighted excerpt for this quote“86”View highlighted excerpt for this quote
Study design: cohort“6”View highlighted excerpt for this quote“2.57 [2.17–3.05]”View highlighted excerpt for this quote“48”View highlighted excerpt for this quote
Location: United States“5”View highlighted excerpt for this quote“2.78 [1.57–4.92]”View highlighted excerpt for this quote“92”View highlighted excerpt for this quote
Location: Europe“6”View highlighted excerpt for this quote“2.10 [1.44–3.06]”View highlighted excerpt for this quote“68”View highlighted excerpt for this quote
Location: China“3”View highlighted excerpt for this quote“2.24 [2.03–2.49]”View highlighted excerpt for this quote“0.0”View highlighted excerpt for this quote
Location: other“3”View highlighted excerpt for this quote“2.75 [1.14–6.63]”View highlighted excerpt for this quote“85”View highlighted excerpt for this quote
Prodromal duration: 10 years or more“11”View highlighted excerpt for this quote“2.06 [1.61–2.63]”View highlighted excerpt for this quote“87”View highlighted excerpt for this quote
Prodromal duration: 5 to 10 years“3”View highlighted excerpt for this quote“2.43 [1.97–3.00]”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote
Prodromal duration: 5 years or less“3”View highlighted excerpt for this quote“5.00 [3.59–6.97]”View highlighted excerpt for this quote“0.0”View highlighted excerpt for this quote
Diagnosis of constipation: frequency of bowel movement“5”View highlighted excerpt for this quote“3.60 [2.24–5.78]”View highlighted excerpt for this quote“81”View highlighted excerpt for this quote
Diagnosis of constipation: medical record“7”View highlighted excerpt for this quote“2.20 [1.77–2.74]”View highlighted excerpt for this quote“68”View highlighted excerpt for this quote
Diagnosis of constipation: other“5”View highlighted excerpt for this quote“1.80 [1.36–2.38]”View highlighted excerpt for this quote“78”View highlighted excerpt for this quote
Bulbar symptoms: oropharyngeal dysphagia

“The 10 studies with subjective outcomes were statistically heterogeneous (p < 0.001), with prevalence rates ranging from 16% to 55%, giving a pooled prevalence estimate with random effect analysis of 35% (95% CI 28–41).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The four studies with objective measurements were statistically homogeneous (p = 0.23), with prevalence rates between 72% and 87%, giving a pooled prevalence estimate of 82% (95% CI 77–87).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In controls the pooled subjective prevalence was 9% (95% CI 2–17), while the pooled objective prevalence was 23% (95% CI 13–32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The pooled relative risk was 3.2 for both subjective outcomes (95% CI 2.32–4.41) and objective outcomes (95% CI 2.08–4.98).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All studies used in our analysis dealt with community-dwelling patients with idiopathic PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, PD patients are three times more likely to have swallowing disorders than healthy controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We even included two studies that reported both subjective and objective judgments within the same patient population; both studies identified much higher prevalence rates for objective ratings compared to subjective ratings (30% vs. 72% in one study; and 37% vs. 84% in the other study)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, there was a significant correlation between subjective dysphagia and disease severity according to five studies” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For example, when focusing on the three largest studies (>400 patients), the study with the lowest dysphagia prevalence included only 5% of patients with late stage PD (Hoehn & Yahr stage 4 or 5)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“whereas the study with the highest dysphagia prevalence (55%) included 20% of patients with late stage PD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This is further corroborated by one study which included only late stage PD patients (which we excluded from the meta-analysis), where subjective dysphagia was reported to be present in no less than 68% of patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This implies that the prevalence is likely to be higher for the total population, including hospitalized and institutionlized PD patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Although esophageal dysphagia has been reported to be present in 60–70% of PD patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“While most questionnaires included in this review investigated oropharyngeal complaints, others (e.g. SCOPA-AUT and PD NMSQuest) did not differentiate between oropharyngeal and esophageal dysphagia, so the possibility that esophageal complaints have contributed to dysphagia in some PD patients cannot be excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Sleep symptoms: REM sleep behavior disorder

“A total of 28 studies with 6869 PD cases were deemed eligible and included in our meta-analysis based on the inclusion and exclusion criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The RBD prevalence rate ranged from 19 to 70 % with an estimated random-effects pooled prevalence of 42.3 % (95 % CI 37.4–47.1 %) as shown in Fig. 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Besides, the shape of funnel plot for our meta-analysis seemed symmetrical, and Begg’s test (z = 1.15, P = 0.252) indicated no statistical evidence of publication bias among studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“And in 11 articles, RBD was diagnosed according to ICSD-2, which included both REM sleep without atonia (RWA) on polysomnography (PSG) and violent dream-enactment behavior” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“As we expected, studies that used a stricter diagnosis criteria would report a higher prevalence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In our subgroup analysis, the difference of prevalence is not significant between the studies with the ICSD-RBD and ICSD-2 criteria (44 vs. 48.5 %).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In meta-regression analysis, we found that the diagnosis criteria of RBD (P = 0.016) and age of PD patients (P = 0.019) were two important causes for the heterogeneity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Older age and longer duration are risk factors for RBD in PD, while male gender is not a risk factor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Second, our meta-analysis is based on cross-sectional designs, and then, the inferences about causality cannot be made.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

SubgroupNumber of studiesEstimated prevalence (%; 95% CI)I2 (%)
Diagnosis: REM Sleep Behavior Disorder Screening Questionnaire“10”View highlighted excerpt for this quote“35.0 (29.0–41.0)”View highlighted excerpt for this quote“92.4”View highlighted excerpt for this quote
Diagnosis: ICSD minimal criteria (clinical interview)“7”View highlighted excerpt for this quote“44.0 (31.6–56.5)”View highlighted excerpt for this quote“96.6”View highlighted excerpt for this quote
Diagnosis: ICSD-2 (polysomnography)“11”View highlighted excerpt for this quote“48.5 (40.6–56.4)”View highlighted excerpt for this quote“81.9”View highlighted excerpt for this quote
Age 60 years or less“11”View highlighted excerpt for this quote“35.7 (25.6–45.8)”View highlighted excerpt for this quote“96.7”View highlighted excerpt for this quote
Age more than 60 years“17”View highlighted excerpt for this quote“46.4 (41.7–51.2)”View highlighted excerpt for this quote“86.5”View highlighted excerpt for this quote
Ethnicity: Caucasian“19”View highlighted excerpt for this quote“42.2 (36.5–48.0)”View highlighted excerpt for this quote“92.5”View highlighted excerpt for this quote
Ethnicity: Asian“9”View highlighted excerpt for this quote“42.2 (32.8–51.6)”View highlighted excerpt for this quote“95.1”View highlighted excerpt for this quote
Disease duration 6 years or less“16”View highlighted excerpt for this quote“41.2 (34.7–47.6)”View highlighted excerpt for this quote“92.8”View highlighted excerpt for this quote
Disease duration more than 6 years“12”View highlighted excerpt for this quote“43.7 (36.1–51.2)”View highlighted excerpt for this quote“94.1”View highlighted excerpt for this quote
Male participants 50% or less“8”View highlighted excerpt for this quote“41.1 (31.2–51.1)”View highlighted excerpt for this quote“95.0”View highlighted excerpt for this quote
Male participants more than 50%“20”View highlighted excerpt for this quote“42.7 (37.0–48.5)”View highlighted excerpt for this quote“93.1”View highlighted excerpt for this quote
Publication year 2010 to 2012“10”View highlighted excerpt for this quote“37.3 (30.3–44.2)”View highlighted excerpt for this quote“86.9”View highlighted excerpt for this quote
Publication year 2013 to 2016“18”View highlighted excerpt for this quote“44.8 (38.8–50.8)”View highlighted excerpt for this quote“94.3”View highlighted excerpt for this quote
Estimation of prevalence was the primary objective“13”View highlighted excerpt for this quote“37.8 (32.2–43.4)”View highlighted excerpt for this quote“89.0”View highlighted excerpt for this quote
Other primary objective“15”View highlighted excerpt for this quote“46.0 (38.2–53.9)”View highlighted excerpt for this quote“95.1”View highlighted excerpt for this quote
Sample size 400 or less“21”View highlighted excerpt for this quote“43.2 (36.1–50.3)”View highlighted excerpt for this quote“91.1”View highlighted excerpt for this quote
Sample size more than 400“7”View highlighted excerpt for this quote“40.5 (32.5–48.5)”View highlighted excerpt for this quote“97.0”View highlighted excerpt for this quote
Moderator (meta-regression)Meta-regression coefficient95% CIP
Year of publication“0.0177002”View highlighted excerpt for this quote“−0.0128755 to 0.048276”View highlighted excerpt for this quote“0.257”View highlighted excerpt for this quote
Ethnicity“−0.0020544”View highlighted excerpt for this quote“−0.1136242 to 0.1095155”View highlighted excerpt for this quote“0.971”View highlighted excerpt for this quote
Primary objective of the study“0.0785029”View highlighted excerpt for this quote“−0.0216877 to 0.1786934”View highlighted excerpt for this quote“0.125”View highlighted excerpt for this quote
Sample size“8.97e−06”View highlighted excerpt for this quote“−0.0001337 to 0.0001516”View highlighted excerpt for this quote“0.902”View highlighted excerpt for this quote
Diagnostic criteria for RBD“0.0677628”View highlighted excerpt for this quote“0.0125304 to 0.1229951”View highlighted excerpt for this quote“0.016”View highlighted excerpt for this quote
Age“0.0122493”View highlighted excerpt for this quote“0.0020541 to 0.0224445”View highlighted excerpt for this quote“0.019”View highlighted excerpt for this quote
Male ratio“−0.0012102”View highlighted excerpt for this quote“−0.005528 to 0.0031076”View highlighted excerpt for this quote“0.583”View highlighted excerpt for this quote
Duration of Parkinson's disease“0.0000548”View highlighted excerpt for this quote“−0.0221684 to 0.022278”View highlighted excerpt for this quote“0.996”View highlighted excerpt for this quote
Long-term morbidity
Dementia, dependency, and nursing home placement at 15 and 20 years

“One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicentre Study of Parkinson’s disease have survived.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The average follow-up for the 52 surviving patients was 15.2 years (SD = 0.7 years); mean prestudy disease duration 23.5 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Their average age at presentation was 56 years (SD = 7.9 years) compared to 62 years for the total initial group and their average age at follow-up was 71 years (SD = 7.9; range, 55–86 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Falls occur in 81% of patients, and 23% sustained fractures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean score of the MMSE was 22.5 (SD = 8.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of 46 patients, 22 tested scored ≥ 26 of 30, and 11 of 46 patients scored <20.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“No patient is still employed, and 40% of patients live in aged care facilities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 30 (58%) were deemed unable to live alone due to physical and/or cognitive disabilities” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Forty-two patients (81%) had fallen due to their Parkinson’s disease with a mean onset of 11.5 years (SD = 2.8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 7 people had fractured their femur neck, 1 a humerus, 1 her jaw, and 4 various other bones due to falling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A striking finding in this study was that 48% of our patients who survived 15 years were demented; this rate compares to a prevalence of 4.8% to 11% in general population studies of people of similar age” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The GDS was fully administered to 41 patients: the mean score was 11.7 of 30 (SD = 5.7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“There were 19 patients who scored <11 (not depressed), 19 who scored 11 to 20 (mildly depressed), and 3 people scored >20 (definite depression).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Formed visual hallucinations were reported at some time by 26 of 52 (50%) by 15 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean time to onset of hallucinations was 10.7 years (SD = 4.0).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Orthostatic hypotension (OR, 2.49; 95% CI, 1.08–5.78) remained as the significant factor associated with hallucinations multivariately.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Only 7 of 136 (5%) continued to follow a less troublesome course without severe fluctuations, significant imbalance, or dementia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Thirty patients (15 men and 15 women) have survived to be included in the 20-year follow-up that ranged from 19.8 to 22 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Their average age is now 74 years (SD = 7.9), and was 54 years at presentation compared to 62 years for the initial total group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Dementia is present in 83% of 20-year survivors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Only one person lives independently and 48% are in nursing homes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At 20 years, the mean Hoehn and Yahr stage ‘‘on’’ was 4.2 and ‘‘off’’ was 4.6.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients lived there for a mean of 34 months (SD = 27) before death.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean activities of daily living score (UPDRS items 5–17) ‘‘on’’ was 19 (SD = 8) and ‘‘off’’ was 27 (SD = 8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Excessive daytime sleepiness is noted in 70%, falls have occurred in 87%, freezing in 81%, fractures in 35%, symptomatic postural hypotension in 48%, urinary incontinence in 71%, moderate dysarthria in 81%, choking in 48%, and hallucinations in 74%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Another 70 patients were demented before they died prior to 20 years, giving a total of 97 (75%) demented predeath.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Urinary incontinence occurred in 22 (71%), fecal incontinence in 5 (17%), and constipation requiring daily laxatives was present in 12 (40%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of the original cohort, 78 were known to have suffered visual hallucinations prior to death” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In this group, only 14/30 (47%) still see their neurologist after 20 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Motor complications and levodopa-unresponsive disability at 15 and 20 years

“Although approximately 95% have experienced L-dopa–induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The average dose of L-dopa for 49 patients was 734 mg per day (SD = 481) taken on average 4.4 times per day (SD = 2.0).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“By 15 years, 49 of 52 (94%) had experienced dyskinesia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In this group of survivors, the mean duration of treatment before the onset of dyskinesia was 5.3 years (SD = 3.6): 4.2 years (SD = 2.9) for the L-dopa group and 6.9 years (SD = 4.0) for the bromocriptine group, a significant difference (t test, P = 0.009).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Thus, 6 of 52 (12%) had experienced severe dyskinesia by 15 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Conversely, 28 of 52 (54%) did not consider their dyskinesia disabling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“End of dose failure was reported by 50 of 52 (96%) patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Mean duration of L-dopa treatment was 6.2 years (SD = 3.6) before the onset of end of dose failure: 5.8 years for the L-dopa group and 6.6 years for the bromocriptine group (t test, P = 0.36, not significant)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Predictable offs occurred in 44 of 52 (85%), unpredictable offs in 18 of 52 (35%), and sudden offs in 12 of 52 (23%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Offs occupied ≤ 25% of the day in 36 of 52 (69%), and 25 to 50% of the day in 7 of 52 (13%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nine patients were considered off for ≥ 75% of the day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All were demented: Stage 4 to 5 on low doses of L-dopa (mean 311 mg/day) or on no L-dopa (3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Dystonia, particularly involving the feet in the early morning had occurred in 29 of 52 (56%), mean onset being 4.1 years (SD = 3.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean onset time for the bromocriptine group was 6.0 years (SD = 1.7), but it was significantly earlier at 2.4 years (SD =1.7, t test, P = 0.002) for the L-dopa group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The major causes of disability in patients surviving for 15 or more years are falls, autonomic disturbance, neuropsychiatric symptoms, and dementia, aspects of the disease that are not improved by L-dopa.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Motor fluctuations and dyskinesia are common but are a less disabling aspect of the disease in the majority.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Clinical milestones: hallucinations, recurrent falls, dementia, and nursing home placement

“One or more milestones were reached in 53.0%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The risk of contracting a milestone condition during the study was independently predicted by two baseline factors: Higher age (age 70 years or more resulted in a hazard rate (HR) of 3.5 (95% confidence interval 2.3–5.5), p < 0.001) and presence of PD-MCI (HR 2.1 (1.3–3.4), p = 0.003).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In these models, we analyzed the baseline factors age, gender, UPDRS motor score, MADRS score and presence or absence of PD-MCI using Enter method.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of the patients who reached the milestones, visual hallucinations appeared after a median of 3.3 (interquartile range 1.3–4.9) years from diagnosis, recurrent falls after 3.8 (2.8–5.2) years, dementia after 4.0 (2.1–4.8) years and nursing home placement after 5.4 (3.9–6.7) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We recruited 185 patients with incident PD and monitored prospectively every six months through seven years for emergence and consequences of four clinical milestones.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The main reason for loss to follow-up was death; only 9 patients (4.9%) withdrew from study follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Median follow-up time was 7.0 (interquartile range (IQR) 6.8–7.1) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Visual hallucinations represented the earliest and most frequent milestone, and almost 40% had experienced hallucinations during 7 years of follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The two most frequent milestones, visual hallucinations and recurrent falls, were highly reversible (in 69.1% and 64.9%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among patients with reversible visual hallucinations, the RRs of experiencing recurrent falls, dementia and nursing home placement were 2.4 (1.4–4.0), 6.6 (3.3–13.2) and 3.5 (1.7–7.3)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with reversible recurrent falling status, the RRs of experiencing visual hallucinations, dementia and nursing home placement were 1.8 (1.2–2.8), 4.2 (2.4–7.3) and 4.4 (2.1–9.3), respectively (all p < 0.01), comparable to the overall RRs presented in Table 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Presence of any milestone was associated with occurrence of other milestones (relative risks 1.9–6.3; all p ≤ 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 34 PD patients (18.4%) died during the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The remaining 23 deaths were preceded by one or more milestone conditions in 69.6% of cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The median (IQR) time from visual hallucinations to death was 2.7 (1.3–4.6) years, whereas recurrent falls preceded death by 2.4 (1.3–2.6) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Development of one milestone condition resulted in a trend towards increased mortality (RR of death during the study 2.0 (0.9–4.7, p = 0.1)), and suffering two or more milestones resulted in an RR for death of 2.7 (1.1–6.5, p = 0.03).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Experiencing two or more milestones increased the risk of death during the study (relative risk 2.7, p = 0.03).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“No patients admitted to a nursing home ever returned to independent living, and death ensued after 2.1 years on average.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For example, the majority (67.6%) of PD patients with visual hallucinations were classified as still having mild disease according to the Hoehn and Yahr scale, whereas only 10.3% were classified as having severe disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Despite the long follow-up, most patients did not undergo all milestone conditions, and none of the milestones occurred in half or more of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Hip and non-vertebral fractures

“Overall, PD patients had an increased risk for both hip fractures (2.40, 95% CI 2.04 to 2.82) and non-vertebral fractures (1.80, 95% CI 1.60 to 2.01) compared to controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The relative risk for hip fractures was higher in men (2.93, 95% CI 2.05 to 4.18) than in women (1.81, 95% CI 1.61 to 2.04).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Seventeen studies (14 cohort and 3 case-control), with a total of 2,329,424 participants, were included in the meta-analysis for hip fractures” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, there was substantial heterogeneity between results of the studies (I2=87.4%, p value <0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The adjusted estimate using the trim and fill method was 2.26, 95% CI: 1.93 to 2.65.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nine cohort studies, with a total of 1,356,711 participants, were included in the meta-analysis for non-vertebral fractures” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The heterogeneity observed between the studies was not statistically significant (I2=30.1%, p value= 0.18).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, the effect size for non-vertebral fractures in male patients with PD (2.26, 95% CI: 1.37 to 3.73), was higher than the one in women (1.82, 95% CI: 1.33 to 2.48), but the confidence intervals overlapped.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This is a clinically important increased risk of hip fracture; for example, the risk is similar to the increased risk of hip fracture in analyses of patients who ever used corticosteroids (2.07 in female and 2.62 in male)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In a cross-sectional study, BMD was found to be 7% lower than in controls” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mortality rate of patients with this disorder has been reported to be doubled after a hip fracture compared with those without the disease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A recent study showed that only 40% of the PD patients diagnosed with fragility fractures were receiving evidence-based treatment for osteoporosis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The majority of the published studies have data from white/Caucasian population and were mainly oriented in Europe and the USA; therefore, this might have affected the results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The effect of PD medication would also be an interesting subgroup analysis, but it was not included in our priori analyses, so the data were not extracted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

SubgroupHip fracture: studiesHip fracture: pooled effect size (95% CI)Non-vertebral fracture: studiesNon-vertebral fracture: pooled effect size (95% CI)
Men“7”View highlighted excerpt for this quote“2.93 (2.05, 4.18)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“2.26 (1.37, 3.73)”View highlighted excerpt for this quote
Women“6”View highlighted excerpt for this quote“1.81 (1.61, 2.04)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“1.82 (1.33, 2.48)”View highlighted excerpt for this quote
Cohort studies“14”View highlighted excerpt for this quote“2.34 (1.98, 2.77)”View highlighted excerpt for this quoteNot applicableNot applicable
Case-control studies“3”View highlighted excerpt for this quote“3.42 (1.72, 6.79)”View highlighted excerpt for this quoteNot applicableNot applicable
Clinical diagnostic criteria reported“3”View highlighted excerpt for this quote“3.00 (1.86, 4.83)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“1.89 (1.37, 2.61)”View highlighted excerpt for this quote
Clinical diagnostic criteria not reported“14”View highlighted excerpt for this quote“2.37 (2.00, 2.79)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“1.82 (1.57, 2.10)”View highlighted excerpt for this quote
Diagnosis of Parkinson's disease“14”View highlighted excerpt for this quote“2.36 (1.98, 2.81)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“1.80 (1.59, 2.05)”View highlighted excerpt for this quote
Diagnosis of parkinsonism“3”View highlighted excerpt for this quote“2.46 (1.87, 3.26)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“1.87 (1.27, 2.76)”View highlighted excerpt for this quote
Asia“3”View highlighted excerpt for this quote“2.39 (2.02, 2.82)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“2.05 (1.71, 2.45)”View highlighted excerpt for this quote
Europe“8”View highlighted excerpt for this quote“2.32 (1.87, 2.89)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“1.57 (1.45, 1.71)”View highlighted excerpt for this quote
Oceania“1”View highlighted excerpt for this quote“1.45 (1.14, 1.84)”View highlighted excerpt for this quoteNot reportedNot reported
United States“5”View highlighted excerpt for this quote“3.03 (2.26, 4.05)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“1.86 (1.58, 2.19)”View highlighted excerpt for this quote
Burden of Parkinson's disease
Humanistic burden and health-related quality of life
Non-motor symptoms and health-related quality of life

“The sample was made up of 411 Parkinson’s disease patients, recruited in 12 movement disorders clinics across 10 countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Mean age (±standard deviation) was 64.48 (±9.92) years old, and disease duration was 8.07 (±5.75) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Higher scores mean poorer HRQoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For each group, PDQ-39 and EQ-5D means and standard deviations were calculated, and group differences were assessed by the Mann-Whitney test.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The Benjamini-Hochberg test for multiple comparisons was applied.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nocturia (68.4% of the sample), fatigue (65.9%), and dribbling saliva (56.7%), were the most frequent complaints.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean number of non-motor symptoms per patient was 11.80 ± 6.03 (range: 0–29), and there was a high correlation between the number of nonmotor symptoms and PDQ-39 and EQ-5D (Table 4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For each NMSS domain, patients with symptoms had significantly worse HRQoL scores than patients without symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“SCOPA-motor (total, motor examination, and activities of daily living subscales) reached the strongest relationship with the EQ-5D index (rS = from −0.58 to −0.67).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The correlation between NMSS and SCOPA-Motor was 0.43.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For each NMSS domain, patients with symptoms had significantly worse HRQoL than patients with no symptoms, except for the EQ-5D in the sexual dysfunction domain and the EQ-5D VAS in the urinary domain (Table 5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The corresponding models accounted for 53% (EQ-5D) and 59% (PDQ-39) of the variance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“NMSS score had the strongest influence on HRQoL as measured by the PDQ-39, whereas considering EQ5D, both SCOPA-motor examination and NMSS were the strongest predictors and almost equivalent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In the models that included the NMSS domains as independent variables, mood/apathy, sleep/fatigue, and miscellaneous domains were the most significant factors for both the PDQ-39 SI and the EQ-5D index, accounting for 50% and 38% of the variance, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Most of the patient population in the study was on dopaminergic therapy and, therefore, the impact of the motor manifestations may be neutralized by effective antiparkinsonian effect.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The results show that non-motor symptoms have, as a whole, a greater impact on HRQoL than motor symptoms and non-motor symptoms progression contributes importantly to HRQoL decline in patients with Parkinson's disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

NMSS domainWith symptoms, nWithout symptoms, nPDQ-39 SI, with symptoms, mean ± SDPDQ-39 SI, without symptoms, mean ± SDPDQ-39 SI, PEQ-5D index, with symptoms, mean ± SDEQ-5D index, without symptoms, mean ± SDEQ-5D index, PEQ-5D VAS, with symptoms, mean ± SDEQ-5D VAS, without symptoms, mean ± SDEQ-5D VAS, P
Cardiovascular“173”View highlighted excerpt for this quote“238”View highlighted excerpt for this quote“32.45 ± 17.85”View highlighted excerpt for this quote“24.79 ± 15.66”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“0.48 ± 0.37”View highlighted excerpt for this quote“0.62 ± 0.32”View highlighted excerpt for this quote“0.0001”View highlighted excerpt for this quote“61.49 ± 21.23”View highlighted excerpt for this quote“65.17 ± 23.01”View highlighted excerpt for this quote“0.05”View highlighted excerpt for this quote
Sleep/fatigue“356”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote“30.11 ± 16.80”View highlighted excerpt for this quote“14.48 ± 11.57”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“0.52 ± 0.35”View highlighted excerpt for this quote“0.79 ± 0.20”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“61.75 ± 21.77”View highlighted excerpt for this quote“75.74 ± 22.45”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Mood/apathy“310”View highlighted excerpt for this quote“100”View highlighted excerpt for this quote“31.31 ± 16.87”View highlighted excerpt for this quote“17.64 ± 13.01”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“0.50 ± 0.35”View highlighted excerpt for this quote“0.74 ± 0.27”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“61.66 ± 22.01”View highlighted excerpt for this quote“70.51 ± 21.21”View highlighted excerpt for this quote“0.0002”View highlighted excerpt for this quote
Perceptual problems/hallucinations“123”View highlighted excerpt for this quote“288”View highlighted excerpt for this quote“36.89 ± 17.25”View highlighted excerpt for this quote“24.22 ± 15.47”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“0.38 ± 0.39”View highlighted excerpt for this quote“0.63 ± 0.30”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“57.15 ± 25.19”View highlighted excerpt for this quote“66.40 ± 20.39”View highlighted excerpt for this quote“0.0004”View highlighted excerpt for this quote
Attention/memory“296”View highlighted excerpt for this quote“115”View highlighted excerpt for this quote“30.65 ± 16.93”View highlighted excerpt for this quote“21.27 ± 15.37”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“0.52 ± 0.36”View highlighted excerpt for this quote“0.66 ± 0.30”View highlighted excerpt for this quote“0.0005”View highlighted excerpt for this quote“61.35 ± 22.21”View highlighted excerpt for this quote“69.52 ± 21.58”View highlighted excerpt for this quote“0.0005”View highlighted excerpt for this quote
Gastrointestinal“302”View highlighted excerpt for this quote“109”View highlighted excerpt for this quote“31.02 ± 17.84”View highlighted excerpt for this quote“19.76 ± 10.92”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“0.49 ± 0.36”View highlighted excerpt for this quote“0.74 ± 0.23”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“61.00 ± 22.48”View highlighted excerpt for this quote“71.04 ± 20.16”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Urinary“338”View highlighted excerpt for this quote“73”View highlighted excerpt for this quote“29.52 ± 17.44”View highlighted excerpt for this quote“21.12 ± 12.97”View highlighted excerpt for this quote“0.0002”View highlighted excerpt for this quote“0.54 ± 0.36”View highlighted excerpt for this quote“0.66 ± 0.28”View highlighted excerpt for this quote“0.001”View highlighted excerpt for this quote“62.82 ± 22.56”View highlighted excerpt for this quote“67.38 ± 20.87”View highlighted excerpt for this quote“0.13”View highlighted excerpt for this quote
Sexual dysfunction“177”View highlighted excerpt for this quote“234”View highlighted excerpt for this quote“29.71 ± 15.97”View highlighted excerpt for this quote“26.75 ± 17.71”View highlighted excerpt for this quote“0.03”View highlighted excerpt for this quote“0.53 ± 0.34”View highlighted excerpt for this quote“0.58 ± 0.35”View highlighted excerpt for this quote“0.09”View highlighted excerpt for this quote“63.17 ± 21.92”View highlighted excerpt for this quote“63.94 ± 22.65”View highlighted excerpt for this quote“0.53”View highlighted excerpt for this quote
Miscellaneous“99”View highlighted excerpt for this quote“312”View highlighted excerpt for this quote“30.38 ± 17.36”View highlighted excerpt for this quote“20.61 ± 13.54”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“0.50 ± 0.36”View highlighted excerpt for this quote“0.73 ± 0.25”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote“61.61 ± 22.32”View highlighted excerpt for this quote“70.02 ± 21.20”View highlighted excerpt for this quote“0.0006”View highlighted excerpt for this quote
Multiple linear regression models of PDQ-39 and EQ-5D scores on motor and non-motor symptom measures
Model (dependent variable)Adjusted R² of the modelIndependent variableStandardized betatSig.
PDQ-39 SI“0.59”View highlighted excerpt for this quoteConstant (unstandardized value)“(23.76)”View highlighted excerpt for this quote“5.55”View highlighted excerpt for this quote“0.000”View highlighted excerpt for this quote
PDQ-39 SI“0.59”View highlighted excerpt for this quoteNMSS total“0.52”View highlighted excerpt for this quote“13.64”View highlighted excerpt for this quote“0.000”View highlighted excerpt for this quote
PDQ-39 SI“0.59”View highlighted excerpt for this quoteSCOPA-motor complications“0.20”View highlighted excerpt for this quote“4.81”View highlighted excerpt for this quote“0.000”View highlighted excerpt for this quote
PDQ-39 SI“0.59”View highlighted excerpt for this quoteSCOPA-motor examination“0.17”View highlighted excerpt for this quote“4.15”View highlighted excerpt for this quote“0.000”View highlighted excerpt for this quote
EQ-5D index“0.53”View highlighted excerpt for this quoteConstant (unstandardized value)“(0.83)”View highlighted excerpt for this quote“9.24”View highlighted excerpt for this quote“0.000”View highlighted excerpt for this quote
EQ-5D index“0.53”View highlighted excerpt for this quoteSCOPA-motor examination“−0.38”View highlighted excerpt for this quote“−9.11”View highlighted excerpt for this quote“0.000”View highlighted excerpt for this quote
EQ-5D index“0.53”View highlighted excerpt for this quoteNMSS total“−0.37”View highlighted excerpt for this quote“−8.74”View highlighted excerpt for this quote“0.000”View highlighted excerpt for this quote
EQ-5D index“0.53”View highlighted excerpt for this quoteSCOPA-motor complications“−0.12”View highlighted excerpt for this quote“−2.71”View highlighted excerpt for this quote“0.000”View highlighted excerpt for this quote
Non-motor symptom domains and PDQ-39 summary index in a multicenter survey

“Apathy was the symptom associated with worse PDQ-39 score but also presence of fatigue, attention/memory, and psychiatric symptoms had a negative impact on QoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Presence of apathy was associated with the worst QoL score (median PDQ-39 SI score = 36.0; IQR: 23.3–47.0) followed by cardiovascular symptoms, fatigue, attention/memory, and respiratory symptoms (Fig. 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The greatest difference in PDQ-39 score (present vs. absent NMSd) was recorded in patients presenting apathy followed by fatigue, attention/memory, and psychiatric symptoms (differences ranged from 15.9 points for apathy to 11.8 for psychiatric symptoms; P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among PDQ-39 dimensions, patients had the best QoL in social support (median = 0; IQR: 12.5) while higher values of PDQ-39 scores (meaning lower QoL) were recorded in emotional wellbeing (median = 31.3) and bodily discomfort (median = 33.3) dimensions scores; for both of them IQR = 16.7–50.0.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Twenty-three percent of patients (N = 246) had missing items in the PDQ-39 questionnaire and were thus excluded from the analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Motor fluctuations and dyskinesia and health-related quality of life in five European countries

“Data were collected cross-sectionally in clinical practice settings via nationally representative samples of specialized physicians (neurologists, plus geriatricians in the UK) and their PD patients between March and July, 2008.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In total, 817 patients were included in our analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All multivariable models were adjusted for age, gender, HY stage, disease duration, and country.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“To facilitate the comparison of the regression coefficients (β) across the QoL instruments the EQ-5D IS was rescaled from 0 (poor QoL) to 100 (good QoL).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For the primary hypotheses, the association of motor complication subtypes with QoL, the global significance level was set at 5% and was adjusted per outcome using a Bonferroni correction. A difference was considered statistically significant if p < 0.025.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“PDQ-39 scores range from 0 to 100. Contrary to the EQ-5D lower values indicate better QoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“These analyses were regarded as explorative, and the p-values of the corresponding regression models are presented for descriptive reasons only.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Thirty-three percent of the patients (varying from 23% in Italy to 58% in France) suffered from motor complications, either a single subtype or a combination of different subtypes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Twenty percent of all patients suffered from a single motor complication, 10.0% from two, 2.3% from three, and 0.5% from all four types of motor complications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Twenty-eight percent of all patients had off-times.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean EQ-5D IS of the total sample was 0.7 (SD 0.2) based on the ratings in the dimensions mobility (33.9% of the patients reported no, 64.8% some,1.2% extreme problems), self-care (55.3% no, 39.9% some, 4.8% extreme problems), usual activities (36.4%, 57.8% some, 5.8% extreme problems), pain/discomfort (45.4% no, 51.1% some, 3.4% extreme problems), and anxiety/depression (54.1% no, 41.6% some, 4.3% extreme problems). The mean PDQ-39 SI was 25.4 (SD 18.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“On-off fluctuations were associated with a 7.1 percentage point decrease in the EQ-5D (p < 0.001) and a 3.6 percentage point deterioration in the PDQ-39 (p = 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“None of the dyskinesia subtypes had a significant effect on the EQ-5D IS or the PDQ-39 SI (Table 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Sensitivity analyses considering motor complication severity indicated that compared to patients without on-off fluctuations the detrimental effect of on-off fluctuations was greater in patients with more severe complications (mild: β=−6.0, p < 0.01; moderate: β=−9.0, p < 0.001; severe: β = −3.2, p = 0.58). A linear trend was, however, not confirmed in the trend analysis (p = 0.48). The same was true for the severity of on-off fluctuations and the PDQ-39 SI (mild: β=2.9, p = 0.09; moderate: β = 5.4, p = 0.01; severe: β = 7.7, p = 0.1; test for linear trend p = 0.07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Dyskinesias were not seen to affect global QoL scores, but had detrimental effects on the PDQ-39 dimensions activities of daily living, cognitions, stigma, and bodily discomfort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In subgroup analyses that excluded patients with present symptoms of depression and/or cognitive impairment the results did not notably alter.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“On-off fluctuations were associated with poorer EQ-5D IS (β = −6.4, p = 0.003) and PDQ-39 SI (β = 4.5, p = 0.01) whereas dyskinesias did not impact QoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The motor complications observed in our sample were mainly mild or moderate limiting the generalizability of results for patients with more severe motor complications as well as the power of the linear trend tests.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The Adelphi PD Specific Programme is an independent study conducted by the Adelphi group on behalf of Solvay Pharmaceuticals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Multivariable associations of motor complication subtypes with EQ-5D and PDQ-39 scores, all subtypes and outcomes
Motor complication subtypeOutcomeRegression coefficient (β)95% CIp-Value
On-off fluctuationsEQ-5D index score (rescaled 0 to 100; higher scores represent better QoL)“−7.1”View highlighted excerpt for this quote“−10.6; −3.6”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 summary index (0 to 100; higher scores represent worse QoL)“3.6”View highlighted excerpt for this quote“0.7; 6.5”View highlighted excerpt for this quote“0.01”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 mobility“8.1”View highlighted excerpt for this quote“4.0; 12.2”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 activities of daily living“7.3”View highlighted excerpt for this quote“3.2; 11.5”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 emotional wellbeing“3.2”View highlighted excerpt for this quote“−0.5; 6.9”View highlighted excerpt for this quote“0.09”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 stigma“2.5”View highlighted excerpt for this quote“−1.7; 6.7”View highlighted excerpt for this quote“0.23”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 social support“2.3”View highlighted excerpt for this quote“−1.1; 5.7”View highlighted excerpt for this quote“0.19”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 cognitions“2.9”View highlighted excerpt for this quote“−0.4; 6.1”View highlighted excerpt for this quote“0.08”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 communication“2.4”View highlighted excerpt for this quote“−1.0; 5.8”View highlighted excerpt for this quote“0.17”View highlighted excerpt for this quote
On-off fluctuationsPDQ-39 bodily discomfort“2.5”View highlighted excerpt for this quote“−1.3; 6.3”View highlighted excerpt for this quote“0.20”View highlighted excerpt for this quote
Peak-dose dyskinesiasEQ-5D index score (rescaled 0 to 100; higher scores represent better QoL)“−2.9”View highlighted excerpt for this quote“−6.9; 1.2”View highlighted excerpt for this quote“0.17”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 summary index (0 to 100; higher scores represent worse QoL)“2.4”View highlighted excerpt for this quote“−0.9; 5.7”View highlighted excerpt for this quote“0.16”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 mobility“3.3”View highlighted excerpt for this quote“−1.3; 8.0”View highlighted excerpt for this quote“0.16”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 activities of daily living“5.9”View highlighted excerpt for this quote“1.2; 10.7”View highlighted excerpt for this quote“0.01”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 emotional wellbeing“2.7”View highlighted excerpt for this quote“−1.6; 7.0”View highlighted excerpt for this quote“0.22”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 stigma“−0.4”View highlighted excerpt for this quote“−5.3; 4.4”View highlighted excerpt for this quote“0.86”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 social support“0.1”View highlighted excerpt for this quote“−3.8; 4.0”View highlighted excerpt for this quote“0.96”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 cognitions“4.0”View highlighted excerpt for this quote“0.3; 7.7”View highlighted excerpt for this quote“0.03”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 communication“3.6”View highlighted excerpt for this quote“−0.3; 7.6”View highlighted excerpt for this quote“0.07”View highlighted excerpt for this quote
Peak-dose dyskinesiasPDQ-39 bodily discomfort“−2.2”View highlighted excerpt for this quote“−6.6; 2.2”View highlighted excerpt for this quote“0.32”View highlighted excerpt for this quote
Biphasic dyskinesiasEQ-5D index score (rescaled 0 to 100; higher scores represent better QoL)“−2.4”View highlighted excerpt for this quote“−10.6; 5.8”View highlighted excerpt for this quote“0.56”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 summary index (0 to 100; higher scores represent worse QoL)“6.1”View highlighted excerpt for this quote“−0.9; 13.0”View highlighted excerpt for this quote“0.09”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 mobility“5.4”View highlighted excerpt for this quote“−4.3; 15.1”View highlighted excerpt for this quote“0.28”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 activities of daily living“4.2”View highlighted excerpt for this quote“−5.4; 13.7”View highlighted excerpt for this quote“0.39”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 emotional wellbeing“5.9”View highlighted excerpt for this quote“−3.0; 14.7”View highlighted excerpt for this quote“0.19”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 stigma“12.6”View highlighted excerpt for this quote“2.7; 22.6”View highlighted excerpt for this quote“0.01”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 social support“2.6”View highlighted excerpt for this quote“−5.4; 10.6”View highlighted excerpt for this quote“0.53”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 cognitions“0.5”View highlighted excerpt for this quote“−7.2; 8.2”View highlighted excerpt for this quote“0.90”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 communication“−0.3”View highlighted excerpt for this quote“−8.2; 7.7”View highlighted excerpt for this quote“0.95”View highlighted excerpt for this quote
Biphasic dyskinesiasPDQ-39 bodily discomfort“2.3”View highlighted excerpt for this quote“−6.6; 11.2”View highlighted excerpt for this quote“0.61”View highlighted excerpt for this quote
Off-dystoniasEQ-5D index score (rescaled 0 to 100; higher scores represent better QoL)“−0.02”View highlighted excerpt for this quote“−5.9; 5.8”View highlighted excerpt for this quote“1.00”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 summary index (0 to 100; higher scores represent worse QoL)“1.6”View highlighted excerpt for this quote“−3.1; 6.4”View highlighted excerpt for this quote“0.51”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 mobility“1.9”View highlighted excerpt for this quote“−4.9; 8.6”View highlighted excerpt for this quote“0.59”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 activities of daily living“1.4”View highlighted excerpt for this quote“−5.4; 8.2”View highlighted excerpt for this quote“0.68”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 emotional wellbeing“3.5”View highlighted excerpt for this quote“−2.7; 9.7”View highlighted excerpt for this quote“0.27”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 stigma“4.6”View highlighted excerpt for this quote“−2.4; 11.5”View highlighted excerpt for this quote“0.20”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 social support“0.5”View highlighted excerpt for this quote“−5.1; 6.1”View highlighted excerpt for this quote“0.85”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 cognitions“−2.9”View highlighted excerpt for this quote“−8.3; 2.5”View highlighted excerpt for this quote“0.29”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 communication“−0.4”View highlighted excerpt for this quote“−6.2; 5.3”View highlighted excerpt for this quote“0.88”View highlighted excerpt for this quote
Off-dystoniasPDQ-39 bodily discomfort“7.4”View highlighted excerpt for this quote“1.1; 13.8”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Motor complication subtypes and PDQ-39 dimensions

“The impact of motor complications of Parkinson’s disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Two groups of patients were excluded, those having undergone surgery of the basal ganglia and those having an alteration of cognitive functions (Mini-Mental State Examination score lower than 24).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The range of possible values of each QL dimension is 0 (best QL) to 100 (worst QL), and the PDQ-SI is obtained by adding the dimension scores and reducing the range to 0 to 100.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Motor complications significantly worsened the PDQ-39 Summary Index (PDQ-SI) of patients with PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Morning akinesia, end-of-dose fluctuations, and “unpredictable offs” decreased QL on the dimensions of Mobility, Activities of Daily Living, Stigma, and Communication.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nocturnal akinesia led to a deterioration of all dimensions of the PDQ-39.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All the motor fluctuations studied significantly worsened the PDQ-SI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Apart from morning dystonias, all the self-reported LIDs studied (peak dose, diphasic, and off) were significantly related to a higher PDQ-SI, as was the dyskinesia score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We were particularly surprised by the impact of nocturnal akinesia, which often faded into the background at the consultation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Motor complicationParticipants with the complication, nPercentage (of all participants for any fluctuation or any dyskinesia; of participants in that class for each subtype)PDQ-SI mean, with the complicationPDQ-SI mean, without the complicationPDQ-SI, P (Student's t test)
Any motor fluctuation“94”View highlighted excerpt for this quote“66”View highlighted excerpt for this quoteNot reportedNot reportedNot reported
Early-morning akinesia“55”View highlighted excerpt for this quote“58.5”View highlighted excerpt for this quote“40.9”View highlighted excerpt for this quote“33.6”View highlighted excerpt for this quote“0.005”View highlighted excerpt for this quote
Nocturnal akinesia“54”View highlighted excerpt for this quote“57.5”View highlighted excerpt for this quote“44.7”View highlighted excerpt for this quote“31.3”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
End-of-dose fluctuations“74”View highlighted excerpt for this quote“78.7”View highlighted excerpt for this quote“41”View highlighted excerpt for this quote“31.6”View highlighted excerpt for this quote“0.0002”View highlighted excerpt for this quote
Paradoxical fluctuations“47”View highlighted excerpt for this quote“50”View highlighted excerpt for this quote“44.2”View highlighted excerpt for this quote“32.6”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Unpredictable offs“34”View highlighted excerpt for this quote“36.2”View highlighted excerpt for this quote“45.5”View highlighted excerpt for this quote“33.5”View highlighted excerpt for this quote“<0.0001”View highlighted excerpt for this quote
Any levodopa-induced dyskinesia“81”View highlighted excerpt for this quote“57”View highlighted excerpt for this quoteNot reportedNot reportedNot reported
Peak-dose dyskinesia“59”View highlighted excerpt for this quote“72.8”View highlighted excerpt for this quote“39.8”View highlighted excerpt for this quote“34.4”View highlighted excerpt for this quote“0.0404”View highlighted excerpt for this quote
Diphasic dyskinesia“14”View highlighted excerpt for this quote“17.3”View highlighted excerpt for this quote“46.1”View highlighted excerpt for this quote“35.5”View highlighted excerpt for this quote“0.0127”View highlighted excerpt for this quote
Off dyskinesia“10”View highlighted excerpt for this quote“12.4”View highlighted excerpt for this quote“49.9”View highlighted excerpt for this quote“35.7”View highlighted excerpt for this quote“0.0097”View highlighted excerpt for this quote
Morning dystonia“27”View highlighted excerpt for this quote“33.3”View highlighted excerpt for this quote“40.7”View highlighted excerpt for this quote“35.6”View highlighted excerpt for this quote“<0.1277”View highlighted excerpt for this quote
Clinical correlates and multivariable predictors of the PDQ-39 Summary Index, including levodopa dosing frequency

“A two-tailed 5% threshold of significance was retained, and only P values lying below this threshold are reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The disease duration led to a significant alteration of the dimensions Mobility (r = +0.46; P < 0.0001), Activities of Daily Living (r = +0.35; P < 0.0001), Stigma (r = +0.27; P = 0.0014), Social Support (r = +0.18; P = 0.03), and Communication (r = +0.35; P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A degradation of the QL was observed with the duration of dopatherapy, in the dimensions Mobility (r = +0.53; P < 0.0001), Activities of Daily Living (r = +0.44; P < 0.0001), Emotional Well-Being (r = +0.26; P < 0.014), Stigma (r = +0.26; P < 0.013), and Communication (r = +0.41; P < 0.0001) and in the PDQ-SI (r = +0.42; P = 0.0002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The severity of disease (H&Y) affected the QL in the dimensions Mobility (r = +0.44; P < 0.0001), Activities of Daily Living (r = +0.49; P < 0.0001), and Communication (r = +0.29; P = 0.0005) and in the PDQ-SI (r = +0.37; P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A higher total Motor score evaluated in an on state according to Part III of the UPDRS led to a degradation of the QL in the dimensions Mobility (r = +0.24; P = 0.0054) and Activities of Daily Living (r = +0.37; P < 0.0001) and in the PDQ-SI (r = +0.24; P = 0.0092).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A greater daily dosage of L-dopa significantly worsened the QL in the dimensions Mobility (r = +0.33; P = 0.0003), Activities of Daily Living (r = +0.31; P = 0.0007), Emotional Well-Being (r = +0.26; P = 0.0048), Stigma (r = +0.31; P = 0.0004), Social Support (r = +0.20; P = 0.027), and Communication (r = +0.28; P = 0.0019) and in the PDQ-SI (r = +0.42; P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A larger number of doses of L-dopa was likewise detrimental for the QL in the dimensions Mobility (r = +0.40; P < 0.0001), Activities of Daily Living (r = +0.30; P = 0.0008), Emotional Well-Being (r = +0.26; P = 0.0048), Stigma (r = +0.33; P = 0.0002), Social Support (r = +0.24; P = 0.01), and Communication (r = +0.24; P = 0.007) and in the PDQ-SI (r = +0.42; P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Inclusion of all factors concerning PD patients (sex and age at PD onset), disease (duration of PD at assessment, H&Y stage, and UPDRS III score), L-dopa treatment (daily dose and number of doses/day) and motor complications (occurrence or not of MF/LIDs and AIMS) in a multivariate linear model showed a contribution of 43% (part of total R-square) to the PDQ-SI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among the explanatory variables, the individual contribution determined by partial R-square was 17% for the number of L-dopa doses per day, 10% for the UPDRS III score, 7% for AIMS, and less than 2% for the other variables.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among clinical characteristics, the number of L-dopa doses was significantly related to age at the onset of PD (r = −0.43; P < 0.0001), disease duration (r = +0.47; P < 0.0001), H&Y stage (r = +0.22; P = 0.012), L-dopa dose (r = +0.83; P < 0.0001), and AIMS (r = +0.47; P = 0.0021) but not to the UPDRS III score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“It may only mean that there is an information overlap between MF/LIDs and the “complexity” of treatment (number of L-dopa doses), which might be the best indication of a difficult case of PD management and, thus, a poor QL in the patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The levels of causality among PD characteristics are somewhat difficult to analyze, because our study did not take into account the chronological sequence of events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Economic burden and healthcare resource utilization
Study population and claims-based definition of advanced disease

“Our data source was the 2013 Chronic Conditions Data Warehouse 100% Medicare dataset, which contains comprehensive claims for all patients with fee-for-service Medicare.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Next, the algorithm searched chronologically for any consecutive 30-day period where the average LED was > 1000 mg/day. Patients with dosing satisfying this criterion were categorized as having advanced PD, regardless of whether they maintained dosing at that level throughout the year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Our LED > 1000 mg dosing threshold was based on the average medication dose observed in clinical trials of device-aided therapies, such as deep brain stimulation (DBS) and carbidopa-levodopa enteral suspension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Our final study sample included 144,703 Medicare beneficiaries with PD (Supporting Information Fig. S1). Twenty percent (n = 28,974) were categorized as having advanced PD via our medication-based algorithm; the remaining 80% were categorized as having mild/moderate PD (Table 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Compared with the mild/moderate PD group, the advanced PD group had a greater percentage of individuals who were younger and male, who had a lower mean RxHCC risk score, and who had an outpatient neurologist visit during the year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Sample characteristics by claims-assigned disease severity, Medicare
CharacteristicOverall (N = 144,703)Mild/moderate PD (n = 115,729)Advanced PD (n = 28,974)
Age 65–69 years, n (%)“16,702 (11.5)”View highlighted excerpt for this quote“11,964 (10.3)”View highlighted excerpt for this quote“4738 (16.4)”View highlighted excerpt for this quote
Age 70–74 years, n (%)“27,882 (19.3)”View highlighted excerpt for this quote“20,685 (17.9)”View highlighted excerpt for this quote“7197 (24.8)”View highlighted excerpt for this quote
Age 75–79 years, n (%)“33,141 (22.9)”View highlighted excerpt for this quote“26,039 (22.5)”View highlighted excerpt for this quote“7102 (24.5)”View highlighted excerpt for this quote
Age ≥80 years, n (%)“66,978 (46.3)”View highlighted excerpt for this quote“57,041 (49.3)”View highlighted excerpt for this quote“9937 (34.3)”View highlighted excerpt for this quote
Male sex, n (%)“70,127 (48.5)”View highlighted excerpt for this quote“53,321 (46.1)”View highlighted excerpt for this quote“16,806 (58.0)”View highlighted excerpt for this quote
Race, White, n (%)“126,830 (87.6)”View highlighted excerpt for this quote“100,878 (87.2)”View highlighted excerpt for this quote“25,952 (89.6)”View highlighted excerpt for this quote
Race, Black, n (%)“6666 (4.6)”View highlighted excerpt for this quote“5860 (5.1)”View highlighted excerpt for this quote“806 (2.8)”View highlighted excerpt for this quote
Race, other, n (%)“11,207 (7.7)”View highlighted excerpt for this quote“8991 (7.8)”View highlighted excerpt for this quote“2216 (7.6)”View highlighted excerpt for this quote
Region, Northeast, n (%)“28,430 (19.6)”View highlighted excerpt for this quote“23,061 (19.9)”View highlighted excerpt for this quote“5369 (18.5)”View highlighted excerpt for this quote
Region, Midwest, n (%)“38,687 (26.7)”View highlighted excerpt for this quote“30,487 (26.3)”View highlighted excerpt for this quote“8200 (28.3)”View highlighted excerpt for this quote
Region, South, n (%)“52,885 (36.5)”View highlighted excerpt for this quote“43,040 (37.2)”View highlighted excerpt for this quote“9845 (34.0)”View highlighted excerpt for this quote
Region, West, n (%)“24,701 (17.1)”View highlighted excerpt for this quote“19,141 (16.5)”View highlighted excerpt for this quote“5560 (19.2)”View highlighted excerpt for this quote
RxHCC risk score, mean (SD)“1.48 (0.46)”View highlighted excerpt for this quote“1.50 (0.46)”View highlighted excerpt for this quote“1.40 (0.45)”View highlighted excerpt for this quote
Outpatient neurologist visit during the study year, n (%)“101,146 (69.9)”View highlighted excerpt for this quote“76,762 (66.3)”View highlighted excerpt for this quote“24,384 (84.2)”View highlighted excerpt for this quote
Unadjusted 12-month Medicare costs by service category and disease severity
Cost categoryOverall (N = 144,703), mean (SD), 2018 US$Mild/moderate PD (n = 115,729), mean (SD), 2018 US$Advanced PD (n = 28,974), mean (SD), 2018 US$P value
All-cause, total“$23,041 ($34,045)”View highlighted excerpt for this quote“$22,553 ($34,147)”View highlighted excerpt for this quote“$24,988 ($33,563)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
All-cause, medical“$16,741 ($31,925)”View highlighted excerpt for this quote“$16,737 ($32,309)”View highlighted excerpt for this quote“$16,763 ($30,348)”View highlighted excerpt for this quote“0.896”View highlighted excerpt for this quote
All-cause, outpatient“$8747 ($9983)”View highlighted excerpt for this quote“$8627 ($10,062)”View highlighted excerpt for this quote“$9230 ($9645)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
All-cause, inpatient“$3183 ($22,656)”View highlighted excerpt for this quote“$3214 ($22,840)”View highlighted excerpt for this quote“$3059 ($21,903)”View highlighted excerpt for this quote“0.272”View highlighted excerpt for this quote
All-cause, durable medical equipment“$535 ($1636)”View highlighted excerpt for this quote“$519 ($1589)”View highlighted excerpt for this quote“$599 ($1811)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
All-cause, skilled nursing facility“$1038 ($6818)”View highlighted excerpt for this quote“$1092 ($7020)”View highlighted excerpt for this quote“$825 ($5932)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
All-cause, home health services“$2282 ($5053)”View highlighted excerpt for this quote“$2270 ($5068)”View highlighted excerpt for this quote“$2327 ($4994)”View highlighted excerpt for this quote“0.077”View highlighted excerpt for this quote
All-cause, hospice“$955 ($6177)”View highlighted excerpt for this quote“$1014 ($6399)”View highlighted excerpt for this quote“$722 ($5187)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
All-cause, pharmaceutical“$6300 ($9567)”View highlighted excerpt for this quote“$5818 ($8568)”View highlighted excerpt for this quote“$8225 ($12,620)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary PD-related, total“$3429 ($7431)”View highlighted excerpt for this quote“$2640 ($5646)”View highlighted excerpt for this quote“$6580 ($11,667)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary PD-related, medical“$1882 ($5795)”View highlighted excerpt for this quote“$1634 ($5265)”View highlighted excerpt for this quote“$2877 ($7468)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary PD-related, outpatient“$763 ($2344)”View highlighted excerpt for this quote“$619 ($1821)”View highlighted excerpt for this quote“$1334 ($3716)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary PD-related, inpatient“$67 ($1643)”View highlighted excerpt for this quote“$44 ($1047)”View highlighted excerpt for this quote“$156 ($3017)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary PD-related, durable medical equipment“$94 ($737)”View highlighted excerpt for this quote“$74 ($606)”View highlighted excerpt for this quote“$175 ($1111)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary PD-related, skilled nursing facility“$65 ($1561)”View highlighted excerpt for this quote“$60 ($1515)”View highlighted excerpt for this quote“$84 ($1732)”View highlighted excerpt for this quote“0.037”View highlighted excerpt for this quote
Primary PD-related, home health services“$483 ($2004)”View highlighted excerpt for this quote“$428 ($1863)”View highlighted excerpt for this quote“$700 ($2476)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary PD-related, hospice“$411 ($3902)”View highlighted excerpt for this quote“$406 ($3926)”View highlighted excerpt for this quote“$428 ($3803)”View highlighted excerpt for this quote“0.387”View highlighted excerpt for this quote
Primary PD-related, pharmaceutical“$1546 ($4431)”View highlighted excerpt for this quote“$1006 ($1947)”View highlighted excerpt for this quote“$3701 ($8783)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Any PD-related, total“$9924 ($22,140)”View highlighted excerpt for this quote“$8922 ($21,524)”View highlighted excerpt for this quote“$13,923 ($24,037)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Any PD-related, medical“$7133 ($21,473)”View highlighted excerpt for this quote“$6674 ($21,282)”View highlighted excerpt for this quote“$8968 ($22,124)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Any PD-related, outpatient“$2199 ($3942)”View highlighted excerpt for this quote“$1925 ($3401)”View highlighted excerpt for this quote“$3289 ($5468)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Any PD-related, inpatient“$2049 ($17,781)”View highlighted excerpt for this quote“$1970 ($17,781)”View highlighted excerpt for this quote“$2367 ($17,780)”View highlighted excerpt for this quote“0.001”View highlighted excerpt for this quote
Any PD-related, durable medical equipment“$145 ($904)”View highlighted excerpt for this quote“$120 ($787)”View highlighted excerpt for this quote“$241 ($1262)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Any PD-related, skilled nursing facility“$550 ($4732)”View highlighted excerpt for this quote“$558 ($4781)”View highlighted excerpt for this quote“$519 ($4529)”View highlighted excerpt for this quote“0.218”View highlighted excerpt for this quote
Any PD-related, home health services“$1693 ($4279)”View highlighted excerpt for this quote“$1597 ($4181)”View highlighted excerpt for this quote“$2074 ($4629)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Any PD-related, hospice“$499 ($4274)”View highlighted excerpt for this quote“$504 ($4337)”View highlighted excerpt for this quote“$477 ($4011)”View highlighted excerpt for this quote“0.327”View highlighted excerpt for this quote
Any PD-related, pharmaceutical“$2789 ($5103)”View highlighted excerpt for this quote“$2247 ($3147)”View highlighted excerpt for this quote“$4956 ($9201)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Distribution of costs across patients and drivers of the highest costs

“For instance, when examining any PD-related costs across patient deciles, mean costs were as low as $483 (SD, $166) in the lowest decile and as high as $48,145 (SD, $55,111) in the highest decile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“More than half (57%) of the patients in the advanced PD group were in the four deciles with the highest costs (as compared with 35% of patients in the mild/moderate group), whereas more than half (54%) of the patients in the mild/moderate group were in the five deciles with the lowest costs (as compared with 30% of the advanced PD group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Further exploration of specific costs among the tenth (highest) decile compared with the next highest (ninth) decile revealed higher costs in every category we examined, with the biggest differences evident for inpatient and skilled nursing facility care (ie, inpatient costs $27,676 vs $2732 for the tenth vs ninth decile, respectively; skilled nursing care $9926 vs $408; Supporting Information Table S1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among those in the mild/moderate group who incurred the highest (tenth decile) costs, 42% of those costs were related to inpatient services, 16% were due to home health care, and 13% were due to skilled nursing facility claims (Supporting Information Table S2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The pattern was even more pronounced for primary PD-related costs; the majority of patients in the advanced PD group (57%) were concentrated in the top three deciles (as compared with 23% of patients in the mild/moderate group; Fig. 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The advanced PD group had mean unadjusted total all-cause costs ($24,988 [SD, $33,563]) that were approximately 10% higher than those of the mild/moderate group ($22,553 [SD, $34,147]), with the majority of the difference coming from higher pharmaceutical costs in the advanced PD group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In keeping with the fact that disease severity was assigned based on medication dose, mean primary PD-related pharmaceutical costs for the advanced PD group were more than triple those of the mild/moderate group ($3701 vs $1006, respectively) and represented a higher proportion of their overall primary PD-related costs (56% vs 38%; data not shown).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“One in three individuals in our mild/moderate PD group did not have a claim for a neurologist visit during our study year, nor did one in six individuals in our advanced PD group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Risk-adjusted costs under alternative definitions of advanced disease
Cost type and definition of advanced diseaseMild/moderate PD, risk-adjusted mean, 2018 US$Advanced PD, risk-adjusted mean, 2018 US$Difference95% CI of difference
All-cause, levodopa > 1000 mg/day“$22,363”View highlighted excerpt for this quote“$26,688”View highlighted excerpt for this quote“$4325”View highlighted excerpt for this quote“$3862–$4788”View highlighted excerpt for this quote
All-cause, LED > 800 mg/day“$21,681”View highlighted excerpt for this quote“$26,433”View highlighted excerpt for this quote“$4751”View highlighted excerpt for this quote“$4426–$5077”View highlighted excerpt for this quote
Primary PD-related, levodopa > 1000 mg/day“$2923”View highlighted excerpt for this quote“$5657”View highlighted excerpt for this quote“$2734”View highlighted excerpt for this quote“$2578–$2890”View highlighted excerpt for this quote
Primary PD-related, LED > 800 mg/day“$2428”View highlighted excerpt for this quote“$5590”View highlighted excerpt for this quote“$3162”View highlighted excerpt for this quote“$3041–$3283”View highlighted excerpt for this quote
Any PD-related, levodopa > 1000 mg/day“$9103”View highlighted excerpt for this quote“$14,119”View highlighted excerpt for this quote“$5016”View highlighted excerpt for this quote“$4678–$5354”View highlighted excerpt for this quote
Any PD-related, LED > 800 mg/day“$8372”View highlighted excerpt for this quote“$13,708”View highlighted excerpt for this quote“$5336”View highlighted excerpt for this quote“$5090–$5582”View highlighted excerpt for this quote
Sensitivity analyses, study limitations, and funding

“Sensitivity analyses using alternate medication thresholds to define advanced PD (ie, levodopa dose > 1000 mg and LED > 800 mg) produced incremental costs of advanced PD that were smaller across all categories, although patterns were similar (Table 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The medication-based algorithm we used to determine advanced disease status is newly developed and has not undergone full validation testing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In contrast, the nature of Medicare claims may have led us to overestimate the true costs of pharmaceutical treatment, because the Part D event files do not capture manufacturer rebates, remuneration (price concessions), and final adjustment for risk sharing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Although our study offers important insights into the health care cost burden of advanced PD within fee-for-service Medicare, our results did not include and may not generalize to patients covered by Medicare Advantage plans that offer coverage for Medicare Parts A, B, and D together, or to those with fee-for-service Medicare without a Part D prescription drug plan.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Further, Medicare does not cover the considerable costs of treatment in long-term care facilities, which have been shown to represent a substantial proportion of overall costs to Medicare beneficiaries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Financial support for the study was provided by AbbVie.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Registry population, cost methods, and study limitations, Sweden

“Annual costs of healthcare contacts, drugs, formal and informal care, and productivity loss associated with PD were estimated using data from PARKreg linked with regional and national healthcare registers between 2013 and 2019.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In total, 960 patients and 1324 observations (patient-years) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In this study, we defined H&Y I-II as early stage, III-IV as advanced stage and V as late stage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Most patient-years were found in H&Y I and II (68%), whereas 25% were in H&Y III, 6% in H&Y IV and 1% in H&Y V.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The variable was presented in the following categories: 0%, 1-<25%, 25-<50%, and 50–100%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Costs are expressed in Swedish kronor (SEK), 2019 prices.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A limitation of the study is that total costs for PD might be underestimated since only healthcare contacts registered with a PD diagnosis as main diagnosis were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Even though the sample in this study covers all disease severity stages, it should be noted that the sample size in H&Y IV-V is relatively low compared to stages I-III, that is, 6% of all the patient-years are found in H&Y stage IV and only 1% in H&Y stage V.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Moreover, off-time is a rough patient-reported estimate which may be affected by a recall bias.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The research has received financial support from AbbVie, Medtronic, and Nordic Infucare (Air Liquide Healthcare).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Cost per patient-year by cost category and Hoehn and Yahr stage, Sweden
Cost categoryH&Y I (n = 410), mean (SD), SEK 2019H&Y II (n = 493), mean (SD), SEK 2019H&Y III (n = 334), mean (SD), SEK 2019H&Y IV (n = 73), mean (SD), SEK 2019H&Y V (n = 14), mean (SD), SEK 2019
Inpatient and outpatient care“11 245 (22 974)”View highlighted excerpt for this quote“22 865 (55 696)”View highlighted excerpt for this quote“28 492 (50 114)”View highlighted excerpt for this quote“18 765 (19 923)”View highlighted excerpt for this quote“37 035 (94 172)”View highlighted excerpt for this quote
Drugs“10 783 (19 237)”View highlighted excerpt for this quote“18 296 (45 897)”View highlighted excerpt for this quote“31 307 (74 725)”View highlighted excerpt for this quote“69 283 (137 407)”View highlighted excerpt for this quote“60 221 (119 896)”View highlighted excerpt for this quote
Formal care“1 186 (12 783)”View highlighted excerpt for this quote“13 183 (120 159)”View highlighted excerpt for this quote“79 259 (279 433)”View highlighted excerpt for this quote“306 465 (372 060)”View highlighted excerpt for this quote“855 038 (606 877)”View highlighted excerpt for this quote
Transport“447 (844)”View highlighted excerpt for this quote“1 218 (5 254)”View highlighted excerpt for this quote“1147 (3 292)”View highlighted excerpt for this quote“2 061 (5 107)”View highlighted excerpt for this quote“1 075 (2 056)”View highlighted excerpt for this quote
Informal care“1 771 (21 700)”View highlighted excerpt for this quote“7 497 (38 903)”View highlighted excerpt for this quote“30 840 (94 830)”View highlighted excerpt for this quote“122 829 (259 001)”View highlighted excerpt for this quote“55 421 (139 705)”View highlighted excerpt for this quote
Productivity loss“36 974 (138 760)”View highlighted excerpt for this quote“67 383 (186 770)”View highlighted excerpt for this quote“63 351 (189 042)”View highlighted excerpt for this quote“37 266 (156 303)”View highlighted excerpt for this quote“47 535 (177 858)”View highlighted excerpt for this quote
Cost per patient-year by cost category and time in OFF, Sweden
Cost category0% of waking time in OFF (n = 826), mean (SD), SEK 20191% to <25% (n = 385), mean (SD), SEK 201925% to <50% (n = 94), mean (SD), SEK 201950% to 100% (n = 19), mean (SD), SEK 2019
Inpatient and outpatient care“16 867 (42 326)”View highlighted excerpt for this quote“26 066 (48 136)”View highlighted excerpt for this quote“29 607 (63 105)”View highlighted excerpt for this quote“27 943 (28 305)”View highlighted excerpt for this quote
Drugs“14 050 (39 228)”View highlighted excerpt for this quote“37 372 (85 054)”View highlighted excerpt for this quote“33 738 (75 940)”View highlighted excerpt for this quote“33 355 (82 353)”View highlighted excerpt for this quote
Formal care“39 400 (206 111)”View highlighted excerpt for this quote“63 175 (212 497)”View highlighted excerpt for this quote“95 469 (323 878)”View highlighted excerpt for this quote“103 141 (256 321)”View highlighted excerpt for this quote
Transport“817 (2 391)”View highlighted excerpt for this quote“1360 (6 095)”View highlighted excerpt for this quote“1 311 (2 459)”View highlighted excerpt for this quote“529 (1 047)”View highlighted excerpt for this quote
Informal care“14 684 (86 443)”View highlighted excerpt for this quote“19 692 (84 972)”View highlighted excerpt for this quote“35 577 (90 886)”View highlighted excerpt for this quote“74 223 (117 835)”View highlighted excerpt for this quote
Productivity loss“35 368 (139 615)”View highlighted excerpt for this quote“78 878 (200 345)”View highlighted excerpt for this quote“105 617 (233 495)”View highlighted excerpt for this quote“179 653 (309 621)”View highlighted excerpt for this quote
Resource use, drug costs, and formal care by disease stage, Sweden

“The percentage of patient-years with at least one stay increased from less than 1% in H&Y I to 14% in H&Y III, and 21% in H&Y V, whereas only 7% in H&Y IV had inpatient admissions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Overall mean drug cost was SEK 22,506. The mean costs in H&Y IV and V were considerable higher than for stages I and II.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (SD) cost for apomorphine infusion, LCIG, and LECIG was SEK 21,635 (85,168) for the 1-<25% off category compared to SEK 4053 (38,622) for the 0% (p < .001), SEK 17,756 (75,592) for the ≥25 to <50% (p < .01) and SEK 19,300 (84,127) for the ≥50% category (p < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Overall mean costs for formal care, including costs for nursing home, home help, personal assistance, home health care and electric wheelchair and scooter, were SEK 51,209. Home help and nursing home accounted for most of the costs, 50 and 30%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The use of informal care was considerably higher in H&Y IV than in the other stages, for 36% of the patient-years informal care of at least 1 h per week was reported and the mean number of hours per year was 634 h.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In our study, the cost ranged from about a similar level in H&Y I, SEK 62,000, but to a considerably higher level in stage V, SEK 1 million mainly driven by costs for formal care and especially cost for nursing home (50% of the patient-years in H&Y V included costs for nursing home).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Study population, cost methods, and limitations in Parkinson's disease psychosis with incident dementia

“A total of 12,484 patients were eligible after our applying the study inclusion and exclusion criteria. Of these, 85.3% (n = 10,609) patients with PDP had a diagnosis for dementia in the post-PDP diagnosis period, while 14.7% (n = 1875) PDP patients did not have a diagnosis of dementia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients in both groups were matched using 1:1 propensity score matching (PSM) methodology using 31 variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients were propensity score‐matched in a 1:1 ratio from the unmatched pool of PDP + D and PDP groups, yielding 1855 PDP + D and 1855 PDP patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“While other studies have posited that 80% of patients with PD progress to dementia in 2 decades, our analysis shows that approximately 85% of patients with PDP have incident dementia within a year after PDP diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Mean age (72 years), gender (50% males), race, and comorbidity profile were similar for both groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Total cost for each claim, were calculated by adding the inpatient Medicare claim payment amount plus the claim pass through amount paid for the days stayed from the inpatient files.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All cost amounts were inflated to 2019 dollars using the Medical Consumer Price Index (CPI) as reported by the US Bureau of Labor Statistics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Second, identification of psychosis was based on a diagnosis of psychosis-related hallucinations and delusions – so it is likely that PDP diagnosis is underestimated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Third, residual confounding may still exist, even though the study was adjusted for potential confounding issues through appropriate propensity score matching and covariate adjustment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Finally, it is important to acknowledge that diagnosis of dementia among patients with PDP may be difficult and, as such, result in underestimates of dementia diagnosis among these patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This study was financially sponsored by Acadia Pharmaceuticals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Hospitalization and emergency room visit rates by type of stay, psychosis with and without incident dementia
Outcome during 12-month follow-upPDP without dementia (n = 1855), n (%)PDP with incident dementia (n = 1855), n (%)p-value
All-cause, any hospitalization“667 (36.0)”View highlighted excerpt for this quote“933 (50.3)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
All-cause, short-term stay“662 (33.6)”View highlighted excerpt for this quote“839 (45.2)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
All-cause, long-term stay“113 (6.0)”View highlighted excerpt for this quote“158 (8.6)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
All-cause, skilled nursing facility stay“291 (15.6)”View highlighted excerpt for this quote“525 (28.4)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
All-cause, emergency room visit“1123 (60.6)”View highlighted excerpt for this quote“1346 (72.6)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
Psychiatric, any hospitalization“227 (12.2)”View highlighted excerpt for this quote“358 (19.2)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
Psychiatric, short-term stay“167 (9.0)”View highlighted excerpt for this quote“228 (12.3)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
Psychiatric, long-term stay“23 (1.2)”View highlighted excerpt for this quote“43 (2.4)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
Psychiatric, skilled nursing facility stay“64 (3.4)”View highlighted excerpt for this quote“140 (7.5)”View highlighted excerpt for this quote“<0.05”View highlighted excerpt for this quote
Psychiatric, emergency room visit“210 (11.3)”View highlighted excerpt for this quote“246 (13.2)”View highlighted excerpt for this quote“NS”View highlighted excerpt for this quote
All-cause short-term, skilled nursing facility, and long-term stay percentages that differ between the abstract and the results
Economic impact of Parkinson's disease on families
Risk factors for caregiver burden

“Forty-nine articles that involved 5387 caregivers of patients with PD were included in this study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All scales revealed caregivers of PD patients had mild to moderate caregiver burden. For the PD patients with longer disease duration, severer disease severity, more negative emotion and cognition impairment, their caregivers intended to have higher caregiver burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Thirty-eight were cross-sectional studies, and eleven were clinic trails.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“As the included articles had a great deal of clinical heterogeneity in terms of participants, statistical methods and measurement tools. The results of systematic review were described by qualitative analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Caregiver spent 6.1 ± 4.5 h per day and 8.1 ± 4.9 years on caregiving.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Sixty-four per cent (1465/2264) of patients were in H&Y stage ≤ 2.5, and thirty-two per cent (729/2264) had H&Y stage ≥ 3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“All of these studies indicated a higher CB in both patients and caregivers with depression and anxiety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The caregiver burden was not improved after deep brain stimulation (DBS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of diagnostic testing
Reimbursement for dopamine transporter SPECT imaging in the United States

“Average reimbursement per study fell from $2,469 (US dollars) in 2011 to 2012 to $1,657 in 2014. CMS reduced average reimbursement by $1,148 in 2014 because of loss of radiopharmaceutical pass-through status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Average reimbursements from CMS versus private payors markedly differed in 2011 to 2012 at $2,266 versus $2,861, respectively, and in 2014 at $1,118 versus $3,470, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The range of CMS payments narrowed over the two time periods from $0 to $2,254 (average $2,266 ± $452) in 2011 to 2012 to $674 to $1,621 (average $1,118 ± $119) in 2014. The range of private payor payments was larger than CMS payments during both time periods, with $0 to $8,754 (average $2,861 ± $2,054) in 2011 to 2012 and $112 to $9,675 (average $3,470 ± $1,570) in 2014.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For example, the first 10 studies from private payors reimbursed, on average, $5,161 more per study than the first 10 CMS studies (average of $7,172 for private payors and $2,011 for CMS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Assuming that I-123 ioflupane cost $2,000, our model based on 2014 data predicts a practice with greater than 60% CMS patients would no longer recover radiopharmaceutical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Payer mix and reimbursement per dopamine transporter SPECT study by payer and period
MeasureJuly 2011 to October 2012January 2014 to December 2014Difference between periods
CMS, share of studies“134/247 (54.2%)”View highlighted excerpt for this quote“73/94 (77.7%)”View highlighted excerpt for this quoteNot applicable
Private insurance, share of studies“105/247 (42.5%)”View highlighted excerpt for this quote“21/94 (22.3%)”View highlighted excerpt for this quoteNot applicable
Veterans Affairs Health Care System, share of studies“6/247 (2.4%)”View highlighted excerpt for this quote“0/94 (0%)”View highlighted excerpt for this quoteNot applicable
Self-pay, share of studies“2/247 (0.9%)”View highlighted excerpt for this quote“0/94 (0%)”View highlighted excerpt for this quoteNot applicable
CMS, average reimbursement (US$)“$2,266”View highlighted excerpt for this quote“$1,118”View highlighted excerpt for this quote“-$1,148”View highlighted excerpt for this quote
CMS, range of reimbursement (US$)“$0-$2,254”View highlighted excerpt for this quote“$674-$1,621”View highlighted excerpt for this quoteNot applicable
Private insurance, average reimbursement (US$)“$2,861”View highlighted excerpt for this quote“$3,470”View highlighted excerpt for this quote“$609”View highlighted excerpt for this quote
Private insurance, range of reimbursement (US$)“$0-$8,754”View highlighted excerpt for this quote“$112-$9,675”View highlighted excerpt for this quoteNot applicable
Private insurance minus CMS, average reimbursement (US$)“$595”View highlighted excerpt for this quote“$2,369”View highlighted excerpt for this quoteNot applicable
Pass-through status, scanner location, and break-even radiopharmaceutical cost
Cost-effectiveness of dopamine transporter SPECT in suspected Parkinson's disease, Germany

“Compared strategies were CE only (EXAM+), SPECT only (SPECT+), SPECT following negative CE (SINGLE+), and SPECT following positive CE (DOUBLE+).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Costs of SPECT amounted to €789 per investigation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Based on our model, expected costs (and ATME) were €946 (52.85 ATME) for EXAM+, €1352 (53.40 ATME) for DOUBLE+, €1731 (32.82 ATME) for SINGLE+, and €2003 (32.96 ATME) for SPECT+; performance of SPECT was induced in 0%, 54%, 56%, and 100% of the patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“DOUBLE+ was more effective and less expensive than SINGLE+ or SPECT+; thus these two do not offer reasonable choices. The ICER of DOUBLE+ compared to EXAM+ was €733 per ATME gained. In sensitivity analyses, the ICER of DOUBLE+ versus EXAM+ ranged from €63 to €2411 per ATME gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“If the decision-maker is not willing to spend approximately €733 for the equivalent of a patient-month with adequate treatment, the diagnostic work-up should include only a clinical examination.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“SPECT should be used as a confirmatory test before treatment initiation and limited to patients with a positive test result in the clinical examination.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Decision model structure, perspective, and treatment costs, Germany

“We developed a decision tree model for several diagnostic work-up strategies to determine diagnostic, therapeutic, and economic outcomes in patients with symptoms of PD who present to a specialized movement disorder outpatient clinic.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We assumed that the correct diagnosis (PD or not) will be available in all patients after 12 months, and therefore chose a time horizon of 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We considered that only patients in Hoehn and Yahr (HY) stage I or II would be examined.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In the model, we counted how many months during the 1-year time horizon each individual was treated appropriately, that is, the number of months a patient with PD received antiparkinsonian therapy or the number of months an individual without PD did not receive such treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The consequence ratio ranged from 5 to 12, with a mean of 8.5.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Economic outcomes included the cost for diagnostic procedures and PD treatment costs. All costs were based on 2002 values. We adopted the perspective of the health care provider.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“1 full year of PD treatment is associated with medication costs of €1,535 or €128 per patient-month. Including initial and follow-up clinical examinations but assuming no SPECT investigation increases the 1-year health care costs to a total of €1,689, which translates to an average of €141 per patient month.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Model inputs, SPECT cost components, and ranges tested in sensitivity analyses
ParameterBase case (costs in euros, 2002 values)Range in sensitivity analyses
Prevalence of PD among referred patients“0.53”View highlighted excerpt for this quote“0.20–0.74”View highlighted excerpt for this quote
Prevalence of parkinsonism among referred patients“0.74”View highlighted excerpt for this quoteNot applicable
Sensitivity of FP-CIT SPECT for parkinsonism“0.975”View highlighted excerpt for this quote“0.90–1.0”View highlighted excerpt for this quote
Specificity of FP-CIT SPECT for parkinsonism“1.0”View highlighted excerpt for this quote“0.73–1.0”View highlighted excerpt for this quote
Sensitivity of clinical examination for PD“0.911”View highlighted excerpt for this quote“0.60–0.911”View highlighted excerpt for this quote
Specificity of clinical examination for PD“0.984”View highlighted excerpt for this quote“0.80–0.984”View highlighted excerpt for this quote
Radionuclide tracer for FP-CIT SPECT“746.50”View highlighted excerpt for this quote“373.25–1,493.00”View highlighted excerpt for this quote
PD medication per year“1,534.50”View highlighted excerpt for this quote“767.25–3,069.00”View highlighted excerpt for this quote
Initial examination, including tests“117.98”View highlighted excerpt for this quote“59.00–236.00”View highlighted excerpt for this quote
Clinical follow-up examination“18.50”View highlighted excerpt for this quote“9.25–37.00”View highlighted excerpt for this quote
Gamma camera cost per SPECT investigation“16.22”View highlighted excerpt for this quoteNot applicable
Mean personnel cost per SPECT investigation“25.88”View highlighted excerpt for this quoteNot applicable
Total cost per SPECT investigation“788.60”View highlighted excerpt for this quoteNot applicable
Consequence ratio“8.5”View highlighted excerpt for this quote“1–20”View highlighted excerpt for this quote
Base-case expected cost, effectiveness, and ICER by diagnostic strategy
One-way sensitivity analyses, SPECT after positive clinical examination versus clinical examination only
Varied parameter and valueEXAM+ cost (euros)EXAM+ ATMEDOUBLE+ cost (euros)DOUBLE+ ATMEDOUBLE+ ICER (euros per ATME)
Base case“946”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“1,352”View highlighted excerpt for this quote“53.4”View highlighted excerpt for this quote“733”View highlighted excerpt for this quote
Prevalence of PD 0.74“1,245”View highlighted excerpt for this quote“34.3”View highlighted excerpt for this quote“1,810”View highlighted excerpt for this quote“34.6”View highlighted excerpt for this quote“2,411”View highlighted excerpt for this quote
Prevalence of PD 0.40“761”View highlighted excerpt for this quote“64.3”View highlighted excerpt for this quote“1,068”View highlighted excerpt for this quote“65.1”View highlighted excerpt for this quote“409”View highlighted excerpt for this quote
Prevalence of PD 0.20“476”View highlighted excerpt for this quote“81.9”View highlighted excerpt for this quote“632”View highlighted excerpt for this quote“83.0”View highlighted excerpt for this quote“148”View highlighted excerpt for this quote
Sensitivity of clinical examination 0.76“864”View highlighted excerpt for this quote“52.2”View highlighted excerpt for this quote“1,249”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“700”View highlighted excerpt for this quote
Sensitivity of clinical examination 0.60“758”View highlighted excerpt for this quote“51.4”View highlighted excerpt for this quote“1,100”View highlighted excerpt for this quote“51.9”View highlighted excerpt for this quote“619”View highlighted excerpt for this quote
Specificity of clinical examination 0.90“1,033”View highlighted excerpt for this quote“47.0”View highlighted excerpt for this quote“1,451”View highlighted excerpt for this quote“50.7”View highlighted excerpt for this quote“113”View highlighted excerpt for this quote
Specificity of clinical examination 0.80“1,131”View highlighted excerpt for this quote“40.6”View highlighted excerpt for this quote“1,563”View highlighted excerpt for this quote“47.5”View highlighted excerpt for this quote“63”View highlighted excerpt for this quote
Sensitivity of FP-CIT SPECT 1.00“946”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“1,663”View highlighted excerpt for this quote“53.5”View highlighted excerpt for this quote“666”View highlighted excerpt for this quote
Sensitivity of FP-CIT SPECT 0.90“946”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“1,319”View highlighted excerpt for this quote“53.2”View highlighted excerpt for this quote“1,109”View highlighted excerpt for this quote
Specificity of FP-CIT SPECT 0.73“946”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“1,355”View highlighted excerpt for this quote“53.2”View highlighted excerpt for this quote“1,062”View highlighted excerpt for this quote
Tracer cost doubled“946”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“1,756”View highlighted excerpt for this quote“53.4”View highlighted excerpt for this quote“1,462”View highlighted excerpt for this quote
Tracer cost halved“946”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“1,150”View highlighted excerpt for this quote“53.4”View highlighted excerpt for this quote“369”View highlighted excerpt for this quote
Initial examination cost doubled“1,064”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“1,470”View highlighted excerpt for this quote“53.4”View highlighted excerpt for this quote“733”View highlighted excerpt for this quote
Initial examination cost halved“887”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“1,293”View highlighted excerpt for this quote“53.4”View highlighted excerpt for this quote“733”View highlighted excerpt for this quote
Medication cost doubled“1,737”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“2,123”View highlighted excerpt for this quote“53.4”View highlighted excerpt for this quote“696”View highlighted excerpt for this quote
Medication cost halved“551”View highlighted excerpt for this quote“52.8”View highlighted excerpt for this quote“967”View highlighted excerpt for this quote“53.4”View highlighted excerpt for this quote“752”View highlighted excerpt for this quote
Consequence ratio 1“946”View highlighted excerpt for this quote“11.6”View highlighted excerpt for this quote“1,352”View highlighted excerpt for this quote“11.5”View highlighted excerpt for this quote“Dom”View highlighted excerpt for this quote
Consequence ratio 5“946”View highlighted excerpt for this quote“33.6”View highlighted excerpt for this quote“1,352”View highlighted excerpt for this quote“33.9”View highlighted excerpt for this quote“1,397”View highlighted excerpt for this quote
Consequence ratio 12“946”View highlighted excerpt for this quote“72.1”View highlighted excerpt for this quote“1,352”View highlighted excerpt for this quote“72.9”View highlighted excerpt for this quote“497”View highlighted excerpt for this quote
Consequence ratio 20“946”View highlighted excerpt for this quote“116.2”View highlighted excerpt for this quote“1,352”View highlighted excerpt for this quote“117.6”View highlighted excerpt for this quote“286”View highlighted excerpt for this quote
Interpretation of the incremental gain and limitations of the decision model

“Although DOUBLE+ was more expensive than EXAM+, DOUBLE+ also yielded between 0.23 and 6.91 additional ATMEs with ICERs varying from €63 to €2,411 per ATME, depending on the parameters varied in the sensitivity analyses. Only for consequence ratios smaller than 1.2, which was outside of the expert’s range, EXAM+ was more effective than DOUBLE+. The ICER of DOUBLE+ compared to EXAM+ improved (i.e., decreased) with decreasing prevalence of PD, decreasing accuracy of clinical examination, increasing accuracy of SPECT, and increasing consequence ratio.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This strategy remains more expensive than clinical examination only: the expected clinical gain was 0.55 ATMEs and the additional average costs were €406 for each patient of the target population (including those after negative clinical examination).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This result represents either assigning 17 additional days of treatment to a patient with PD or withholding about 2 additional days (i.e., 17 divided by 8.5) of treatment and side effects from a patient without PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, as in all diagnostic studies, the optimal test strategy depends on the pretest probability of the disease, in this case the prevalence of PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Increasing PD prevalence to 74%, which may not be entirely unlikely for a highly specialized movement disorder clinic, leads to an ICER of more than €2,400 per ATME.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“As data were lacking on health-related quality of life indices (utilities) in early treated and nontreated patients with and without PD, we were unable to convert this outcome into QALYs, which was suggested for the reference case of a cost–effectiveness analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Hence, our analysis may be biased against SPECT and overestimating the true cost–effectiveness ratios of this technology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Third, we did not consider other types of parkinsonian syndromes such as multisystem atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal ganglionic degeneration (CBGD), or Lewy body disease in our decision analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Fifth, it must be kept in mind that the results of this study are limited to a specialized movement disorder clinic.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Cost of alpha-synuclein seed amplification assay and skin biopsy testing

No evidence found.

Approaches to treatment

Current treatment options and standard of care
Levodopa
Initial therapy: levodopa compared with dopamine agonists in early disease

“Initial treatment with levodopa provides superior motor benefit compared to treatment with dopamine agonists, whereas levodopa is more likely than dopamine agonists to cause dyskinesia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Long-acting forms of levodopa and levodopa with entacapone do not appear to differ in efficacy from immediate-release levodopa for motor symptoms in early disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There is a higher risk of impulse control disorders associated with the use of dopamine agonists than levodopa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The trend over time demonstrates that levodopa provides greater benefit for motor symptoms than DAs, with the majority of studies demonstrating significantly greater improvement in the participants’ UPDRS part III score for up to 5 years of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“With longer periods of follow-up, an increasing proportion of participants (90% of patients at 6 years and 100% at 10 years) originally randomized to DAs were taking supplemental levodopa, therefore minimizing the difference between groups for this outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Initial treatment with levodopa is more likely to induce dyskinesia than initial treatment with DAs for up to 5 years of follow-up, but the prevalence of severe or disabling dyskinesia during this 5-year period is low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The minimal clinically important difference (MCID) in the UPDRS part III score was determined by consensus to be 3 points; changes of 1 point or less were considered unimportant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The MCID in the risk of dyskinesia was determined by consensus to be 15%; RDs ≤5% were considered clinically unimportant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Effect of levodopa on disease progression: placebo-controlled trial

“The severity of parkinsonism increased more in the placebo group than in all the groups receiving levodopa: the mean difference between the total score on the UPDRS at baseline and at 42 weeks was 7.8 units in the placebo group, 1.9 units in the group receiving levodopa at a dose of 150 mg daily, 1.9 in those receiving 300 mg daily, and −1.4 in those receiving 600 mg daily (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The subjects receiving the highest dose of levodopa had significantly more dyskinesia, hypertonia, infection, headache, and nausea than those receiving placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of a total of 361 subjects enrolled in the study, 317 (88 percent) took the study medication for 40 weeks, and 311 (86 percent) completed the 2 weeks of washout (Fig. 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We need to consider that a two-week washout from levodopa may have been insufficient to eliminate fully the effect of the medication on symptoms, and the results observed may be related to a profound effect of levodopa on symptoms that persists for a long time after the drug has been withdrawn.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The clinical data suggest that levodopa either slows the progression of Parkinson’s disease or has a prolonged effect on the symptoms of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In contrast, the neuroimaging data suggest either that levodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The potential long-term effects of levodopa on Parkinson’s disease remain uncertain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At the end of the study, when the SPECT neuroimaging studies were performed, the subjects were still taking levodopa, so it is possible to assume that levodopa has a pharmacologic effect on the dopamine transporter that interferes with and reduces the binding of the β-CIT ligand.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

CharacteristicPlaceboLevodopa 150 mg/dayLevodopa 300 mg/dayLevodopa 600 mg/dayP value
Participants, no.“90”View highlighted excerpt for this quote“92”View highlighted excerpt for this quote“88”View highlighted excerpt for this quote“91”View highlighted excerpt for this quoteNot applicable
Male sex, %“72”View highlighted excerpt for this quote“63”View highlighted excerpt for this quote“67”View highlighted excerpt for this quote“68”View highlighted excerpt for this quote“0.62”View highlighted excerpt for this quote
White race, %“90”View highlighted excerpt for this quote“91”View highlighted excerpt for this quote“93”View highlighted excerpt for this quote“88”View highlighted excerpt for this quote“0.67”View highlighted excerpt for this quote
Age, years, mean ± SD“64.9±10.3”View highlighted excerpt for this quote“64.3±10.6”View highlighted excerpt for this quote“63.8±12.1”View highlighted excerpt for this quote“65.2±10.7”View highlighted excerpt for this quote“0.84”View highlighted excerpt for this quote
Duration of disease, months, mean ± SD“5.3±5.6”View highlighted excerpt for this quote“5.7±6.1”View highlighted excerpt for this quote“7.6±7.5”View highlighted excerpt for this quote“6.0±6.1”View highlighted excerpt for this quote“0.10”View highlighted excerpt for this quote
Total UPDRS score, mean ± SD“27.7±12.0”View highlighted excerpt for this quote“27.2±12.6”View highlighted excerpt for this quote“27.5±11.6”View highlighted excerpt for this quote“29.4±13.9”View highlighted excerpt for this quote“0.63”View highlighted excerpt for this quote
UPDRS motor component, mean ± SD“18.8±8.9”View highlighted excerpt for this quote“18.6±9.1”View highlighted excerpt for this quote“18.9±8.8”View highlighted excerpt for this quote“20.5±10.8”View highlighted excerpt for this quote“0.51”View highlighted excerpt for this quote
Hoehn–Yahr scale score, mean ± SD“1.8±0.5”View highlighted excerpt for this quote“1.9±0.6”View highlighted excerpt for this quote“1.8±0.5”View highlighted excerpt for this quote“1.9±0.6”View highlighted excerpt for this quote“0.57”View highlighted excerpt for this quote
Change from baseline to week 42, mean ± SDPlaceboLevodopa 150 mg/dayLevodopa 300 mg/dayLevodopa 600 mg/dayP value for trend
Primary rater, participants, no.“70”View highlighted excerpt for this quote“78”View highlighted excerpt for this quote“82”View highlighted excerpt for this quote“81”View highlighted excerpt for this quoteNot applicable
Primary rater, total UPDRS score“7.8±9.0”View highlighted excerpt for this quote“1.9±6.0”View highlighted excerpt for this quote“1.9±6.9”View highlighted excerpt for this quote“−1.4±7.7”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary rater, mental component“0.3±1.5”View highlighted excerpt for this quote“0.0±1.5”View highlighted excerpt for this quote“0.1±1.2”View highlighted excerpt for this quote“0.1±1.4”View highlighted excerpt for this quote“0.18”View highlighted excerpt for this quote
Primary rater, ADL component“2.3±3.4”View highlighted excerpt for this quote“0.5±2.3”View highlighted excerpt for this quote“0.4±2.9”View highlighted excerpt for this quote“−0.3±3.0”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Primary rater, motor component“5.2±6.4”View highlighted excerpt for this quote“1.4±5.5”View highlighted excerpt for this quote“1.4±5.3”View highlighted excerpt for this quote“−1.4±5.9”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Treating investigator, total UPDRS score“9.0±10.4”View highlighted excerpt for this quote“4.0±8.2”View highlighted excerpt for this quote“4.0±8.4”View highlighted excerpt for this quote“1.0±9.9”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Treating investigator, mental component“0.5±1.3”View highlighted excerpt for this quote“−0.1±1.4”View highlighted excerpt for this quote“0.1±1.4”View highlighted excerpt for this quote“0.1±1.6”View highlighted excerpt for this quote“0.31”View highlighted excerpt for this quote
Treating investigator, ADL component“2.5±4.0”View highlighted excerpt for this quote“0.8±3.1”View highlighted excerpt for this quote“1.0±2.8”View highlighted excerpt for this quote“0.3±3.5”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Treating investigator, motor component“6.0±7.6”View highlighted excerpt for this quote“3.2±6.4”View highlighted excerpt for this quote“3.0±6.4”View highlighted excerpt for this quote“0.6±7.7”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Striatal β-CIT uptake, change from baseline to week 40PlaceboLevodopa 150 mg/dayLevodopa 300 mg/dayLevodopa 600 mg/dayP value for dose–response
Substudy cohort, participants, no.“29”View highlighted excerpt for this quote“33”View highlighted excerpt for this quote“37”View highlighted excerpt for this quote“36”View highlighted excerpt for this quoteNot applicable
Substudy cohort, change, %, mean ± SD“−2.6±11.3”View highlighted excerpt for this quote“−4.7±10.8”View highlighted excerpt for this quote“−3.7±9.1”View highlighted excerpt for this quote“−6.9±8.1”View highlighted excerpt for this quote“0.15”View highlighted excerpt for this quote
Substudy cohort, P value compared with placeboNot applicable“0.46”View highlighted excerpt for this quote“0.63”View highlighted excerpt for this quote“0.11”View highlighted excerpt for this quoteNot applicable
Excluding scans without dopaminergic deficit, participants, no.“26”View highlighted excerpt for this quote“28”View highlighted excerpt for this quote“34”View highlighted excerpt for this quote“28”View highlighted excerpt for this quoteNot applicable
Excluding scans without dopaminergic deficit, change, %, mean ± SD“−1.4±10.0”View highlighted excerpt for this quote“−6.0±10.3”View highlighted excerpt for this quote“−4.0±9.4”View highlighted excerpt for this quote“−7.2±7.6”View highlighted excerpt for this quote“0.036”View highlighted excerpt for this quote
Excluding scans without dopaminergic deficit, P value compared with placeboNot applicable“0.16”View highlighted excerpt for this quote“0.40”View highlighted excerpt for this quote“0.015”View highlighted excerpt for this quoteNot applicable
Dose-dependent dyskinesia, wearing off, and other adverse events over 40 weeks of levodopa
Adverse eventPlacebo (N = 90)Levodopa 150 mg/day (N = 92)Levodopa 300 mg/day (N = 88)Levodopa 600 mg/day (N = 91)P value for trend
Dyskinesia, no. (%)“3 (3.3)”View highlighted excerpt for this quote“3 (3.3)”View highlighted excerpt for this quote“2 (2.3)”View highlighted excerpt for this quote“15 (16.5)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Dystonia, no. (%)“19 (21.1)”View highlighted excerpt for this quote“19 (20.7)”View highlighted excerpt for this quote“14 (15.9)”View highlighted excerpt for this quote“12 (13.2)”View highlighted excerpt for this quote“0.30”View highlighted excerpt for this quote
Wearing off, no. (%)“12 (13.3)”View highlighted excerpt for this quote“15 (16.3)”View highlighted excerpt for this quote“16 (18.2)”View highlighted excerpt for this quote“27 (29.7)”View highlighted excerpt for this quote“0.06”View highlighted excerpt for this quote
On–off, no. (%)“3 (3.3)”View highlighted excerpt for this quote“1 (1.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (3.3)”View highlighted excerpt for this quote“0.26”View highlighted excerpt for this quote
Freezing of gait, no. (%)“13 (14.4)”View highlighted excerpt for this quote“9 (9.8)”View highlighted excerpt for this quote“6 (6.8)”View highlighted excerpt for this quote“5 (5.5)”View highlighted excerpt for this quote“0.15”View highlighted excerpt for this quote
Nausea, no. (%)“12 (13.3)”View highlighted excerpt for this quote“15 (16.3)”View highlighted excerpt for this quote“23 (26.1)”View highlighted excerpt for this quote“29 (31.9)”View highlighted excerpt for this quote“0.001”View highlighted excerpt for this quote
Headache, no. (%)“3 (3.3)”View highlighted excerpt for this quote“7 (7.6)”View highlighted excerpt for this quote“5 (5.7)”View highlighted excerpt for this quote“12 (13.2)”View highlighted excerpt for this quote“0.03”View highlighted excerpt for this quote
Hypertonia, no. (%)“1 (1.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (1.1)”View highlighted excerpt for this quote“5 (5.5)”View highlighted excerpt for this quote“0.03”View highlighted excerpt for this quote
Infection, no. (%)“1 (1.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“6 (6.6)”View highlighted excerpt for this quote“0.01”View highlighted excerpt for this quote
Dizziness, no. (%)“6 (6.7)”View highlighted excerpt for this quote“10 (10.9)”View highlighted excerpt for this quote“5 (5.7)”View highlighted excerpt for this quote“14 (15.4)”View highlighted excerpt for this quote“0.13”View highlighted excerpt for this quote
Somnolence, no. (%)“2 (2.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (5.7)”View highlighted excerpt for this quote“5 (5.5)”View highlighted excerpt for this quote“0.07”View highlighted excerpt for this quote
Fracture, no. (%)“4 (4.4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0.01”View highlighted excerpt for this quote
Leg pain, no. (%)“7 (7.8)”View highlighted excerpt for this quote“6 (6.5)”View highlighted excerpt for this quote“3 (3.4)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0.006”View highlighted excerpt for this quote
Effect of levodopa on disease progression: delayed-start trial

“A total of 445 patients were randomly assigned: 222 to the early-start group and 223 to the delayed-start group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The change in UPDRS score from baseline to week 80 was −1.0±13.1 points and −2.0±13.0 points, respectively (difference, 1.0 point; 95% confidence interval [CI], −1.5 to 3.5; P = 0.44); this finding of no significant between-group difference at week 80 implies that levodopa had no disease-modifying effect.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The change in the UPDRS score from baseline to week 40 was −3.1±10.2 in the early-start group and 2.0±12.3 in the delayed-start group (difference, −5.1 points; 95% CI, −7.2 to −2.9), favoring the early-start group and reflecting the effect of levodopa on symptoms of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Because of a need for symptomatic relief, 87 patients in the delayed-start group proceeded to receive the phase 2 trial medication (levodopa) before week 40, and 24 patients in the early-start group proceeded to open-label treatment with the same dose of levodopa.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The rates of dyskinesia and levodopa-related fluctuations in motor response did not differ significantly between the two groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“During the first 40 weeks of the trial, the incidence of nausea was higher in the early-start group than in the delayed start-group (23.0% vs. 14.3%, P = 0.02) (Table 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At 80 weeks, the percentage of patients with motor complications, including dyskinesias and fluctuations in motor response, did not differ significantly between the two groups (Table S5 in the Supplementary Appendix).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with early Parkinson’s disease, the clinical diagnosis may be incorrect in up to 15% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among patients with early Parkinson's disease who were evaluated over the course of 80 weeks, treatment with levodopa in combination with carbidopa had no disease-modifying effect.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Effect of levodopa on disease progression: 5-year follow-up of the delayed-start trial

“A total of 321 patients completed the 5-year visit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The adjusted square root transformed total Unified Parkinson’s Disease Rating Scale did not differ between treatment groups at 3 (estimated difference, 0.17; standard error, 0.13; P = 0.18) and 5 years (estimated difference, 0.24; standard error, 0.13; P = 0.07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We did not find a difference in disease progression or in prevalence of motor complications between patients with early PD starting treatment with a low dose of levodopa 40 weeks earlier versus 40 weeks later over the subsequent 5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 413 patients (93%) still had the diagnosis PD, and 27 patients (6%) did not have PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A substantial strength of the study is the high proportion of originally randomly assigned patients (77%) who completed the 5-year follow-up, minimizing the risk of bias caused by dropout.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Another limitation is the absence of a distinction between on or off drug state (ie, wearing off) while the UPDRS motor score was administrated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“During the study, 11 of 205 patients (5%) in the earlystart group and 22 of 213 patients (10%) in the delayed-start group died (P = 0.06).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, the difference in unadjusted between-group total UPDRS change score from baseline to 5 years is below the clinically important difference” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The outcomes were square root transformed due to skewness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“An estimate higher than zero indicates a higher score in the early-start group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

OutcomeEarly-start group, change from baseline, mean ± SDDelayed-start group, change from baseline, mean ± SDEstimated difference, square root transformed (SE)P value
3 years, UPDRS total (I + II + III)“2.6±11.4”View highlighted excerpt for this quote“0.9±12.8”View highlighted excerpt for this quote“0.17 (0.13)”View highlighted excerpt for this quote“0.18”View highlighted excerpt for this quote
3 years, UPDRS I“−0.2±1.8”View highlighted excerpt for this quote“−0.3±1.8”View highlighted excerpt for this quote“0.07 (0.09)”View highlighted excerpt for this quote“0.45”View highlighted excerpt for this quote
3 years, UPDRS II“1.3±4.2”View highlighted excerpt for this quote“1.1±3.7”View highlighted excerpt for this quote“0.03 (0.08)”View highlighted excerpt for this quote“0.68”View highlighted excerpt for this quote
3 years, UPDRS III“1.5±8.8”View highlighted excerpt for this quote“0.1±9.7”View highlighted excerpt for this quote“0.16 (0.11)”View highlighted excerpt for this quote“0.18”View highlighted excerpt for this quote
3 years, UPDRS IV“1.0±1.9”View highlighted excerpt for this quote“1.4±2.4”View highlighted excerpt for this quote“−0.13 (0.09)”View highlighted excerpt for this quote“0.18”View highlighted excerpt for this quote
3 years, Levy A“0.6±7.2”View highlighted excerpt for this quote“−0.4±8.1”View highlighted excerpt for this quote“0.14 (0.11)”View highlighted excerpt for this quote“0.20”View highlighted excerpt for this quote
3 years, Levy B“0.7±2.1”View highlighted excerpt for this quote“0.6±2.2”View highlighted excerpt for this quote“0.02 (0.08)”View highlighted excerpt for this quote“0.83”View highlighted excerpt for this quote
5 years, UPDRS total (I + II + III)“11.5±17.0”View highlighted excerpt for this quote“8.2±16.2”View highlighted excerpt for this quote“0.24 (0.13)”View highlighted excerpt for this quote“0.07”View highlighted excerpt for this quote
5 years, UPDRS I“0.4±2.2”View highlighted excerpt for this quote“0.2±1.9”View highlighted excerpt for this quote“0.11 (0.08)”View highlighted excerpt for this quote“0.17”View highlighted excerpt for this quote
5 years, UPDRS II“3.7±4.7”View highlighted excerpt for this quote“3.2±5.3”View highlighted excerpt for this quote“0.09 (0.08)”View highlighted excerpt for this quote“0.25”View highlighted excerpt for this quote
5 years, UPDRS III“7.4±13.7”View highlighted excerpt for this quote“4.7±11.9”View highlighted excerpt for this quote“0.21 (0.12)”View highlighted excerpt for this quote“0.09”View highlighted excerpt for this quote
5 years, UPDRS IV“2.4±2.9”View highlighted excerpt for this quote“2.2±2.4”View highlighted excerpt for this quote“<0.01 (0.09)”View highlighted excerpt for this quote“0.97”View highlighted excerpt for this quote
5 years, Levy A“4.7±10.9”View highlighted excerpt for this quote“2.9±9.4”View highlighted excerpt for this quote“0.15 (0.12)”View highlighted excerpt for this quote“0.20”View highlighted excerpt for this quote
5 years, Levy B“2.1±3.0”View highlighted excerpt for this quote“1.5±2.4”View highlighted excerpt for this quote“0.11 (0.08)”View highlighted excerpt for this quote“0.16”View highlighted excerpt for this quote
Levodopa compared with levodopa-sparing initial therapy: pragmatic trial

“Between Nov 9, 2000, and Dec 22, 2009, 1620 patients were assigned to study groups (528 to levodopa, 632 to dopamine agonist, 460 to MAOBI).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“With 3-year median follow-up, PDQ-39 mobility scores averaged 1·8 points (95% CI 0·5–3·0, p=0·005) better in patients randomly assigned to levodopa than those assigned to levodopa-sparing therapy, with no increase or attrition of benefit during 7 years’ observation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Very small but persistent benefits are shown for patient-rated mobility scores when treatment is initiated with levodopa compared with levodopa-sparing therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients in the levodopa group were more likely to develop dyskinesias than those in the levodopa-sparing group (hazard ratio [HR] 1·52, 95% CI 1·16–2·00, p=0·003; figure 5), but there was no difference in motor fluctuations (1·11, 0·90–1·37, p=0·3; appendix).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Thus, the benefits of levodopa compared with levodopa-sparing are unquestionably small.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Thus, there seem to be no grounds for concerns that use of levodopa as first-line therapy results in worse long-term outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Dopamine agonists
Dopamine agonists compared with levodopa in early disease: impulse control disorders and other adverse effects

“DAs (vs levodopa) are associated with an increased risk of ICDs, EDS, sudden-onset sleep, nausea, and hallucinations in patients with early PD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Conclusion (moderate confidence): In early PD, DAs are probably more likely than levodopa to cause ICDs at 2 years (3 Class III studies, RD 23.2%, 95% confidence interval [CI] 14.3–32.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Conclusion (low confidence): In early PD, DAs are possibly more likely than levodopa to cause ICDs at 5 years (2 Class III studies, RD 23.7%, 95% CI 1.1–46.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The MCID in the risk of ICDs was determined by consensus to be 2%; RDs ≤1% were considered clinically unimportant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although initial treatment with DAs is possibly more likely to cause hallucinations than treatment with levodopa, the difference between treatments for this outcome is small for the first 5 years of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although the trend suggests that AE-related discontinuation of treatment is higher with DAs than with levodopa at all time points, confidence in the evidence is low or very low due to study quality or poor precision of estimates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Non-ergot dopamine agonists: evidence-based review implications for clinical practice by indication
Prolonged-release dopamine agonists and early-morning OFF periods: observational study
Monoamine oxidase B inhibitors
Levodopa compared with MAO-B inhibitors in early disease: systematic review findings

“Studies comparing treatment with levodopa to treatment with MAO-B inhibitors early in the disease course provide Class IV evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These studies demonstrate greater improvement in mobility with levodopa than with MAO-B inhibitors, a higher risk of AE-related discontinuation with MAO-B inhibitors, and that >60% of individuals randomized to MAO-B inhibitors will require additional therapy within 2 to 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were inadequate data on the effect of levodopa vs MAO-B inhibitors on motor symptoms, preventing effect size calculations (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There are no studies comparing the efficacy of selegiline and rasagiline in the treatment of early PD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Prescribing information for selegiline and rasagiline caution against their use with selective serotonin reuptake inhibitors (SSRIs); however, serotonin syndrome is rarely reported in patients with PD on concomitant therapy with an MAO-B inhibitor and an SSRI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

MAO-B inhibitors compared with dopamine agonists as initial therapy

“PDQ-39 mobility scores were 1·4 points (95% CI 0·0–2·9, p=0·05) better in patients allocated MAOBI than in those allocated dopamine agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“MAOBI as initial levodopa-sparing therapy was at least as effective as dopamine agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Rates of dyskinesia were similar (HR 0·85, 95% CI 0·60−1·22, p=0·4), but motor fluctuations were higher (HR 1·32, 95% CI 1·01−1·72, p=0·04) in the dopamine agonist group than in the MAOBI group (appendix).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“5-year decline in MMSE was greater in participants allocated dopamine agonists than in those allocated MAOBI (2·4 [SD 4·4] vs 1·3 [3·7], p=0·04), but there was no significant difference in the number of patients developing dementia (HR 1·11, 95% CI 0·77−1·59, p=0·6; appendix), entering institutional care (1·08, 0·70−1·64, p=0·7, appendix), or dying (0·96, 0·73−1·28, p=0·8, appendix).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Notably, the onset of dyskinesia was not significantly higher with MAOBI than with dopamine agonists, and fewer motor fluctuations were reported with initial MAOBI therapy, so avoiding motor complications should not be a reason to prefer dopamine agonists over MAOBI therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Catechol-O-methyltransferase inhibitors
Levodopa initiated with entacapone in early disease

“We performed a prospective 134-week double-blind trial comparing the risk of developing dyskinesia in 747 PD patients randomized to initiate L-dopa therapy with L-dopa/carbidopa (LC) or L-dopa/carbidopa/entacapone (LCE), administered 4× daily at 3.5-hour intervals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Eligible subjects were men or women aged 30 to 70 years with a diagnosis of PD based on UK brain bank criteria and a disease duration of <5 years from time of diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Prior exposure to L-dopa for >30 days or within 8 weeks prior to entry, and previous use of a COMT inhibitor, were not permitted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“L-dopa/carbidopa in both groups was initiated at a dose of 50/12.5mg twice daily, and titrated to 100/25 (target dose) or 150/37.5mg 4× daily administered at 3.5-hour intervals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“With a follow-up time of 134 weeks and an estimated dropout rate of 15%, a sample size of 740 patients provided >80% power to detect a 25% reduction in dyskinesia frequency using the 2-sided log-rank test at an alpha level of 5%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In comparison to LC, patients receiving LCE had a shorter time to onset of dyskinesia (hazard ratio, 1.29; p = 0.04) and increased frequency at week 134 (42% vs 32%; p = 0.02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Kaplan-Meier survival curves show that patients randomized to L-dopa/carbidopa/entacapone (LCE) had greater risk of developing dyskinesia than patients receiving L-dopa/carbidopa (LC) (Cox proportional hazard ratio, 1.29; 95% confidence interval [CI], 1.0–1.65; p = 0.038).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients in the LCE group received greater L-dopa dose equivalents than LC-treated patients (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“There was a trend to improved UPDRS scores in LCE-treated subjects (difference at final visit, 1.2 points; p = 0.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Survival time estimates for the first quartile of patients were 90.7 weeks (95% CI, 65.3–104.0) for the LCE group and 117.1 weeks (95% CI, 92.1–132.6) for LC-treated patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 541 subjects (72.6%) completed their study drug treatment as planned; 265 (71.0%) in the LCE group and 276 (74.2%) in the LC group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“LCE showed a trend toward improved UPDRS scores and reduced wearing off compared to LC, consistent with the approved indication of entacapone as an adjunct to L-dopa.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean L-dopa dose at the end of the titration period was 305.2 and 306.8mg/day in the LCE and LC groups, respectively, and they remained comparable throughout the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This analysis indicates that LCE-treated patients received significantly more L-dopa dose equivalents than LC patients at the completion of titration, at the time of onset of dyskinesia, and at the final study visit (see Table 5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“STRIDE-PD does not support the early administration of L-dopa in combination with entacapone to reduce the risk of motor complications using the dosing regimen employed in this trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Baseline characteristicLevodopa/carbidopa/entacapone (n = 373)Levodopa/carbidopa (n = 372)
Age, years, mean ± SD“60.6±8.7”View highlighted excerpt for this quote“59.8±8.2”View highlighted excerpt for this quote
Men, no. (%)“245 (65.7%)”View highlighted excerpt for this quote“222 (59.7%)”View highlighted excerpt for this quote
Caucasian, no. (%)“352 (94.4%)”View highlighted excerpt for this quote“357 (96.0%)”View highlighted excerpt for this quote
Weight, kg, mean ± SD“79.7±15.8”View highlighted excerpt for this quote“79.1±16.9”View highlighted excerpt for this quote
Duration of disease, years, mean ± SD“2.0±1.6”View highlighted excerpt for this quote“2.0±1.7”View highlighted excerpt for this quote
UPDRS total (II + III), mean ± SD“32.7±12.6”View highlighted excerpt for this quote“31.5±11.9”View highlighted excerpt for this quote
UPDRS Part III (motor), mean ± SD“23.1±9.5”View highlighted excerpt for this quote“22.4±9.0”View highlighted excerpt for this quote
Hoehn & Yahr stage, mean ± SD“1.9±0.5”View highlighted excerpt for this quote“1.9±0.5”View highlighted excerpt for this quote
PDQ-39, mean ± SD“25.2±15.0”View highlighted excerpt for this quote“22.9±13.7”View highlighted excerpt for this quote
Previous antiparkinson medication, no. (%)“263 (70.5%)”View highlighted excerpt for this quote“266 (71.5%)”View highlighted excerpt for this quote
Dopamine agonist use, no. (%)“217 (58.2%)”View highlighted excerpt for this quote“217 (58.3%)”View highlighted excerpt for this quote
Levodopa/carbidopa/entacapone compared with levodopa/carbidopa: dyskinesia, wearing off, and dose equivalents
OutcomeLevodopa/carbidopa/entacapone (n = 373)Levodopa/carbidopa (n = 372)P value
Dyskinesia frequency at 208 weeks, no. (%)“144 (38.6)”View highlighted excerpt for this quote“123 (33.1)”View highlighted excerpt for this quote“0.110”View highlighted excerpt for this quote
Time to dyskinesia, first-quartile estimate, weeks (95% CI)“90.7 (65.3–104.0)”View highlighted excerpt for this quote“117.1 (92.1–132.6)”View highlighted excerpt for this quote“0.038”View highlighted excerpt for this quote
Disabling dyskinesia, no. (%)“32 (8.6)”View highlighted excerpt for this quote“23 (6.2)”View highlighted excerpt for this quote“0.201”View highlighted excerpt for this quote
Dyskinesia by direct observation, no. (%)“130 (34.9)”View highlighted excerpt for this quote“110 (29.6)”View highlighted excerpt for this quote“0.118”View highlighted excerpt for this quote
Dyskinesia by patient history, no. (%)“141 (37.8)”View highlighted excerpt for this quote“113 (30.4)”View highlighted excerpt for this quote“0.031”View highlighted excerpt for this quote
Dyskinesia by direct observation or patient history on 2 consecutive visits, no. (%)“120 (32.2)”View highlighted excerpt for this quote“99 (26.6)”View highlighted excerpt for this quote“0.092”View highlighted excerpt for this quote
Dyskinesia by direct observation on 2 consecutive visits, no. (%)“84 (22.5)”View highlighted excerpt for this quote“77 (20.7)”View highlighted excerpt for this quote“0.550”View highlighted excerpt for this quote
Dyskinesia frequency at 134 weeks, no.“128”View highlighted excerpt for this quote“103”View highlighted excerpt for this quote“0.016”View highlighted excerpt for this quote
UPDRS II + III, change from baseline to week 130“8.4”View highlighted excerpt for this quote“7.2”View highlighted excerpt for this quote“0.18”View highlighted excerpt for this quote
Wearing off frequency at 208 weeks, no. (%)“165 (44.2%)”View highlighted excerpt for this quote“189 (50.8%)”View highlighted excerpt for this quote“0.07”View highlighted excerpt for this quote
Wearing off frequency at 130 weeks, no. (%)“139 (45.6%)”View highlighted excerpt for this quote“161 (48.3%)”View highlighted excerpt for this quote“0.53”View highlighted excerpt for this quote
Time to wearing off, weeks, mean ± SD“72.9±50.9”View highlighted excerpt for this quote“78.5±51.5”View highlighted excerpt for this quote“0.53”View highlighted excerpt for this quote
Time to wearing off, first-quartile estimate, weeks“78.0”View highlighted excerpt for this quote“76.0”View highlighted excerpt for this quote“0.6”View highlighted excerpt for this quote
Time to wearing off, hazard ratio (95% CI)“0.94 (0.76–1.17)”View highlighted excerpt for this quoteNot applicableNot reported
Hoehn & Yahr stage, change from baseline“0.4”View highlighted excerpt for this quote“0.3”View highlighted excerpt for this quote“NS”View highlighted excerpt for this quote
Schwab & England score, change from baseline“−1.4”View highlighted excerpt for this quote“−1.4”View highlighted excerpt for this quote“0.95”View highlighted excerpt for this quote
PDQ-39, change from baseline“2.2”View highlighted excerpt for this quote“2.4”View highlighted excerpt for this quote“0.77”View highlighted excerpt for this quote
Levodopa dose equivalents at end of titration“533.4”View highlighted excerpt for this quote“420.1”View highlighted excerpt for this quote“0.001”View highlighted excerpt for this quote
Levodopa dose equivalents at onset of dyskinesia“659.9”View highlighted excerpt for this quote“535.2”View highlighted excerpt for this quote“0.001”View highlighted excerpt for this quote
Levodopa dose equivalents at final study visit“524.1”View highlighted excerpt for this quote“432.6”View highlighted excerpt for this quote“0.001”View highlighted excerpt for this quote
Adverse events with levodopa/carbidopa/entacapone compared with levodopa/carbidopa in early disease
Amantadine
Adenosine A2A receptor antagonists
On-demand therapies
Device-aided therapies
Deep brain stimulation in early motor complications

“In this 2-year trial, we randomly assigned 251 patients with Parkinson's disease and early motor complications (mean age, 52 years; mean duration of disease, 7.5 years) to undergo neurostimulation plus medical therapy or medical therapy alone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For the primary outcome of quality of life, the mean score for the neurostimulation group improved by 7.8 points, and that for the medical-therapy group worsened by 0.2 points (between-group difference in mean change from baseline to 2 years, 8.0 points; P = 0.002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Time with good mobility and no troublesome dyskinesia, as recorded by the patients in daily diaries, increased by 20% in the neurostimulation group, with a between-group difference of 1.9 hours (P = 0.01)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Time with bad mobility was significantly shortened in the neurostimulation group, with a between-group difference of 1.8 hours (P = 0.006)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The levodopa-equivalent daily dose was reduced by 39% in the neurostimulation group but was increased by 21% in the medical-therapy group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Serious adverse events related to surgical implantation or the neurostimulation device occurred in 17.7% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Deep brain stimulation in early motor complications: serious adverse events
Serious adverse eventNeurostimulation (N = 124), participants with event (%)Medical therapy (N = 127), participants with event (%)
Any serious adverse event“68 (54.8)”View highlighted excerpt for this quote“56 (44.1)”View highlighted excerpt for this quote
Death, all by suicide“2 (1.6)”View highlighted excerpt for this quote“1 (0.8)”View highlighted excerpt for this quote
Event related to medication or stimulation“24 (19.4)”View highlighted excerpt for this quote“38 (29.9)”View highlighted excerpt for this quote
Worsening of mobility“5 (4.0)”View highlighted excerpt for this quote“11 (8.7)”View highlighted excerpt for this quote
Motor fluctuations“0”View highlighted excerpt for this quote“7 (5.5)”View highlighted excerpt for this quote
Psychosis or hallucinations“0”View highlighted excerpt for this quote“6 (4.7)”View highlighted excerpt for this quote
Impulse control disorder“1 (0.8)”View highlighted excerpt for this quote“5 (3.9)”View highlighted excerpt for this quote
Depression“6 (4.8)”View highlighted excerpt for this quote“1 (0.8)”View highlighted excerpt for this quote
Suicide attempt“2 (1.6)”View highlighted excerpt for this quote“2 (1.6)”View highlighted excerpt for this quote
Event related to surgery or device“22 (17.7)”View highlighted excerpt for this quoteNot applicable
Impaired wound healing“4 (3.2)”View highlighted excerpt for this quoteNot applicable
Intracerebral abscess or edema“2 (1.6)”View highlighted excerpt for this quoteNot applicable
Dislocation of device“4 (3.2)”View highlighted excerpt for this quoteNot applicable
Reoperation necessary“2 (1.6)”View highlighted excerpt for this quoteNot applicable
Deep brain stimulation in early motor complications: trial population and funding

“Patients with Parkinson’s disease were eligible for the study if they met the following inclusion criteria: an age of 18 to 60 years; disease duration of 4 years or more; a disease severity rating below stage 3 in the on-medication condition, according to the Hoehn and Yahr scale, with scores ranging from 0 to 5 and higher scores indicating more severe disease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The mean duration of Parkinson’s disease was 7.5 years, and patients were included in the study a mean of 1.7 years after the onset of levodopa-induced motor complications of any severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This patient population with relatively mild parkinsonian motor signs differed from the populations in previous controlled studies of neurostimulation: the mean duration of disease in the patients in our study was only 7.5 years, as compared with 11.1 to 13.8 years” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Medtronic provided additional funding for the study but had no role in the study design, data accrual, data analysis, or manuscript preparation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Neurostimulation may be a therapeutic option for patients at an earlier stage than current recommendations suggest.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Focused ultrasound pallidotomy

“In the active-treatment group, 45 patients (69%) had a response, as compared with 7 (32%) in the control group (difference, 37 percentage points; 95% confidence interval, 15 to 60; P = 0.003).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Pallidotomy-related adverse events in the active-treatment group included dysarthria, gait disturbance, loss of taste, visual disturbance, and facial weakness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At 6 months, among 50 patients who initially underwent FUSA of the globus pallidus internus and had available data, 38 (76%) had a response; 53 of 65 patients in the active-treatment group were available for the 12-month follow-up, and 37 of 53 (70%) had a response at 12 months” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 45 patients in the active-treatment group who had a response at 3 months, 6 were lost to follow-up and 9 no longer had a response at 12 months” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Gait disturbance and loss of taste were mild, and they resolved; however, moderate dysarthria in one patient persisted for 1 year. Visual disturbance and mild facial weakness were observed in one patient each at 3 months and were resolved by 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Fifteen adverse events in the active-treatment group (10 patients) and 1 adverse event in the control group fulfilled FDA criteria for a serious adverse event during the 12-month follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The nonfatal pulmonary embolism, which occurred within 1 week after treatment, was the only serious adverse event categorized by the data and safety monitoring board as procedure-related.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Focused ultrasound subthalamotomy

“Among 40 enrolled patients, 27 were assigned to focused ultrasound subthalamotomy (active treatment) and 13 to the sham procedure (control).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Focused ultrasound subthalamotomy in one hemisphere improved motor features of Parkinson's disease in selected patients with asymmetric signs. Adverse events included speech and gait disturbances, weakness on the treated side, and dyskinesia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“the between-group difference was 8.1 points (95% CI, 6.0 to 10.3; P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The change from baseline to 12 months in the MDS-UPDRS III score for the more affected side among 25 patients with available data in the active-treatment group was 11.6 points (95% CI, 9.9 to 13.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Among the 27 patients in the active-treatment group, new-onset dyskinesia on the treated side occurred in 12 patients, persisted in 3 at the 4-month primary safety evaluation, and persisted in 2 at 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Speech disturbance developed in 15 patients (56%) in the active-treatment group and persisted in 3 patients at 4 months and in 1 patient at 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Strength in both patients had recovered at 12 months, but hand clumsiness and asymmetric stride persisted in both.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In 6 patients in the active-treatment group, some of these deficits were present at 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“No complications of the active procedure were detected by MRI, except for perilesional edema, which resolved by 4 months in all the patients in this group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“There were no intracerebral hemorrhages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Limitations of current therapies
Summary

No available therapy has been shown to modify the course of Parkinson's disease. The 2018 International Parkinson and Movement Disorder Society evidence-based review found no clinically useful interventions to prevent or delay progression, and in the LEAP delayed-start trial (445 participants) early levodopa had no disease-modifying effect over 80 weeks. Treatment is therefore symptomatic, and each symptomatic class carries a trade-off.

Initial levodopa gives greater motor benefit than initial dopamine agonists, but long-term oral use is complicated by motor and nonmotor fluctuations in up to 80% of patients. In STRIDE-PD (747 participants), dyskinesia was present at week 134 in 42% of participants who started levodopa/carbidopa/entacapone and 32% of those who started levodopa/carbidopa. In the 5-year follow-up of LEAP, 46 of 160 early-start and 62 of 161 delayed-start participants had dyskinesia.

Adjunctive oral therapy for motor fluctuations yields off-time reductions near the 1-hour minimal clinically important difference. In a network meta-analysis of 74 randomized controlled trials (18,693 participants), the weighted mean reduction in daily off-time relative to placebo was 1.1 hours for dopamine agonists, 0.9 hours for MAO-B inhibitors, and 0.8 hours for COMT inhibitors, and all three classes increased the odds of dyskinesia (odds ratios 3.0, 1.6, and 3.3). Head-to-head evidence is limited. In the PD MED trial of initial therapy (1,620 participants), 179 of 632 participants (28%) assigned dopamine agonists and 104 of 460 (23%) assigned MAO-B inhibitors discontinued their allocated treatment because of side effects, compared with 11 of 528 (2%) assigned levodopa.

The currently available dopamine agonists act mainly on D2/D3 receptors and carry neuropsychiatric and sleep-related risks. In a cross-sectional study of 3,090 participants, impulse control disorders were present in 17.1% of those taking a dopamine agonist and 6.9% of those not taking one (odds ratio 2.72). In a longitudinal cohort of 306 participants without impulse control disorders at baseline, the 5-year cumulative incidence was 46.1% overall and 51.5% among dopamine agonist users. The pooled relative risk of somnolence with pramipexole or ropinirole compared with placebo was 4.98. Reducing or stopping a dopamine agonist can cause dopamine agonist withdrawal syndrome, which occurred in 5 of 26 participants (19%) in a retrospective cohort and 12 of 51 (24%) in a prospective cohort.

Device-aided therapies add procedural and tolerability burdens. In EARLYSTIM, serious adverse events related to surgical implantation or the device occurred in 17.7% of participants. Discontinuation with subcutaneous foslevodopa/foscarbidopa was 35.1% in the 12-week randomized trial and 44.8% in the 12-month open-label study.

Dyskinesia and wearing-off prevalence after early or delayed levodopa initiation

“At 5 years, 46 of 160 patients in the early-start group and 62 of 161 patients in the delayed-start group experienced dyskinesia (P = 0.06).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The prevalence of wearing off at 5 years did not differ between the early-start (58/160 patients, 36%) and delayed-start group (58/161 patients, 36%) (Supporting Information Table S3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, the prevalence of any wearing off during the waking day at 5 years was 36% for both treatment groups and mainly consisted of patients with 1% to 25% of the time during the waking day spent in off drug state.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, there was no between-group difference at week 80 in the prevalence of dyskinesia, but there was a higher prevalence of early signs of motor response fluctuations in the delayed-start group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The results showed that motor complications are not associated with the duration of levodopa use, but that they are associated with disease duration and a higher levodopa daily dose.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Levodopa motor complications: pooled risk estimate at 4 to 6 years and its clinical significance

“Hence, it seems likely that the approximate 40% frequency of motor fluctuations and slightly less than 40% frequency of dyskinesias is a very reasonable risk estimate relating to 4–6 years of levodopa treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For example, in one series, dyskinesias and motor fluctuations were reported in over 90% of young-onset PD patients within 5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, these findings should not be interpreted as estimates of clinically important levodopa motor complication morbidity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“By 4 to 6 years, slightly more than one-third of these modern era patients had experienced dyskinesias (the median of 21 clinical series).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“As shown in Table 1, only three modern era series were identified that reported the cumulative dyskinesia frequency at very long durations of therapy (≥9 years); the median dyskinesia frequency in this group was nearly 90%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Hence, the clinically important morbidity may be substantially less than the frequency values tabulated herein.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Duration of levodopa therapy, modern era seriesDyskinesia, median %, unweightedDyskinesia, median %, weighted by NDyskinesia, rangeDyskinesia, total NMotor fluctuations, median %, unweightedMotor fluctuations, median %, weighted by NMotor fluctuations, rangeMotor fluctuations, total N
7–12 months“7.5”View highlighted excerpt for this quote“7.0”View highlighted excerpt for this quote“0–38.9%”View highlighted excerpt for this quote“432”View highlighted excerpt for this quote“1.5”View highlighted excerpt for this quote“3.0”View highlighted excerpt for this quote“0–16%”View highlighted excerpt for this quote“112”View highlighted excerpt for this quote
13–24 months“25.9”View highlighted excerpt for this quote“28.7”View highlighted excerpt for this quote“10.3–35.4%”View highlighted excerpt for this quote“575”View highlighted excerpt for this quote“45.7”View highlighted excerpt for this quote“47.9”View highlighted excerpt for this quote“0–50.4%”View highlighted excerpt for this quote“700”View highlighted excerpt for this quote
2.5–3.5 years“28.0”View highlighted excerpt for this quote“26.9”View highlighted excerpt for this quote“13.2–40%”View highlighted excerpt for this quote“747”View highlighted excerpt for this quote“23.3”View highlighted excerpt for this quote“31.0”View highlighted excerpt for this quote“5–35.1%”View highlighted excerpt for this quote“849”View highlighted excerpt for this quote
4–6 years“38.5”View highlighted excerpt for this quote“36.2”View highlighted excerpt for this quote“8–64%”View highlighted excerpt for this quote“1,599”View highlighted excerpt for this quote“42.1”View highlighted excerpt for this quote“40.8”View highlighted excerpt for this quote“11.8–60%”View highlighted excerpt for this quote“1,817”View highlighted excerpt for this quote
9–15+ years“87.8”View highlighted excerpt for this quote“87.8”View highlighted excerpt for this quote“60.7–95.5%”View highlighted excerpt for this quote“514”View highlighted excerpt for this quote“69.6”View highlighted excerpt for this quote“69.6”View highlighted excerpt for this quote“40.9–82.9%”View highlighted excerpt for this quote“514”View highlighted excerpt for this quote
Dyskinesia risk with levodopa and dopamine agonist initiation strategies

“Long-acting dopamine agonists are associated with a reduced risk of inducing motor complications” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“but have less efficacy than L-dopa and are associated with other side effects such as psychosis and impulse control disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Furthermore, nearly all dopamine agonist-treated patients eventually require L-dopa and develop dyskinesias at a rate similar to what is observed when L-dopa is initiated without dopamine agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Thus, the development of a treatment strategy that provides the benefits of L-dopa with reduced motor complications remains among the major unmet medical needs in PD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Further, higher doses of L-dopa in both LC and LCE groups were associated with increased dyskinesias (26.4% of 375 patients receiving ≤400mg/day of L-dopa compared with 45.4% of 370 patients receiving >400mg/day; p = 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The study confirms that higher doses of L-dopa are associated with an increased risk of dyskinesia, and supports careful L-dopa dose titration, using the lowest dose of L-dopa that provides satisfactory clinical control.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Discontinuation of levodopa-sparing therapy because of side effects

“179 (28%) of 632 patients allocated dopamine agonists and 104 (23%) of 460 patients allocated MAOBI discontinued allocated treatment because of side-effects compared with 11 (2%) of 528 patients allocated levodopa (p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For compliance, participants allocated MAOBI or dopamine agonists were significantly more likely to discontinue their allocated drug class than those allocated levodopa: 7-year probabilities were 72% for MAOBI, 50% for dopamine agonists, and 7% for levodopa (p<0·0001, figure 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The side-effects (mainly psychological, sleep disturbance, and gastrointestinal) were usually mild, only 16 patients (nine given dopamine agonists, four given MAOBI, and three given levodopa) had serious adverse events believed to be possibly related to trial treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Participants allocated and still taking MAOBI or dopamine agonists were also significantly more likely than those allocated levodopa to need a drug from another class added to their treatment: 2-year probabilities were 64% for MAOBI, 40% for dopamine agonists, and 20% for levodopa (p<0·0001, appendix).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Dopamine agonist withdrawal syndrome: review

“Dopamine agonist withdrawal syndrome affects even up to 24% of PD patients treated with DAs in whom the medication was tapered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Dopamine agonist withdrawal syndrome remains a therapeutic challenge as it is refractory to levodopa (LD), other PD therapies, anti-depressants, and anti-psychotics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Based on a thorough literature review, it may develop in around 8–24% of PD patients during DAs withdrawal” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The majority of the literature agrees that the major risk factors for the development of DAWS are as follows: high cumulative DAs exposure, high baseline dose (the higher the dose and the longer the duration of use, the greater the risk of developing DAWS), high peak DAs dose (≥ 150 mg LEDD), diagnosis of ICD in the past, increased vulnerability to addictive behaviors, and neurobiological causes such as mesocorticolimbic dysfunction” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Symptoms of DAWS can last for several months or even years or resolve spontaneously without management” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“There is no specific treatment of DAWS with proven efficacy. Treatment in this syndrome should always be individualized, symptomatic, and long-term. This syndrome is refractory to LD. Reintroduction of DAs seems to be the only procedure alleviating the symptoms of DAWS” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Place in treatment, anticipated use, and care setting
Summary

Tavapadon was studied in 2 settings. As monotherapy in early Parkinson's disease, TEMPO-1 (529 participants) and TEMPO-2 (304 participants) enrolled adults aged 40 to 80 years with disease duration under 3 years who were treatment-naive or had less than 3 months of prior dopaminergic treatment. As an adjunct to levodopa, TEMPO-3 (507 participants) enrolled adults with motor fluctuations on a fixed levodopa dose. The company describes the drug as studied as a once-daily oral treatment.

In early disease, tavapadon enters a setting in which the AAN guideline asks clinicians to counsel on the benefits and risks of levodopa, dopamine agonists, and MAO-B inhibitors, permits a dopamine agonist as initial therapy in select patients younger than 60 years at higher risk of dyskinesia, and advises against dopamine agonists in patients older than 70 years or with impulse control disorders, cognitive impairment, excessive daytime sleepiness, or hallucinations.

As an adjunct, tavapadon joins dopamine agonists, MAO-B inhibitors, COMT inhibitors, extended-release amantadine, and istradefylline. In pooled analyses, oral adjunct classes reduce off-time by 0.8 to 1.1 hours per day relative to placebo; TEMPO-3 reported a 1.1-hour increase in good on-time relative to placebo.

The proposed differentiation is D1/D5 selectivity, hypothesized to lower the risk of impulse control disorders, somnolence, and other adverse events attributed to D2/D3 stimulation. A 2026 meta-analysis rated the estimates for impulse control disorder (relative risk 2.02, 95% CI 0.51 to 8.00; 1 trial) and somnolence (pooled relative risk 1.20, 95% CI 0.37 to 3.92) as very low certainty and found that no trial used an active comparator or lasted longer than 27 weeks. A 2026 review stated that studies of drugs selectively targeting D1 receptors do not support improved safety and tolerability.

NICE advises seeking specialist advice before modifying therapy once dyskinesia or motor fluctuations develop. Analysts quoted at approval expected gradual uptake while Medicare coverage was negotiated.

Background and interpretation of the flexible-dose monotherapy trial

“Current dopaminergic therapies for Parkinson’s disease carry significant limitations: levodopa can cause long-term motor complications, while D2/D3 receptor-targeting dopamine agonists can produce non-motor adverse effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Although a broad range of investigative therapies are in development for symptomatic treatment of Parkinson’s disease, many recent trials have focused on the treatment of advanced Parkinson’s disease, and few novel therapies have been approved for monotherapy in early-stage Parkinson’s disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A key unmet need for Parkinson’s disease is the availability of treatment modalities that provide a balance of dopamine signalling to improve motor symptoms while reducing the risk of specific adverse events associated with current D2/D3 receptor-targeting dopamine agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Tavapadon showed significant and clinically meaningful improvements in Parkinson’s disease motor symptoms, with low incidence of somnolence and impulse control disorders. However, the short observation period limits conclusions about long-term tolerability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The results of TEMPO-2, alongside the evidence from the TEMPO-1 and TEMPO-3 trials, provide a comprehensive body of evidence supporting the efficacy of tavapadon across the different stages of Parkinson’s disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“More data are required to compare tavapadon with approved D2/D3 dopamine agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Positioning against existing dopamine agonists and adjuncts in a meta-analysis

“When viewed alongside the existing literature, the efficacy observed with tavapadon appears broadly comparable to that reported for established dopamine agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This magnitude of improvement is clinically meaningful and is broadly comparable to benefits reported for established adjunctive therapies such as opicapone, safinamide, and entacapone” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Discontinuation due to adverse events was, however, significantly more frequent with tavapadon (RR 2.72; 95% CI 1.07 to 6.96), and the substantial heterogeneity of that estimate (I² = 65.2%) indicates that tolerability is strongly influenced by titration strategy, patient population and adverse-event management. Tolerability, rather than serious harm, is therefore the principal safety consideration for clinical use.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“On present evidence that profile is untested, and the class cannot yet be preferred on neuropsychiatric grounds.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Longer-term, adequately powered, head-to-head comparative studies are necessary before its place within treatment algorithms can be defined.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Heterogeneity of treatment effect
Concomitant dopamine agonists and dyskinesia with levodopa/carbidopa/entacapone

“These effects were more pronounced in patients receiving dopamine agonists at baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In patients receiving dopamine agonists, LCE-treated patients had a greater risk of dyskinesia (hazard ration, 1.55; p = 0.006), and a greater frequency of dyskinesia (41.9% vs 31.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“However, there was no difference in the time to onset (hazard ratio, 0.99; 95% CI, 0.68–1.45; p = 0.96) or frequency (34% vs 35.5%) of dyskinesia between patients in the LCE and LC groups for those not receiving dopamine agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Kaplan-Meier survival curves show that among patients who were receiving dopamine agonists at baseline, those randomized to L-dopa/carbidopa/entacapone (LCE) had greater risk of developing dyskinesia than those receiving L-dopa/carbidopa (LC) (Cox proportional hazard ratio, 1.55; 95% confidence interval [CI], 1.13–2.13; p = 0.006).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The estimated first quartile time to onset of dyskinesia was 78.9 weeks for the LCE group and 117.4 weeks for LC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The adjusted mean difference in change from baseline to final visit in UPDRS score between the LCE and LC groups was greater in those receiving concomitant dopamine agonists (difference, 1.8; p = 0.08) than in those who were not (difference, −0.1; p = 0.95).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients on dopamine agonists were younger (58.7±8.6 vs 62.3±7.8 years; p < 0.001), had longer disease duration (2.5±1.6 vs 1.3±1.5 years; p < 0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients receiving dopamine agonists had a higher frequency of dyskinesias, and LCE was significantly more prone than LC to induce dyskinesias in this subpopulation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This is likely because patients on dopamine agonists were younger at baseline, were about 5 years younger at disease onset, had longer disease duration, and probably had greater disease severity as they had comparable baseline UPDRS scores despite receiving dopamine agonists.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“It is interesting that LCE did not increase the frequency or shorten the time to onset of dyskinesia in patients not on dopamine agonists, despite higher L-dopa dose equivalents, similar to what was observed in the FIRST-STEP study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Dyskinesia frequency by age, sex, body weight, disease duration, and MAO-B inhibitor use with levodopa/carbidopa with or without entacapone
SubgroupLevodopa/carbidopa/entacapone, no./total (%)Levodopa/carbidopa, no./total (%)P value
Age <65 years“102/223 (45.7)”View highlighted excerpt for this quote“95/253 (37.5)”View highlighted excerpt for this quote“0.021”View highlighted excerpt for this quote
Age ≥65 years“42/150 (28.0)”View highlighted excerpt for this quote“28/119 (23.5)”View highlighted excerpt for this quote“0.162”View highlighted excerpt for this quote
Men“90/245 (36.7)”View highlighted excerpt for this quote“65/222 (29.3)”View highlighted excerpt for this quote“0.043”View highlighted excerpt for this quote
Women“54/128 (42.2)”View highlighted excerpt for this quote“58/150 (38.7)”View highlighted excerpt for this quote“0.191”View highlighted excerpt for this quote
Body weight <75 kg“61/142 (43.0)”View highlighted excerpt for this quote“67/164 (40.9)”View highlighted excerpt for this quote“0.374”View highlighted excerpt for this quote
Body weight ≥75 kg“83/231 (35.9)”View highlighted excerpt for this quote“56/208 (26.9)”View highlighted excerpt for this quote“0.018”View highlighted excerpt for this quote
Disease duration <2 years“75/157 (47.8)”View highlighted excerpt for this quote“50/168 (29.8)”View highlighted excerpt for this quote“<0.001”View highlighted excerpt for this quote
Disease duration ≥2 years“69/216 (31.9)”View highlighted excerpt for this quote“73/204 (35.8)”View highlighted excerpt for this quote“0.514”View highlighted excerpt for this quote
Without MAO-B inhibitor“123/335 (36.7)”View highlighted excerpt for this quote“115/343 (33.5)”View highlighted excerpt for this quote“0.170”View highlighted excerpt for this quote
With MAO-B inhibitor“21/38 (55.3)”View highlighted excerpt for this quote“8/29 (27.6)”View highlighted excerpt for this quote“0.005”View highlighted excerpt for this quote
Care management intervention strategies
Tapering dopamine agonists: approach and management of withdrawal syndrome

“There is scarce information or guidelines on how to discontinue DAs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“When reducing the DAs dose, the general rule is to individualize the process, reducing in small doses, and with careful observation. Authors suggest even slower tapering than proposed (according to available sources) in Table 3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The implementation of these new methods implicates the reduction or withdrawal of previously used medications. Dopamine agonists are usually the first ones to be reduced. Thus, advanced therapies can be considered as a factor possibly contributing to the development of DAWS” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A practical conclusion is to cautiously reduce DAs and LD after implementation of advanced therapies. Our suggestion is even to increase this time and prolong the reduction at small steps during the first 6 months after surgery or pump therapy initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Therapeutic decision: consider reintroducing DAs (another type and dose), carefully monitor for ICD or other side effects, consider personalized symptomatic treatment, consider non-pharmacologic treatment (psychotherapy, physiotherapy, occupational therapy, psychosocial support).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nevertheless, the most important management is the slow-as-possible tapering of DAs, and only when necessary.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Other product development or post-marketing obligations required by the FDA
Postmarketing requirements and commitments in the FDA approval letter

No evidence found.

Ongoing post-approval monitoring
Expected outcomes of therapy
Summary

Available treatments, tavapadon included, are symptomatic. Clinically meaningful thresholds used in this indication are about 1 hour per day for change in off-time or on-time without troublesome dyskinesia (MDS review threshold 1 hour; pramipexole extended-release trials 1.0 to 1.3 hours), 4 points for MDS-UPDRS Part III in the MDS review (anchor-based estimates of -3.25 points for improvement and 4.63 points for worsening), and 4.9 points for combined MDS-UPDRS Parts II and III as cited by TEMPO-1. In early disease, tavapadon reduced the combined Parts II and III score from baseline by 9.7 points (5 mg) and 10.2 points (15 mg) at week 26 in TEMPO-1, which the investigators described as approximately twice the minimal clinically important difference, and a meta-analysis of 2 monotherapy trials estimated a placebo-adjusted improvement of 10.55 points. As an adjunct, TEMPO-3 reported a least-squares mean reduction in off-time of 1.88 hours from baseline and a placebo-adjusted increase in good on-time of 1.1 hours; the pooled estimate from 2 adjunctive trials was 1.09 hours. No randomized trial of tavapadon identified by that meta-analysis lasted longer than 27 weeks.

Minimal clinically important difference for MDS-UPDRS Part III
Minimal clinically important differences for MDS-UPDRS Parts I and II